


**CUMULATIVE
SUPPLEMENT 7
JULY 2020**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2020

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**Cumulative Supplement 7
July 2020**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**CUMULATIVE SUPPLEMENT 7
JULY 2020**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACP NIMBLE BUYER INC (ACP NIMBLE)	COSETTE PHARMACEUTICALS INC (COSETTE)
AMNEAL PHARMACEUTICALS CO GMBH (AMNEAL PHARMS CO)	AMNEAL EU LTD (AMNEAL EU)
AMERICAN ANTIBIOTICS INC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)

AMERICAN ANTIBIOTICS LLC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	PHARMACEUTICS INTERNATIONAL INC (PII)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
SHIRE DEVELOPMENT INC (SHIRE)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SHIRE DEVELOPMENT LLC (SHIRE DEV LLC)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SHIRE DEVELOPMENT LLC (SHIRE LLC)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SUVEN LIFE SCIENCES LTD (SUVEN LIFE)	SUVEN PHARMACEUTICALS LTD (SUVEN PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2019</u>	<u>MAR</u> <u>2020</u>	<u>JUN</u> <u>2020</u>	<u>SEP</u> <u>2020</u>	<u>DEC</u> <u>2020</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20567 2743 (13.3%)	20367 2635 (12.9%)	20382 2660 (13.1%)		
MULTISOURCE	17824 (86.7%)	17732 (87.1%)	17722 (86.9%)		
THERAPEUTICALLY EQUIVALENT	17740 (86.3%)	17659 (86.7%)	17649 (86.6%)		
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)	73 (0.4%)	73 (0.4%)		
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)		
NEW MOLECULAR ENTITIES APPROVED	17	24	25		
NUMBER OF APPLICANTS	1162	1166	1189		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

>A>	<u>ABAMETAPIR</u>							
>A>	LOTION;TOPICAL							
>A>	XEGLYZE							
>A>	+! DR REDDYS LABS SA	0.74%			N206966	001	Jul 24, 2020	Jul NEWA
	<u>ABIRATERONE ACETATE</u>							
	TABLET;ORAL							
	ABIRATERONE ACETATE							
AB	DR REDDYS LABS LTD	250MG			A208416	001	May 18, 2020	May NEWA
	<u>ACARBOSE</u>							
	TABLET;ORAL							
	ACARBOSE							
	@ EMCURE PHARMS LTD	25MG			A202271	001	Feb 07, 2012	Mar DISC
	@	50MG			A202271	002	Feb 07, 2012	Mar DISC
	@	100MG			A202271	003	Feb 07, 2012	Mar DISC
	<u>ACETAMINOPHEN</u>							
	SOLUTION;INTRAVENOUS							
	ACETAMINOPHEN							
>A> AP	MYLAN	1GM/100ML (10MG/ML)			A213255	001	Aug 07, 2020	Jul NEWA
	<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE</u>							
	CAPSULE;ORAL							
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA	TARO PHARM INDS LTD	300MG;50MG;40MG			A213046	001	Jul 01, 2020	Jun NEWA
	TABLET;ORAL							
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
	@ HIKMA PHARMS	325MG;50MG;40MG			A089718	001	Jun 12, 1995	Feb DISC
>A> AA	NESHER PHARMS	325MG;50MG;40MG			A211543	001	Jul 17, 2020	Jul NEWA
	@ SPECGX LLC	325MG;50MG;40MG			A087804	001	Jan 24, 1985	May DISC
	<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>							
	CAPSULE;ORAL							
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE							
>A> AB	STRIDES PHARMA	325MG;50MG;40MG;30MG			A204649	001	Jul 08, 2020	Jul NEWA
	<u>ACETAMINOPHEN; HYDROCODONE BITARTRATE</u>							
	TABLET;ORAL							
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	@ ACTAVIS LABS FL INC	300MG;5MG			A206470	001	Jun 02, 2016	Feb DISC
	@	300MG;7.5MG			A206470	002	Jun 02, 2016	Feb DISC
	@	300MG;10MG			A206470	003	Jun 02, 2016	Feb DISC
	@ GRANULES PHARMS	325MG;5MG			A211729	001	Jan 03, 2020	Jun DISC
	@	325MG;7.5MG			A211729	002	Jan 03, 2020	Jun DISC
	@	325MG;10MG			A211729	003	Jan 03, 2020	Jun DISC
	@ PAR PHARM	300MG;5MG			A205001	001	Jul 05, 2016	May DISC
	@	300MG;7.5MG			A205001	002	Jul 05, 2016	May DISC
	@	300MG;10MG			A205001	003	Jul 05, 2016	May DISC
	@ XIROMED	325MG;5MG			A211690	001	Feb 07, 2020	Mar DISC
AA		325MG;5MG			A211690	001	Feb 07, 2020	Feb CAHN
AA		325MG;5MG			A211690	001	Feb 07, 2020	Jan NEWA
	@	325MG;7.5MG			A211690	002	Feb 07, 2020	Mar DISC
AA		325MG;7.5MG			A211690	002	Feb 07, 2020	Feb CAHN
AA		325MG;7.5MG			A211690	002	Feb 07, 2020	Jan NEWA
	@	325MG;10MG			A211690	003	Feb 07, 2020	Mar DISC
AA		325MG;10MG			A211690	003	Feb 07, 2020	Feb CAHN
AA		325MG;10MG			A211690	003	Feb 07, 2020	Jan NEWA
	<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</u>							
	SOLUTION;ORAL							
	OXYCODONE AND ACETAMINOPHEN							
	MIKART INC	300MG/5ML;10MG/5ML			A202142	001	Nov 27, 2018	Feb CMFD
	TABLET;ORAL							
	OXYCODONE AND ACETAMINOPHEN							
	@ GRANULES PHARMS	325MG;2.5MG			A211708	001	Oct 31, 2019	May DISC
	@	325MG;5MG			A211708	002	Oct 31, 2019	May DISC
	@	325MG;7.5MG			A211708	003	Oct 31, 2019	May DISC
	@	325MG;10MG			A211708	004	Oct 31, 2019	May DISC
	@ WATSON LABS	325MG;5MG			A040171	001	Oct 30, 1997	Apr DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

@		325MG;7.5MG	A040535	001	Sep 05, 2003	Apr DISC
@		325MG;10MG	A040535	002	Sep 05, 2003	Apr DISC
@	XIROMED	325MG;5MG	A207574	001	Dec 13, 2016	Mar DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@	APOTEX	325MG;37.5MG	A078778	001	Apr 07, 2014	Feb DISC
@	GRAVITI PHARMS	325MG;37.5MG	A076914	001	Jul 26, 2006	Apr CAHN
@	MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017	May DISC
@	NOSTRUM LABS INC	325MG;37.5MG	A078778	001	Apr 07, 2014	Apr CAHN

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB	BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Apr NEWA
AB		250MG	A207503	002	Apr 30, 2020	Apr NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	!	XGEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Feb CAHN
----	---	-------------	--------------------	---------	-----	--------------	----------

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

AT		SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Mar CAHN
----	--	-----------------	----	---------	-----	--------------	----------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		COSETTE	2%;1%	A040609	001	Feb 06, 2006	May CAHN
----	--	---------	-------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

@	DAVA PHARMS INC	200MG	A074833	001	Apr 22, 1997	May DISC
---	-----------------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

ACYCLOVIR

AB	!	PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan CHRS
----	---	------------------	----	---------	-----	--------------	----------

ZOVIRAX

AB	+	BAUSCH	5%	N021478	001	Dec 30, 2002	Jan CHRS
----	---	--------	----	---------	-----	--------------	----------

OINTMENT;TOPICAL

ACYCLOVIR

AB		SOLARIS PHARMA CORP	5%	A212495	001	Apr 07, 2020	Mar NEWA
----	--	---------------------	----	---------	-----	--------------	----------

AB		XIROMED	5%	A201501	001	Jan 29, 2020	Jan NEWA
----	--	---------	----	---------	-----	--------------	----------

SUSPENSION;ORAL

ACYCLOVIR

AB		HERITAGE PHARMS INC	200MG/5ML	A212718	001	Apr 23, 2020	Apr NEWA
----	--	---------------------	-----------	---------	-----	--------------	----------

>A> AB		NOVITIUM PHARMA	200MG/5ML	A212252	001	Jul 10, 2020	Jul NEWA
--------	--	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

ACYCLOVIR

AB	!	HETERO LABS LTD V	800MG	A203834	002	Oct 29, 2013	Jan CHRS
----	---	-------------------	-------	---------	-----	--------------	----------

ZOVIRAX

+	@	MYLAN	400MG	N020089	001	Apr 30, 1991	Jan DISC
---	---	-------	-------	---------	-----	--------------	----------

+	@		800MG	N020089	002	Apr 30, 1991	Jan DISC
---	---	--	-------	---------	-----	--------------	----------

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

AP		EXELA PHARMA	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun NEWA
----	--	--------------	-----------------	---------	-----	--------------	----------

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB		ALEOR DERMACEUTICALS	0.3%	A213508	001	Jun 18, 2020	Jun NEWA
----	--	----------------------	------	---------	-----	--------------	----------

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

@ MYLAN LABS LTD	3MG/ML	A078640	001	Mar 21, 2014	Apr DISC
------------------	--------	---------	-----	--------------	----------

AIR POLYMER-TYPE AFOAM; INTRAUTERINE
EXEM FOAM KIT

>D>	+ @ GISKIT	10ML	N212279	001	Nov 07, 2019	Jul CAHN
>A>	+ @	10ML	N212279	001	Nov 07, 2019	Jul CAHN
>A>	+ @	10ML	N212279	001	Nov 07, 2019	Jul CAHN
	+ @	10ML	N212279	001	Nov 07, 2019	Jun DISC

ALBENDAZOLETABLET; ORAL
ALBENDAZOLE

AB	LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jun NEWA
----	-----------	-------	---------	-----	--------------	----------

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
ALBUTEROL SULFATE

AB1	CIPLA	EQ 0.09MG BASE/INH	A209959	001	Apr 08, 2020	Mar NFTG
AB2	PERRIGO PHARMS CO	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar CTEC
AB		EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Feb NFTG

PROAIR HFA

AB2	+! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Mar CTEC
AB	+!	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Feb CFTG

PROVENTIL-HFA

AB1	+! 3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	Mar CFTG
AB1	+! KINDEVA	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	AUROBINDO PHARMA LTD	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Apr NEWA
AN		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Apr NEWA
	@ BAUSCH AND LOMB	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Feb DISC
AN	! NEPHRON	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb CHRS

SYRUP; ORAL

ALBUTEROL SULFATE

>D> AA	VISTAPHARM	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	Jul DISC
>A>	@	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	Jul DISC

TABLET; ORAL

ALBUTEROL SULFATE

>D> AB	APPCO	EQ 2MG BASE	A207046	001	Jun 29, 2018	Jul CAHN
>D> AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Jul CAHN
>D> AB	ARISE	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jul DISC
>A>	@	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jul DISC
>D> AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jul DISC
>A>	@	EQ 4MG BASE	A210948	002	Mar 15, 2019	Jul DISC
AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657	001	May 14, 2020	May NEWA
AB		EQ 4MG BASE	A213657	002	May 14, 2020	May NEWA
>A> AB	RISING	EQ 2MG BASE	A207046	001	Jun 29, 2018	Jul CAHN
>A> AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

VOLMAX

+ @ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992	Mar CRLD
+ @	EQ 8MG BASE	N019604	001	Dec 23, 1992	Mar CRLD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>A> AN	AUROBINDO PHARMA LTD	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Jul NEWA
	@ WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Apr DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

@ EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Apr DISC
@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Apr DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@	DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb	DISC
@		0.5MG	A074174	002	Oct 19, 1993	Feb	DISC
@		1MG	A074174	003	Oct 19, 1993	Feb	DISC
@		2MG	A074174	004	Oct 19, 1993	Feb	DISC
@	OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008	Jun	DISC
@		0.5MG	A078491	002	Sep 25, 2008	Jun	DISC
@		1MG	A078491	003	Sep 25, 2008	Jun	DISC
@		2MG	A078491	004	Dec 12, 2008	Jun	DISC

XANAX

AB	+	UPJOHN	0.25MG	N018276	001		Apr	CAHN
AB	+		0.5MG	N018276	002		Apr	CAHN
AB	+	!	1MG	N018276	003		Apr	CAHN
AB	+		2MG	N018276	004	Nov 27, 1985	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

XANAX XR

AB	+	UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr	CAHN
AB	+		1MG	N021434	002	Jan 17, 2003	Apr	CAHN
AB	+		2MG	N021434	003	Jan 17, 2003	Apr	CAHN
AB	+	!	3MG	N021434	004	Jan 17, 2003	Apr	CAHN

ALVIMOPAN

CAPSULE; ORAL

ALVIMOPAN

@	WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun	DISC	
+	!	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun	CTEC

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	!	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jun	CHRS
AB		INVATECH	100MG	A210129	001	Mar 02, 2020	Feb	NEWA
AB		RUBICON	100MG	A212044	001	May 21, 2020	May	NEWA
AB		SANDOZ	100MG	A071293	001	Feb 18, 1987	Jun	CHRS

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB		INVATECH	100MG	A210215	001	Mar 10, 2020	Feb	NEWA
----	--	----------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+		OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020	Apr	NEWA
---	--	----------------	---------------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP		TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar	CMFD
----	--	-----------------	------------------	---------	-----	--------------	-----	------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+	!	FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan	CHRS
---	---	--------------------	--	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SYRUP; ORAL

AMINOCAPROIC ACID

>A>	AA	TULEX PHARMS INC	1.25GM/5ML	A212494	001	Aug 11, 2020	Jul	NEWA
	AA	VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb	NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>A>	AB	UNICHEM LABS LTD	200MG	A213446	001	Jul 21, 2020	Jul	NEWA
-----	----	------------------	-------	---------	-----	--------------	-----	------

AMISULPRIDESOLUTION; INTRAVENOUS
BARHEMSYS

+! ACACIA 5MG/2ML (2.5MG/ML) N209510 001 Feb 26, 2020 Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		SANDOZ	10MG	A085968	004			Jan	CMS1
AB	!		25MG	A085968	002			Jan	CMS1
AB			75MG	A085968	006			Jan	CMS1
AB			100MG	A085968	003			Jan	CMS1
AB			150MG	A085968	005			Jan	CMS1
AB		@ UPSHER SMITH LABS	25MG	A212654	001	Apr 07, 2020		May	DISC
AB			25MG	A212654	001	Apr 07, 2020		Mar	NEWA

AMLODIPINE BENZOATE

SUSPENSION; ORAL

KATERZIA

+! AZURITY EQ 1MG BASE/ML N211340 001 Jul 08, 2019 May CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

		@ HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007		Feb	DISC
		@	EQ 5MG BASE	A077262	002	Jul 09, 2007		Feb	DISC
		@	EQ 10MG BASE	A077262	003	Jul 09, 2007		Feb	DISC
		@ MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012		May	DISC
		@	EQ 10MG BASE	A201380	002	Apr 13, 2012		May	DISC
>D>	AB	MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005		Jul	DISC
>A>		@	EQ 2.5MG BASE	A076418	001	Oct 03, 2005		Jul	DISC
>D>	AB		EQ 5MG BASE	A076418	002	Oct 03, 2005		Jul	DISC
>A>		@	EQ 5MG BASE	A076418	002	Oct 03, 2005		Jul	DISC
>D>	AB		EQ 10MG BASE	A076418	003	Oct 03, 2005		Jul	DISC
>A>		@	EQ 10MG BASE	A076418	003	Oct 03, 2005		Jul	DISC
		@ WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007		Apr	DISC
		@	EQ 5MG BASE	A077671	002	Jul 19, 2007		Apr	DISC
		@	EQ 10MG BASE	A077671	003	Jul 19, 2007		Apr	DISC
		NORVASC							
AB	+	UPJOHN	EQ 2.5MG BASE	N019787	001	Jul 31, 1992		Jun	CAHN
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992		Jun	CAHN
AB	+!		EQ 10MG BASE	N019787	003	Jul 31, 1992		Jun	CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019		Feb	CMFD
AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019		Feb	CMFD
AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019		Feb	CMFD
		CADUET							
AB	+	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004		May	CAHN
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004		May	CAHN
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004		May	CAHN
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004		May	CAHN
AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004		May	CAHN
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004		May	CAHN
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004		May	CAHN
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004		May	CAHN
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004		May	CAHN
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004		May	CAHN
AB	+!		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004		May	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	PAR PHARM	EQ 2.5MG BASE;10MG	A 078381	001	Jul 29, 2010	May	DISC
@		EQ 5MG BASE;10MG	A 078381	002	Jul 29, 2010	May	DISC
@		EQ 5MG BASE;20MG	A 078381	003	Jul 29, 2010	May	DISC
@		EQ 5MG BASE;40MG	A 078381	005	Jul 29, 2010	May	DISC
@		EQ 10MG BASE;20MG	A 078381	004	Jul 29, 2010	May	DISC
@		EQ 10MG BASE;40MG	A 078381	006	Jul 29, 2010	May	DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

>D>	@	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A 202491	001	Nov 03, 2016	Jul	CMFD
>A>	AB		EQ 5MG BASE;12.5MG;20MG	A 202491	001	Nov 03, 2016	Jul	CMFD
>D>		@	EQ 5MG BASE;12.5MG;40MG	A 202491	002	Nov 03, 2016	Jul	CMFD
>A>	AB		EQ 5MG BASE;12.5MG;40MG	A 202491	002	Nov 03, 2016	Jul	CMFD
>D>		@	EQ 5MG BASE;25MG;40MG	A 202491	003	Nov 03, 2016	Jul	CMFD
>A>	AB		EQ 5MG BASE;25MG;40MG	A 202491	003	Nov 03, 2016	Jul	CMFD
>D>		@	EQ 10MG BASE;12.5MG;40MG	A 202491	004	Nov 03, 2016	Jul	CMFD
>A>	AB		EQ 10MG BASE;12.5MG;40MG	A 202491	004	Nov 03, 2016	Jul	CMFD
>D>		@	EQ 10MG BASE;25MG;40MG	A 202491	005	Nov 03, 2016	Jul	CMFD
>A>	AB		EQ 10MG BASE;25MG;40MG	A 202491	005	Nov 03, 2016	Jul	CMFD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;12.5MG;160MG	A 206180	001	Dec 19, 2017	Mar	CPOT		
AB			EQ 5MG BASE;25MG;160MG	A 206180	002	Dec 19, 2017	Mar	CPOT		
AB			EQ 10MG BASE;12.5MG;160MG	A 206180	003	Dec 19, 2017	Mar	CPOT		
AB			EQ 10MG BASE;25MG;160MG	A 206180	004	Dec 19, 2017	Mar	CPOT		
AB			EQ 10MG BASE;25MG;320MG	A 206180	005	Dec 19, 2017	Mar	CPOT		
AB		LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A 200797	001	Jun 03, 2015	Mar	CPOT		
AB			EQ 5MG BASE;25MG;160MG	A 200797	002	Jun 03, 2015	Mar	CPOT		
AB			EQ 10MG BASE;12.5MG;160MG	A 200797	003	Jun 03, 2015	Mar	CPOT		
AB			EQ 10MG BASE;25MG;160MG	A 200797	004	Jun 03, 2015	Mar	CPOT		
AB			EQ 10MG BASE;25MG;320MG	A 200797	005	Jun 03, 2015	Mar	CPOT		
AB		@	PAR PHARM	EQ 5MG BASE;12.5MG;160MG	A 201087	001	Jun 01, 2015	May	DISC	
AB			@	EQ 5MG BASE;12.5MG;160MG	A 201087	001	Jun 01, 2015	Mar	CPOT	
AB			@	EQ 5MG BASE;25MG;160MG	A 201087	002	Jun 01, 2015	May	DISC	
AB			@	EQ 5MG BASE;25MG;160MG	A 201087	002	Jun 01, 2015	Mar	CPOT	
AB			@	EQ 10MG BASE;12.5MG;160MG	A 201087	003	Jun 01, 2015	May	DISC	
AB			@	EQ 10MG BASE;12.5MG;160MG	A 201087	003	Jun 01, 2015	Mar	CPOT	
AB			@	EQ 10MG BASE;25MG;160MG	A 201087	004	Jun 01, 2015	May	DISC	
AB			@	EQ 10MG BASE;25MG;160MG	A 201087	004	Jun 01, 2015	Mar	CPOT	
AB			@	EQ 10MG BASE;25MG;320MG	A 201087	005	Jun 01, 2015	May	DISC	
AB			@	EQ 10MG BASE;25MG;320MG	A 201087	005	Jun 01, 2015	Mar	CPOT	
AB		@	TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A 200435	001	Sep 25, 2012	Mar	CPOT	
AB			@	EQ 5MG BASE;25MG;160MG	A 200435	002	Sep 25, 2012	Mar	CPOT	
AB			@	EQ 10MG BASE;12.5MG;160MG	A 200435	005	Sep 25, 2012	Mar	CPOT	
AB			@	EQ 10MG BASE;25MG;160MG	A 200435	003	Sep 25, 2012	Mar	CPOT	
AB			@	EQ 10MG BASE;25MG;320MG	A 200435	004	Sep 25, 2012	Mar	CPOT	
AB			@	TORRENT	EQ 5MG BASE;12.5MG;160MG	A 201593	001	Jun 03, 2015	Mar	CPOT
AB			@	EQ 5MG BASE;25MG;160MG	A 201593	002	Jun 03, 2015	Mar	CPOT	
AB			@	EQ 10MG BASE;12.5MG;160MG	A 201593	003	Jun 03, 2015	Mar	CPOT	
AB			@	EQ 10MG BASE;25MG;160MG	A 201593	004	Jun 03, 2015	Mar	CPOT	
AB			@	EQ 10MG BASE;25MG;320MG	A 201593	005	Jun 03, 2015	Mar	CPOT	
AB			EXFORGE HCT							
AB	+	NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N 022314	001	Apr 30, 2009	Mar	CPOT		
AB	+		EQ 5MG BASE;25MG;160MG	N 022314	002	Apr 30, 2009	Mar	CPOT		
AB	+		EQ 10MG BASE;12.5MG;160MG	N 022314	003	Apr 30, 2009	Mar	CPOT		
AB	+		EQ 10MG BASE;25MG;160MG	N 022314	004	Apr 30, 2009	Mar	CPOT		
AB	+		EQ 10MG BASE;25MG;320MG	N 022314	005	Apr 30, 2009	Mar	CPOT		

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@	PAR PHARM INC	EQ 5MG BASE;160MG	A 090011	001	Mar 28, 2013	Jun	DISC
@		EQ 5MG BASE;320MG	A 090011	003	Mar 28, 2013	Jun	DISC
@		EQ 10MG BASE;160MG	A 090011	002	Mar 28, 2013	Jun	DISC
@		EQ 10MG BASE;320MG	A 090011	004	Mar 28, 2013	Jun	DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS
 AMMONIA N 13
 AP CARDINAL HLTH 414 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A203700 001 Feb 25, 2013 May CAHN

AMMONIUM LACTATE

CREAM; TOPICAL
 AMMONIUM LACTATE
 @ WATSON LABS INC EQ 12% BASE A076829 001 Feb 07, 2006 Apr DISC
 LOTION; TOPICAL
 AMMONIUM LACTATE
 @ WATSON LABS INC EQ 12% BASE A075575 001 Jun 11, 2002 Apr DISC

AMOXAPINE

TABLET; ORAL
 AMOXAPINE
 @ WATSON PHARMS TEVA 25MG A072418 001 Aug 01, 1989 Jan CMS1
 @ 50MG A072419 001 Aug 01, 1989 Jan CMS1

AMOXICILLIN

CAPSULE; ORAL
 AMOXICILLIN
 >D> AB DAVA PHARMS INC 250MG A062884 001 Feb 25, 1988 Jul DISC
 >A> @ 250MG A062884 001 Feb 25, 1988 Jul DISC
 >D> AB 500MG A062881 001 Feb 25, 1988 Jul DISC
 >A> @ 500MG A062881 001 Feb 25, 1988 Jul DISC
 TABLET, CHEWABLE; ORAL
 AMOXICILLIN
 AB HIKMA 125MG A205274 001 Jun 25, 2020 Jun NEWA
 AB 250MG A205274 002 Jun 25, 2020 Jun NEWA
 AB TEVA 125MG A064013 002 Sep 11, 1995 Jun CTEC
 AB ! 250MG A064013 001 Dec 22, 1992 Jun CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
 AUGMENTIN ES-600
 >D> + @ NEOPHARMA 600MG/5ML; EQ 42.9MG BASE/5ML N050755 001 Jun 22, 2001 Jul CMFD
 >A> AB + 600MG/5ML; EQ 42.9MG BASE/5ML N050755 001 Jun 22, 2001 Jul CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
 AB ANI PHARMS INC 1.25MG; 1.25MG; 1.25MG; 1.25MG A205401 001 Jan 22, 2019 Jan CAHN
 AB 2.5MG; 2.5MG; 2.5MG; 2.5MG A205401 002 Jan 22, 2019 Jan CAHN
 AB 3.75MG; 3.75MG; 3.75MG; 3.75MG A205401 003 Jan 22, 2019 Jan CAHN
 AB 5MG; 5MG; 5MG; 5MG A205401 004 Jan 22, 2019 Jan CAHN
 AB 6.25MG; 6.25MG; 6.25MG; 6.25MG A205401 005 Jan 22, 2019 Jan CAHN
 AB 7.5MG; 7.5MG; 7.5MG; 7.5MG A205401 006 Jan 22, 2019 Jan CAHN
 AB ELITE LABS INC 1.25MG; 1.25MG; 1.25MG; 1.25MG A212037 001 Dec 11, 2019 May CAHN
 AB 2.5MG; 2.5MG; 2.5MG; 2.5MG A212037 002 Dec 11, 2019 May CAHN
 AB 3.75MG; 3.75MG; 3.75MG; 3.75MG A212037 003 Dec 11, 2019 May CAHN
 AB 5MG; 5MG; 5MG; 5MG A212037 004 Dec 11, 2019 May CAHN
 AB 6.25MG; 6.25MG; 6.25MG; 6.25MG A212037 005 Dec 11, 2019 May CAHN
 AB 7.5MG; 7.5MG; 7.5MG; 7.5MG A212037 006 Dec 11, 2019 May CAHN
 AB MYLAN 1.25MG; 1.25MG; 1.25MG; 1.25MG A211876 001 Jun 24, 2020 Jun NEWA
 AB 2.5MG; 2.5MG; 2.5MG; 2.5MG A211876 002 Jun 24, 2020 Jun NEWA
 AB 3.75MG; 3.75MG; 3.75MG; 3.75MG A211876 003 Jun 24, 2020 Jun NEWA
 AB 5MG; 5MG; 5MG; 5MG A211876 004 Jun 24, 2020 Jun NEWA
 AB 6.25MG; 6.25MG; 6.25MG; 6.25MG A211876 005 Jun 24, 2020 Jun NEWA
 AB 7.5MG; 7.5MG; 7.5MG; 7.5MG A211876 006 Jun 24, 2020 Jun NEWA
 @ NESHER PHARMS 1.25MG; 1.25MG; 1.25MG; 1.25MG A210080 001 Jul 17, 2019 Jan DISC
 @ 2.5MG; 2.5MG; 2.5MG; 2.5MG A210080 002 Jul 17, 2019 Jan DISC
 @ 3.75MG; 3.75MG; 3.75MG; 3.75MG A210080 003 Jul 17, 2019 Jan DISC
 @ 5MG; 5MG; 5MG; 5MG A210080 004 Jul 17, 2019 Jan DISC
 @ 6.25MG; 6.25MG; 6.25MG; 6.25MG A210080 005 Jul 17, 2019 Jan DISC
 @ 7.5MG; 7.5MG; 7.5MG; 7.5MG A210080 006 Jul 17, 2019 Jan DISC
 AB SUN PHARM INDUSTRIES 1.25MG; 1.25MG; 1.25MG; 1.25MG A211715 001 May 17, 2019 Apr CMFD
 AB 2.5MG; 2.5MG; 2.5MG; 2.5MG A211715 002 May 17, 2019 Apr CMFD
 AB 3.75MG; 3.75MG; 3.75MG; 3.75MG A211715 003 May 17, 2019 Apr CMFD
 AB 5MG; 5MG; 5MG; 5MG A211715 004 May 17, 2019 Apr CMFD
 AB 6.25MG; 6.25MG; 6.25MG; 6.25MG A211715 005 May 17, 2019 Apr CMFD

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Apr	CMFD
	@ TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Apr	DISC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Apr	DISC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Apr	DISC
	@	5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Apr	DISC
	@	6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Apr	DISC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Apr	DISC
		DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE					
	@ BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013	Apr	DISC
	@	2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013	Apr	DISC
	@	3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013	Apr	DISC
	@	5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013	Apr	DISC
	@	6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013	Apr	DISC
	@	7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013	Apr	DISC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BIONPHARMA INC	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Mar	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Mar	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Mar	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Mar	NEWA
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Mar	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Mar	NEWA
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018	May	CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018	May	CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018	May	CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018	May	CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018	May	CAHN
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018	May	CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018	May	CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan	NEWA	
AA		10MG	A212582	002	Feb 04, 2020	Jan	NEWA	
AA	HAVIX	5MG	A212901	001	May 22, 2020	May	NEWA	
AA		10MG	A212901	002	May 22, 2020	May	NEWA	
>A>	AA	MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jul	NEWA
>A>	AA		10MG	A213898	002	Jul 14, 2020	Jul	NEWA
AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb	NEWA	
AA		10MG	A211861	002	Mar 11, 2020	Feb	NEWA	

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb	CAHN
---	-------------	-----------	---------	-----	--------------	-----	------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan	CAHN
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan	CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

@	DAVA PHARMS INC	EQ 500MG BASE	A062882	001	Feb 25, 1988	Mar	DISC
!	SANDOZ	EQ 500MG BASE	A064082	002	Aug 29, 1995	Mar	CHRS
>D>		FOR SUSPENSION;ORAL					
>D>		AMPICILLIN TRIHYDRATE					
>D>	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	Jul	DISC
>A>	@	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	Jul	DISC
>D>	!	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	Jul	DISC
>A>	@	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	Jul	DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@ BARR EQ 0.5MG BASE
 @ EQ 1MG BASE

A076530 001 Apr 18, 2005 Apr DISC
 A076530 002 Apr 18, 2005 Apr DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>A> AB @ APOTEX INC 1MG
 EUGIA PHARMA 1MG
 @ MYLAN 1MG

A200654 001 May 11, 2012 Feb DISC
 A212434 001 Jul 24, 2020 Jul NEWA
 A091051 001 Jun 28, 2010 Jan DISC

APIXABAN

TABLET; ORAL

APIXABAN

>A> AB ACCORD HLTHCARE 2.5MG
 >A> AB 5MG
 >D> AB BIONPHARMA INC 2.5MG
 >A> @ 2.5MG
 AB 2.5MG
 >D> AB 5MG
 >A> @ 5MG
 AB 5MG
 @ MICRO LABS 2.5MG
 @ 5MG
 @ MYLAN 2.5MG
 @ 5MG

A210180 001 Jul 28, 2020 Jul NEWA
 A210180 002 Jul 28, 2020 Jul NEWA
 A210152 001 Apr 08, 2020 Jul DISC
 A210152 001 Apr 08, 2020 Jul DISC
 A210152 001 Apr 08, 2020 Mar NEWA
 A210152 002 Apr 08, 2020 Jul DISC
 A210152 002 Apr 08, 2020 Jul DISC
 A210152 002 Apr 08, 2020 Mar NEWA
 A210013 001 Dec 23, 2019 Jun DISC
 A210013 002 Dec 23, 2019 Jun DISC
 A210128 001 Dec 23, 2019 Jan DISC
 A210128 002 Dec 23, 2019 Jan DISC

>D> AB + BRISTOL MYERS SQUIBB 2.5MG
 >A> + 2.5MG
 >D> AB +! 5MG
 >A> +! 5MG

N202155 001 Dec 28, 2012 Jul CTEC
 N202155 001 Dec 28, 2012 Jul CTEC
 N202155 002 Dec 28, 2012 Jul CTEC
 N202155 002 Dec 28, 2012 Jul CTEC

APOMORPHINE HYDROCHLORIDE

FILM; SUBLINGUAL

KYNMOBI

+ SUNOVION PHARMS INC 10MG
 + 15MG
 + 20MG
 + 25MG
 +! 30MG

N210875 001 May 21, 2020 May NEWA
 N210875 002 May 21, 2020 May NEWA
 N210875 003 May 21, 2020 May NEWA
 N210875 004 May 21, 2020 May NEWA
 N210875 005 May 21, 2020 May NEWA

INJECTABLE; SUBCUTANEOUS

APOKYN

>A> @ MDD US 20MG/2ML (10MG/ML)
 >A> +! 30MG/3ML (10MG/ML)
 >D> @ US WORLDMEDS 20MG/2ML (10MG/ML)
 >D> +! 30MG/3ML (10MG/ML)

N021264 001 Apr 20, 2004 Jul CAHN
 N021264 002 Apr 20, 2004 Jul CAHN
 N021264 001 Apr 20, 2004 Jul CAHN
 N021264 002 Apr 20, 2004 Jul CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP +! HIKMA PHARM CO LTD 250MG/2.5ML (100MG/ML)
 AP + 250MG/2.5ML (100MG/ML)

N203049 001 Jan 05, 2012 Mar CHRS
 N203049 001 Jan 05, 2012 Mar CRLD

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

@ TEVA PHARMS USA 250MG/250ML (1MG/ML)

N206769 001 Dec 15, 2014 Mar DISC

ARTESUNATE

POWDER; INTRAVENOUS

ARTESUNATE

+! AMIVAS 110MG/VIAL

N213036 001 May 26, 2020 May NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+! DEPROCO 4%;EQ 0.0085MG BASE/1.7ML (4%;EQ
 0.005MG BASE/ML)
 +! 4%;EQ 0.017MG BASE/1.7ML (4%;EQ
 0.01MG BASE/ML)

N022010 001 Mar 30, 2006 Mar CTEC
 N020971 001 Apr 03, 2000 Feb CTEC

INJECTABLE; INJECTION

ULTACAN FORTE

@ HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Feb DISC
----------------	---	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

+ ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan CMS1
------------	---------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA STRIDES PHARMA	325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Mar CAHN
-------------------	-------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC FORTE

>D> @ GALT PHARMS	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Jul CMFD
>A> !	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Jul CMFD

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

@ HERITAGE PHARMS INC	325MG; 200MG	A089594	001	Mar 31, 1989	May DISC
-----------------------	--------------	---------	-----	--------------	----------

@ NOVAST LABS	325MG; 200MG	A040832	001	Jan 07, 2010	May DISC
---------------	--------------	---------	-----	--------------	----------

@ SANDOZ	325MG; 200MG	A040116	001	Apr 25, 1996	May DISC
----------	--------------	---------	-----	--------------	----------

>D> ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

>D> ! STEVENS J	325MG; 400MG	A081145	001	Jan 31, 1995	Jul DISC
>A> @	325MG; 400MG	A081145	001	Jan 31, 1995	Jul DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>A> AA @ ACTAVIS LABS FL INC	325MG; 4.8355MG	A090084	001	Mar 22, 2011	Jun DISC
EPIC PHARMA LLC	325MG; 4.8355MG	A040910	001	Jul 16, 2020	Jul NEWA

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

@ BRISTOL MYERS SQUIBB	81MG; 20MG	N021387	001	Jun 24, 2003	May CPOT
------------------------	------------	---------	-----	--------------	----------

@	81MG, N/A; N/A, 20MG	N021387	001	Jun 24, 2003	May CDFR
---	----------------------	---------	-----	--------------	----------

@	81MG; 40MG	N021387	002	Jun 24, 2003	May CPOT
---	------------	---------	-----	--------------	----------

@	81MG, N/A; N/A, 40MG	N021387	002	Jun 24, 2003	May CDFR
---	----------------------	---------	-----	--------------	----------

@	81MG; 80MG	N021387	003	Jun 24, 2003	May CPOT
---	------------	---------	-----	--------------	----------

@	81MG, N/A; N/A, 80MG	N021387	003	Jun 24, 2003	May CDFR
---	----------------------	---------	-----	--------------	----------

@	325MG; 20MG	N021387	004	Jun 24, 2003	May CPOT
---	-------------	---------	-----	--------------	----------

@	325MG, N/A; N/A, 20MG	N021387	004	Jun 24, 2003	May CDFR
---	-----------------------	---------	-----	--------------	----------

@	325MG; 40MG	N021387	005	Jun 24, 2003	May CPOT
---	-------------	---------	-----	--------------	----------

@	325MG, N/A; N/A, 40MG	N021387	005	Jun 24, 2003	May CDFR
---	-----------------------	---------	-----	--------------	----------

@	325MG; 80MG	N021387	006	Jun 24, 2003	May CPOT
---	-------------	---------	-----	--------------	----------

@	325MG, N/A; N/A, 80MG	N021387	006	Jun 24, 2003	May CDFR
---	-----------------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB AMNEAL	EQ 150MG BASE	A209717	002	Jun 01, 2020	May NEWA
AB	EQ 200MG BASE	A209717	003	Jun 01, 2020	May NEWA
AB	EQ 300MG BASE	A209717	004	Jun 01, 2020	May NEWA
@ MYLAN	EQ 150MG BASE	A208177	001	Sep 24, 2018	Feb DISC
@	EQ 200MG BASE	A208177	002	Sep 24, 2018	Feb DISC
@	EQ 300MG BASE	A208177	003	Sep 24, 2018	Feb DISC
AB ZYDUS PHARMS	EQ 150MG BASE	A210575	001	Jun 04, 2020	Jun NEWA
AB	EQ 200MG BASE	A210575	002	Jun 04, 2020	Jun NEWA
AB	EQ 300MG BASE	A210575	003	Jun 04, 2020	Jun NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	HLTHCARE	25MG	A 073026	002	May 01, 1992	Jun CMS1
AB		50MG	A 073026	003	Sep 17, 1991	Jun CMS1

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

@ MYLAN

50MG;25MG

A 074203 001 Oct 31, 1993 May DISC

@

100MG;25MG

A 074203 002 Oct 31, 1993 May DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A 204991	001	Mar 06, 2019	Jan CMFD
AB		EQ 20MG BASE	A 204991	002	Mar 06, 2019	Jan CMFD
AB		EQ 40MG BASE	A 204991	003	Mar 06, 2019	Jan CMFD
AB		EQ 80MG BASE	A 204991	004	Mar 06, 2019	Jan CMFD
>D>	PERRIGO R AND D	EQ 10MG BASE	A 208478	001	Jun 23, 2020	Jul DISC
>A>	@	EQ 10MG BASE	A 208478	001	Jun 23, 2020	Jul DISC
AB		EQ 10MG BASE	A 208478	001	Jun 23, 2020	Jun NEWA
>D>		EQ 20MG BASE	A 208478	002	Jun 23, 2020	Jul DISC
>A>	@	EQ 20MG BASE	A 208478	002	Jun 23, 2020	Jul DISC
AB		EQ 20MG BASE	A 208478	002	Jun 23, 2020	Jun NEWA
	LIPITOR					
AB	+ UPJOHN	EQ 10MG BASE	N 020702	001	Dec 17, 1996	Jun CAHN
AB	+	EQ 20MG BASE	N 020702	002	Dec 17, 1996	Jun CAHN
AB	+	EQ 40MG BASE	N 020702	003	Dec 17, 1996	Jun CAHN
AB	+	EQ 80MG BASE	N 020702	004	Apr 07, 2000	Jun CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

@ SCOV3

EQ 10MG BASE;10MG

A 206084 001 Apr 26, 2017 Apr DISC

EQ 10MG BASE;10MG

A 206084 001 Apr 26, 2017 Mar CAHN

@

EQ 20MG BASE;10MG

A 206084 002 Apr 26, 2017 Apr DISC

EQ 20MG BASE;10MG

A 206084 002 Apr 26, 2017 Mar CAHN

@

EQ 40MG BASE;10MG

A 206084 003 Apr 26, 2017 Apr DISC

EQ 40MG BASE;10MG

A 206084 003 Apr 26, 2017 Mar CAHN

@

EQ 80MG BASE;10MG

A 206084 004 Apr 26, 2017 Apr DISC

!

EQ 80MG BASE;10MG

A 206084 004 Apr 26, 2017 Mar CAHN

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

+! ALCON LABS INC

1%

N 208151 001 Dec 01, 2016 Feb CRLD

!

1%

N 208151 001 Dec 01, 2016 Feb CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	LEADING PHARMA LLC	0.025MG;2.5MG	A 213413	001	Feb 20, 2020	Feb NEWA
AA	MAYNE PHARMA INC	0.025MG;2.5MG	A 210789	001	Jun 03, 2020	May NEWA
	@ PAR PHARM	0.025MG;2.5MG	A 040357	001	May 02, 2000	May DISC

AVAPRITINIB

TABLET;ORAL

AYVAKIT

+ BLUEPRINT MEDICINES

100MG

N 212608 001 Jan 09, 2020 Jan NEWA

+

200MG

N 212608 002 Jan 09, 2020 Jan NEWA

+!

300MG

N 212608 003 Jan 09, 2020 Jan NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	EUROHLTH INTL SARL	100MG/VIAL	A 209337	001	Jun 08, 2020	Jun NEWA
----	--------------------	------------	----------	-----	--------------	----------

AZATHIOPRINE

TABLET; ORAL		AZATHIOPRINE						
AB	ALKEM LABS LTD	25MG		A208687	001	Mar 27, 2020	Mar	NEWA
AB		50MG		A208687	002	Mar 27, 2020	Mar	NEWA
AB		75MG		A208687	003	Mar 27, 2020	Mar	NEWA
AB		100MG		A208687	004	Mar 27, 2020	Mar	NEWA
AB	RISING	50MG		A075568	001	Dec 13, 1999	May	CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC		AZELASTINE HYDROCHLORIDE						
AT	GLAND PHARMA LTD	0.05%		A210092	001	Feb 25, 2020	Feb	NEWA
SPRAY, METERED; NASAL		AZELASTINE HYDROCHLORIDE						
AB	AUROBINDO PHARMA LTD	EQ 0.125MG BASE/SPRAY		A212289	001	May 08, 2020	Apr	NEWA

AZITHROMYCIN

FOR SUSPENSION; ORAL		AZITHROMYCIN						
	@ TARO	EQ 200MG BASE/5ML		A211521	001	Dec 11, 2019	May	DISC
	@ TEVA PHARMS	EQ 100MG BASE/5ML		A065419	001	Jun 24, 2008	Apr	DISC
	@	EQ 200MG BASE/5ML		A065419	002	Jun 24, 2008	Apr	DISC
INJECTABLE; INJECTION		AZITHROMYCIN						
	@ HIKMA	EQ 500MG BASE/VIAL		A065265	001	Jan 18, 2007	Mar	CAHN
	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL		A204732	001	Jan 26, 2017	Mar	DISC
TABLET; ORAL		AZITHROMYCIN						
AB	ALEMBIC PHARMS LTD	EQ 250MG BASE		A211791	001	Jan 28, 2020	Jan	NEWA
AB		EQ 500MG BASE		A211792	001	Jan 28, 2020	Jan	NEWA
AB		EQ 600MG BASE		A211793	001	Jan 27, 2020	Jan	NEWA
	@ MYLAN	EQ 600MG BASE		A065360	001	Jan 08, 2007	Jan	DISC
	@ YUNG SHIN PHARM	EQ 600MG BASE		A211068	001	May 08, 2020	Jun	DISC
AB		EQ 600MG BASE		A211068	001	May 08, 2020	Apr	NEWA

BACITRACIN

INJECTABLE; INJECTION		BACIIM						
	@ X GEN PHARMS	50,000 UNITS/VIAL		A064153	001	May 09, 1997	Mar	DISC
		BACITRACIN						
	@ AKORN	50,000 UNITS/VIAL		A206719	001	Oct 20, 2017	Mar	DISC
	@ FRESENIUS KABI USA	50,000 UNITS/VIAL		A065116	001	Dec 03, 2002	Mar	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC		LUMI-SPORYN						
AT	+ CASPER PHARMA LLC	EQ 400 UNITS/GM; EQ 3.5MG BASE/GM; EQ 10,000 UNITS/GM		N050417	001		May	CTNA

BACLOFEN

INJECTABLE; INTRATHECAL		BACLOFEN						
	@ MAIA PHARMS INC	0.5MG/ML		A210048	001	Sep 11, 2019	Mar	DISC
	@	2MG/ML		A210048	002	Sep 11, 2019	Mar	DISC
TABLET; ORAL		BACLOFEN						
	@ MYLAN	20MG		A077121	002	Jul 29, 2005	Jan	DISC
	@ MYLAN PHARMS INC	10MG		A090334	001	Feb 18, 2010	Apr	DISC
	@	20MG		A090334	002	Feb 18, 2010	Apr	DISC
AB	RUBICON	5MG		A209102	001	Nov 28, 2017	Apr	CTEC
>A>	AB UNICHEM LABS LTD	10MG		A212067	001	Jul 09, 2020	Jul	NEWA
>A>	AB	20MG		A212067	002	Jul 09, 2020	Jul	NEWA
AB	ZYDUS	5MG		A211659	003	Apr 17, 2020	Apr	NEWA

BARIUM SULFATE

SUSPENSION; ORAL		ENTERO VU 24%						
+!	BRACCO	24% (144GM/600ML)		N208143	008	May 29, 2020	Jun	NEWA

BEDAQUILINE FUMARATETABLET;ORAL
SIRTURO

+ JANSSEN THERAP EQ 20MG BASE N204384 002 May 27, 2020 May NEWA

BEMPEDOIC ACIDTABLET;ORAL
NEXLETOL

+! ESPERION THERAPS INC 180MG N211616 001 Feb 21, 2020 Feb NEWA

BEMPEDOIC ACID; EZETIMIBETABLET;ORAL
NEXLIZET

+! ESPERION THERAPS INC 180MG;10MG N211617 001 Feb 26, 2020 Feb NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE

AB	COREPHARMA	5MG	A077128	001	Mar 08, 2006	Feb CAHN
AB		10MG	A077128	002	Mar 08, 2006	Feb CAHN
AB		20MG	A077128	003	Mar 08, 2006	Feb CAHN
AB		40MG	A077128	004	Mar 08, 2006	Feb CAHN
>D> AB	MYLAN	5MG	A076430	001	Feb 11, 2004	Jul DISC
>A>	@	5MG	A076430	001	Feb 11, 2004	Jul DISC
>D> AB		10MG	A076430	002	Feb 11, 2004	Jul DISC
>A>	@	10MG	A076430	002	Feb 11, 2004	Jul DISC
>D> AB		20MG	A076430	003	Feb 11, 2004	Jul DISC
>A>	@	20MG	A076430	003	Feb 11, 2004	Jul DISC
>D> AB		40MG	A076430	004	Feb 11, 2004	Jul DISC
>A>	@	40MG	A076430	004	Feb 11, 2004	Jul DISC

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	Jun DISC
@		10MG;12.5MG	A078794	002	Aug 21, 2014	Jun DISC
@		20MG;12.5MG	A078794	003	Aug 21, 2014	Jun DISC
@		20MG;25MG	A078794	004	Aug 21, 2014	Jun DISC

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+! BAUSCH 0.4%;0.3% N211039 001 Mar 09, 2020 Mar NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

@	EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Mar DISC
@	SPECGX LLC	50MG	A040773	001	Apr 25, 2007	Apr DISC
@	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

@	MYLAN	1.5%	A206220	001	Mar 18, 2019	Feb DISC
	BEPREVE					
+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB ! GLENMARK GENERICS EQ 0.05% BASE A078930 001 Sep 23, 2008 Feb CHRS

DIPROLENE AF

+ @ MERCK SHARP DOHME EQ 0.05% BASE N019555 001 Apr 27, 1987 Feb DISC

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

@ ACTAVIS MID ATLANTIC EQ 0.05% BASE A070281 001 Jul 31, 1985 Apr DISC

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

>A> AB	CADILA	EQ 0.05% BASE	A214048	001	Jul 14, 2020	Jul CAHN
>A> AB	ZYDUS PHARMS	EQ 0.05% BASE	A214048	001	Jul 14, 2020	Jul NEWA

SPRAY;TOPICAL

BETAMETHASONE DIPROPIONATE									
	@ TARO PHARMS	EQ 0.05% BASE/SPRAY		A211722	001	Jun 17, 2020		Jun	DISC
AB		EQ 0.05% BASE/SPRAY		A211722	001	Jun 17, 2020		Jun	NFTG
SERNIVO									
	+! ENCORE DERMAT	EQ 0.05% BASE/SPRAY		N208079	001	Feb 05, 2016		Jun	CTEC
AB	+!	EQ 0.05% BASE/SPRAY		N208079	001	Feb 05, 2016		Jun	CFTG

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

CREAM;TOPICAL									
>A>	WYNZORA								
>A>	+! MC2	0.064%;0.005%		N213422	001	Jul 20, 2020		Jul	NEWA
SUSPENSION;TOPICAL									
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE									
AB	TOLMAR	0.064%;0.005%		A210765	001	May 11, 2020		Apr	NFTG
AB	+! LEO PHARMA AS	0.064%;0.005%		N022185	001	May 09, 2008		Apr	CFTG

BETHANECHOL CHLORIDE

TABLET;ORAL									
BETHANECHOL CHLORIDE									
AA	! AMNEAL PHARM	5MG		A040855	001	Nov 21, 2007		Jan	CHRS
AA	!	10MG		A040855	002	Nov 21, 2007		Jan	CHRS
AA	!	25MG		A040855	003	Nov 21, 2007		Jan	CHRS
>D> AA		50MG		A040855	004	Nov 21, 2007		Jul	CHRS
>A> AA	!	50MG		A040855	004	Nov 21, 2007		Jul	CHRS
>D> AA	HERITAGE PHARMA	5MG		A091256	001	May 04, 2010		Jul	DISC
>A>	@	5MG		A091256	001	May 04, 2010		Jul	DISC
>D> AA		10MG		A091256	002	May 04, 2010		Jul	DISC
>A>	@	10MG		A091256	002	May 04, 2010		Jul	DISC
>D> AA		25MG		A091256	003	May 04, 2010		Jul	DISC
>A>	@	25MG		A091256	003	May 04, 2010		Jul	DISC
>D> AA		50MG		A091256	004	May 04, 2010		Jul	DISC
>A>	@	50MG		A091256	004	May 04, 2010		Jul	DISC
	@ IMPAX LABS	25MG		A040721	003	Nov 01, 2006		Jan	CMS1
URECHOLINE									
	@ ODYSSEY PHARMS	5MG		A089095	001	Dec 19, 1985		Jan	DISC
	@	10MG		A088440	001	May 29, 1984		Jan	DISC
	@	25MG		A088441	001	May 29, 1984		Jan	DISC
>D> AA	!	50MG		A089096	001	Dec 19, 1985		Jul	DISC
>A>	@	50MG		A089096	001	Dec 19, 1985		Jul	DISC

BEXAROTENE

CAPSULE;ORAL									
BEXAROTENE									
AB	ANI PHARMS INC	75MG		A209861	001	May 08, 2018		Jan	CAHN
AB	HIKMA	75MG		A203663	001	Jun 16, 2020		Jun	NEWA

BICALUTAMIDE

TABLET;ORAL									
BICALUTAMIDE									
	@ MYLAN	50MG		A079185	001	Jul 06, 2009		Jan	DISC

BIMATOPROST

IMPLANT;OPHTHALMIC									
DURYSTA									
	+! ALLERGAN INC	10MCG		N211911	001	Mar 04, 2020		Mar	NEWA
SOLUTION/DROPS;TOPICAL									
BIMATOPROST									
AT	ALEMBIC PHARMS LTD	0.03%		A210515	001	Jan 21, 2020		Jan	NEWA

BISOPROLOL FUMARATE

TABLET;ORAL									
BISOPROLOL FUMARATE									
	@ TEVA PHARMS	5MG		A075644	001	Jun 26, 2001		Apr	DISC
	@	10MG		A075644	002	Jun 26, 2001		Apr	DISC

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>A>	AB	EDENBRIDGE PHARMS	2.5MG; 6.25MG	A212678	001	Jul 09, 2020	Jul	NEWA
>A>	AB		5MG; 6.25MG	A212678	002	Jul 09, 2020	Jul	NEWA
>A>	AB		10MG; 6.25MG	A212678	003	Jul 09, 2020	Jul	NEWA

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

@ APOTEX

250MG/VIAL

A204876 001 Jul 06, 2017 Feb DISC

BOSENTAN

TABLET; ORAL

BOSENTAN

AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan	NEWA
AB			125MG	A211461	002	Jan 23, 2020	Jan	NEWA
		@ CIPLA	62.5MG	A210342	001	Jan 03, 2020	Jun	DISC
		@	125MG	A210342	002	Jan 03, 2020	Jun	DISC
		@ MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan	DISC
		@	125MG	A205173	002	Jan 15, 2020	Jan	DISC

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

>D>	+	AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jul	CAHN
>A>	+	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jul	CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

QOLIANA

AT	+	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Jun	CHRS
AT	+		0.15%	N021764	001	May 22, 2006	Jun	CRLD

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AT2		GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar	NEWA
-----	--	------------------	---------------	---------	-----	--------------	-----	------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

@ MYLAN

EQ 2.5MG BASE

A076962 001 Sep 24, 2004 Jun DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	AA	ALKEM LABS LTD	2MG/5ML; 10MG/5ML; 30MG/5ML	A210647	001	Jul 14, 2020	Jul	NEWA
	AA	LANNETT CO INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A213125	001	Apr 17, 2020	Apr	NEWA
	AA	WES PHARMA INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A211170	001	Jun 16, 2020	Jun	NEWA

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

+! SALIX

2MG/ACTUATION

N205613 001 Oct 07, 2014 Feb CAHN

CAPSULE; ORAL

BUDESONIDE

>D>	AB	APPCO	3MG	A207367	001	Apr 07, 2017	Jul	CAHN
>A>	AB	RISING	3MG	A207367	001	Apr 07, 2017	Jul	CAHN

SUSPENSION; INHALATION

BUDESONIDE

>A>	AN	LUPIN	0.5MG/2ML	A210897	001	Nov 09, 2018	Jul	CAHN
>D>	AN	LUPIN ATLANTIS	0.5MG/2ML	A210897	001	Nov 09, 2018	Jul	CAHN

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

>A> BREZTRI AEROSPHERE

>A> +! ASTRAZENECA AB 0.16MG/INH;0.0048MG/INH;0.009MG/INH N212122 001 Jul 23, 2020 Jul NEWA
HBUMETANIDE

TABLET; ORAL

BUMETANIDE

AB RISING 0.5MG A212019 001 Dec 12, 2019 Jan CAHN
AB 1MG A212019 002 Dec 12, 2019 Jan CAHN
AB 2MG A212019 003 Dec 12, 2019 Jan CAHNBUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

AB AMNEAL 5MCG/HR A211586 001 Apr 14, 2020 Mar NEWA
AB 7.5MCG/HR A211586 002 Apr 14, 2020 Mar NFTG
AB 10MCG/HR A211586 003 Apr 14, 2020 Mar NEWA
AB 15MCG/HR A211586 004 Apr 14, 2020 Mar NEWA
AB 20MCG/HR A211586 005 Apr 14, 2020 Mar NEWA

BUTRANS

AB + PURDUE PHARMA LP 7.5MCG/HR N021306 005 Jun 30, 2014 Mar CFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL

BUNAVAIL

+ @ BDSI EQ 2.1MG BASE; EQ 0.3MG BASE N205637 001 Jun 06, 2014 Jun DISC

+ @ EQ 4.2MG BASE; EQ 0.7MG BASE N205637 002 Jun 06, 2014 Jun DISC

+ @ EQ 6.3MG BASE; EQ 1MG BASE N205637 003 Jun 06, 2014 Jun DISC

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB MYLAN TECHNOLOGIES EQ 2MG BASE; EQ 0.5MG BASE A211785 001 Apr 17, 2020 Apr NEWA
AB EQ 4MG BASE; EQ 1MG BASE A211785 002 Apr 17, 2020 Apr NEWA

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

>A> AB MAYNE PHARMA INC EQ 2MG BASE; EQ 0.5MG BASE A206953 001 Jul 17, 2020 Jul NEWA

>A> AB EQ 8MG BASE; EQ 2MG BASE A206953 002 Jul 17, 2020 Jul NEWA

AB RHODES PHARMS EQ 2MG BASE; EQ 0.5MG BASE A205601 001 Mar 30, 2020 Mar NEWA

AB EQ 8MG BASE; EQ 2MG BASE A205601 002 Mar 30, 2020 Mar NEWA

>A> AB WES PHARMA INC EQ 2MG BASE; EQ 0.5MG BASE A209069 001 Jul 17, 2020 Jul NEWA

>A> AB EQ 8MG BASE; EQ 2MG BASE A209069 002 Jul 17, 2020 Jul NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB CADILA PHARMS LTD 75MG A208606 001 Jan 16, 2020 Jan NEWA

AB 100MG A208606 002 Jan 16, 2020 Jan NEWA

AB MICRO LABS 75MG A207403 001 Apr 17, 2020 Apr NEWA

AB 100MG A207403 002 Apr 17, 2020 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ JUBILANT GENERICS 100MG A202774 001 Oct 11, 2013 Feb DISC

@ 150MG A202774 002 Oct 11, 2013 Feb DISC

@ 150MG A202775 001 Oct 11, 2013 Feb DISC

@ 150MG A207459 001 Jun 30, 2017 Feb DISC

@ 200MG A202774 003 Oct 11, 2013 Feb DISC

@ 300MG A207459 002 Jun 30, 2017 Feb DISC

@ WATSON LABS INC 100MG A077455 001 Jul 19, 2010 Apr DISC

@ 150MG A077455 002 Mar 12, 2008 Apr DISC

@ 200MG A077455 003 Jul 19, 2010 Apr DISC

AB1 YICHANG HUMANWELL 100MG A211347 001 Oct 16, 2018 Jun CMFD

AB1 150MG A211347 002 Oct 16, 2018 Jun CMFD

AB1 200MG A211347 003 Oct 16, 2018 Jun CMFD

AB3 ZHEJIANG JUTAI PHARM 150MG A211200 002 Apr 29, 2020 Jun NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CONTRAVE

+! NALPROPION 90MG;8MG N200063 001 Sep 10, 2014 Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD 7.5MG A078246 005 Feb 21, 2020 Jun NEWA
 AB ! MYLAN 7.5MG A075467 002 Mar 28, 2001 Jun CHRS
 >D> @ OXFORD PHARMS 5MG A075388 001 May 09, 2002 Jul CMFD
 >A> AB 5MG A075388 001 May 09, 2002 Jul CMFD
 >D> @ 10MG A075388 002 May 09, 2002 Jul CMFD
 >A> AB 10MG A075388 002 May 09, 2002 Jul CMFD
 >D> @ 15MG A075388 003 May 09, 2002 Jul CMFD
 >A> AB 15MG A075388 003 May 09, 2002 Jul CMFD

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

AP MYLAN INSTITUTIONAL 6MG/ML A208536 001 Nov 20, 2017 Apr CTNA
 @ MYLAN LABS LTD 6MG/ML A205184 001 Jul 13, 2018 Feb DISC

BUTABARBITAL SODIUM

TABLET;ORAL
BUTISOL SODIUM

+ @ MYLAN SPECIALITY LP 30MG N000793 004 May DISC

CABERGOLINE

TABLET;ORAL
CABERGOLINE

@ MYLAN 0.5MG A202947 001 Dec 02, 2013 Jan DISC

CALCITRIOL

CAPSULE;ORAL
CALCITRIOL

AB SUN PHARM 0.25MCG A204556 001 Feb 21, 2019 Mar CMFD
 AB 0.5MCG A204556 002 Feb 21, 2019 Mar CMFD

INJECTABLE;INJECTION
CALCITRIOL

AP ! AKORN 0.001MG/ML A078066 001 Jan 29, 2008 Jan CTEC
 AP GLAND PHARMA LTD 0.001MG/ML A211030 001 Feb 03, 2020 Jan NEWA

CALCIUM ACETATE

CAPSULE;ORAL
CALCIUM ACETATE

@ LOTUS PHARM CO LTD 667MG A203298 001 Jul 26, 2016 Jan DISC

>A> CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

>A> SOLUTION;ORAL
>A> XYWAV

>A> +! JAZZ 0.234GM/ML;0.096GM/ML;0.13GM/ML;0.4GM/ML N212690 001 Jul 21, 2020 Jul NEWA

CAPECITABINE

TABLET;ORAL
CAPECITABINE

AB RELIANCE LIFE 150MG A211724 001 Apr 27, 2020 Apr NEWA
 AB 500MG A211724 002 Apr 27, 2020 Apr NEWA

CAPMATINIB HYDROCHLORIDE

TABLET;ORAL
TABRECTA

+ NOVARTIS PHARM EQ 150MG BASE N213591 001 May 06, 2020 May NEWA
 +! EQ 200MG BASE N213591 002 May 06, 2020 May NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Feb	CAHN
@		25MG	A074737	002	Oct 28, 1998	Feb	CAHN
@		50MG	A074737	003	Oct 28, 1998	Feb	CAHN
@		100MG	A074737	004	Oct 28, 1998	Feb	CAHN
@	SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	May	DISC
@		25MG	A212223	002	Oct 30, 2019	May	DISC
@		50MG	A212223	003	Oct 30, 2019	May	DISC
@		100MG	A212223	004	Oct 30, 2019	May	DISC
@	TEVA	12.5MG	A074322	001	Feb 13, 1996	Apr	DISC
@		25MG	A074322	002	Feb 13, 1996	Apr	DISC
@		50MG	A074322	003	Feb 13, 1996	Apr	DISC
@		100MG	A074322	004	Feb 13, 1996	Apr	DISC
@	WATSON LABS	12.5MG	A074386	001	May 23, 1996	Apr	DISC
@		25MG	A074386	002	May 23, 1996	Apr	DISC
@		50MG	A074386	003	May 23, 1996	Apr	DISC
@		100MG	A074386	004	May 23, 1996	Apr	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011	May	CMFD
AB		200MG	A076697	002	May 20, 2011	May	CMFD
AB		300MG	A076697	003	May 20, 2011	May	CMFD

TABLET; ORAL

CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Mar	CTEC
AB	UMEDICA LABS PVT LTD	100MG	A207798	001	Apr 15, 2020	Mar	NEWA
AB		200MG	A207798	002	Apr 15, 2020	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	UNIQUE PHARM	100MG	A211623	001	Apr 24, 2020	Apr	NEWA
AB		200MG	A211623	002	Apr 24, 2020	Apr	NEWA
AB		400MG	A211623	003	Apr 24, 2020	Apr	NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>A>	AB	MYLAN	12.5MG; 200MG; 50MG	A203424	001	Aug 13, 2020	Jul	NEWA
>A>	AB		18.75MG; 200MG; 75MG	A203424	002	Aug 13, 2020	Jul	NEWA
>A>	AB		25MG; 200MG; 100MG	A203424	003	Aug 13, 2020	Jul	NEWA
>A>	AB		31.25MG; 200MG; 125MG	A203424	004	Aug 13, 2020	Jul	NEWA
>A>	AB		37.5MG; 200MG; 150MG	A203424	005	Aug 13, 2020	Jul	NEWA
>A>	AB		50MG; 200MG; 200MG	A203424	006	Aug 13, 2020	Jul	NEWA
		STALEVO 125						
>D>	+	ORION PHARMA	31.25MG; 200MG; 125MG	N021485	006	Aug 29, 2008	Jul	CTEC
>A>	AB	+	31.25MG; 200MG; 125MG	N021485	006	Aug 29, 2008	Jul	CTEC
		STALEVO 200						
>D>	+	ORION PHARMA	50MG; 200MG; 200MG	N021485	004	Aug 02, 2007	Jul	CTEC
>A>	AB	+	50MG; 200MG; 200MG	N021485	004	Aug 02, 2007	Jul	CTEC
		STALEVO 50						
>D>	+	ORION PHARMA	12.5MG; 200MG; 50MG	N021485	001	Jun 11, 2003	Jul	CTEC
>A>	AB	+	12.5MG; 200MG; 50MG	N021485	001	Jun 11, 2003	Jul	CTEC
		STALEVO 75						
>D>	+	ORION PHARMA	18.75MG; 200MG; 75MG	N021485	005	Aug 29, 2008	Jul	CTEC
>A>	AB	+	18.75MG; 200MG; 75MG	N021485	005	Aug 29, 2008	Jul	CTEC

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

+	@	MERCK SHARP DOHME	25MG; 100MG	N019856	002	Dec 24, 1992	Jan	DISC
---	---	-------------------	-------------	---------	-----	--------------	-----	------

CARBOPLATININJECTABLE; INJECTION
CARBOPLATIN

>A> AP EUGIA PHARMA 600MG/60ML (10MG/ML) A205487 004 Aug 03, 2020 Jul NEWA

INJECTABLE; INTRAVENOUS
CARBOPLATIN

>A> ! ACCORD HLTHCARE 1GM/100ML (10MG/ML) A206775 005 Apr 06, 2020 Jul NEWA
 @ EUGIA PHARMA 50MG/5ML (10MG/ML) A205487 001 Mar 28, 2016 Mar DISC
 @ 150MG/15ML (10MG/ML) A205487 002 Mar 28, 2016 Mar DISC
 @ 450MG/45ML (10MG/ML) A205487 003 Mar 28, 2016 Mar DISC
 @ PLIVA LACHEMA 50MG/5ML (10MG/ML) A078631 001 Dec 02, 2008 Apr DISC
 @ 150MG/15ML (10MG/ML) A078631 002 Dec 02, 2008 Apr DISC
 @ 450MG/45ML (10MG/ML) A078631 003 Dec 02, 2008 Apr DISC
 @ 600MG/60ML (10MG/ML) A078631 004 Dec 02, 2008 Apr DISC
 @ TEVA PHARMS USA 50MG/5ML (10MG/ML) A077139 001 Sep 21, 2005 May DISC
 @ 150MG/15ML (10MG/ML) A077139 002 Sep 21, 2005 May DISC
 @ 450MG/45ML (10MG/ML) A077139 003 Sep 21, 2005 May DISC
 @ 600MG/60ML (10MG/ML) A077139 004 Sep 21, 2005 May DISC

CARFILZOMIBPOWDER; INTRAVENOUS
CARFILZOMIB

AP APOTEX 30MG/VIAL A211185 001 Mar 20, 2020 Mar NFTG
 AP 60MG/VIAL A209425 001 Mar 16, 2020 Mar NEWA
 KYPROLIS
 AP + ONYX THERAP 30MG/VIAL N202714 002 Jun 03, 2016 Mar CFTG

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

@ HIKMA INTL PHARMS 350MG A040124 001 Jan 24, 1996 Feb DISC
 AA OXFORD PHARMS 350MG A040188 001 Mar 07, 1997 Apr CMFD

>A> CEDAZURIDINE; DECITABINE

>A> TABLET; ORAL
 >A> INQOVI
 >A> +! OTSUKA 100MG; 35MG N212576 001 Jul 07, 2020 Jul NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

>A> AP ASTRAL EQ 1GM BASE/VIAL A212721 001 Jul 21, 2020 Jul NEWA
 >A> AP EQ 2GM BASE/VIAL A212721 002 Jul 21, 2020 Jul NEWA

CEFIXIMEFOR SUSPENSION; ORAL
SUPRAX

@ LUPIN PHARMS 100MG/5ML A065129 001 Feb 23, 2004 Jan DISC

TABLET; ORAL
SUPRAX

@ LUPIN PHARMS 400MG A065130 001 Feb 12, 2004 Jan DISC

CEFOXITIN SODIUMINJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER

@ MYLAN INSTITUTIONAL EQ 20MG BASE/ML A063182 001 Jan 25, 1993 Mar DISC
 @ EQ 40MG BASE/ML A063182 002 Jan 25, 1993 Mar DISC

CEFPROZILFOR SUSPENSION; ORAL
CEFPROZIL

@ TEVA PHARMS 125MG/5ML A065236 001 Dec 08, 2005 Apr DISC
 @ 250MG/5ML A065236 002 Dec 08, 2005 Apr DISC

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB NANJING 200MG A213598 001 May 13, 2020 Apr NEWA
 AB TIANJIN TIANYAO 50MG A207872 001 Feb 25, 2020 Feb NEWA
 AB 100MG A207872 002 Feb 25, 2020 Feb NEWA
 AB 200MG A207872 003 Feb 25, 2020 Feb NEWA

CAPSULE;ORAL
CELECOXIB

AB		400MG	A207872	004	Feb 25, 2020	Feb	NEWA
AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan	CDFR
AB		100MG	A210628	002	Nov 27, 2019	Jan	CDFR
AB		200MG	A210628	003	Nov 27, 2019	Jan	CDFR
AB		400MG	A210628	004	Nov 27, 2019	Jan	CDFR
AB	YILING PHARM LTD	50MG	A211412	001	Mar 06, 2020	Feb	NEWA
AB		100MG	A211412	002	Mar 06, 2020	Feb	NEWA
AB		200MG	A211412	003	Mar 06, 2020	Feb	NEWA
AB		400MG	A211412	004	Mar 06, 2020	Feb	NEWA

SOLUTION;ORAL
ELYXYB

+!	DR REDDYS	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN
+!		25MG/ML	N212157	001	May 05, 2020	May	NEWA

CENOAMATE

TABLET;ORAL
XCOPRI

+	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Mar	NEWA
+		25MG	N212839	002	Mar 10, 2020	Mar	NEWA
+		50MG	N212839	003	Mar 10, 2020	Mar	NEWA
+		100MG	N212839	004	Mar 10, 2020	Mar	NEWA
+		150MG	N212839	005	Mar 10, 2020	Mar	NEWA
+!		200MG	N212839	006	Mar 10, 2020	Mar	NEWA

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

>A>	AB	MISEMER	5MG;2.5MG	A210579	001	Jul 29, 2020	Jul	NEWA
>A>	AB	SUNRISE PHARM INC	5MG;2.5MG	A211421	001	Jul 07, 2020	Jul	NFTG
		LIBRAX						
>D>	+!	BAUSCH	5MG;2.5MG	N012750	001		Jul	CFTG
>A>	AB	+!	5MG;2.5MG	N012750	001		Jul	CFTG
		+!	5MG;2.5MG	N012750	001		Jun	CAHN

CHLOROQUINE PHOSPHATE

TABLET;ORAL

ARALEN

+	@	SANOFI AVENTIS US	500MG	N006002	001		Apr	CPOT
		CHLOROQUINE PHOSPHATE						
	@	HIKMA PHARMS	EQ 150MG BASE	A083082	001		Feb	DISC
	@		250MG	A083082	001		Apr	CPOT
AA			500MG	A083082	002	Sep 17, 1999	Apr	CPOT
	@	IMPAX LABS	250MG	A080880	001		Apr	CPOT
	@		500MG	A040516	001	Aug 29, 2003	Apr	CPOT
AA		IPCA LABS LTD	250MG	A090610	001	Dec 03, 2009	Apr	CPOT
AA			500MG	A090249	001	Dec 03, 2009	Apr	CPOT
	@	MD PHARM	250MG	A087228	001		Apr	CPOT
AA	!	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb	CHRS
AA	!		250MG	A091621	001	Jan 21, 2011	Apr	CPOT
AA	!		500MG	A090612	001	Jan 21, 2011	Apr	CPOT
	@	PUREPAC PHARM	250MG	A080886	001		Apr	CPOT
	@	TEVA	250MG	A087504	001	Jan 13, 1982	Apr	CPOT
	@	WATSON LABS	250MG	A087979	001	Dec 21, 1982	Apr	CPOT
	@		500MG	A088030	001	Dec 21, 1982	Apr	CPOT

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>A>	AP	AUROBINDO PHARMA LTD	25MG/ML	A211816	001	Jul 07, 2020	Jul	NEWA
>D>	!	WEST-WARD PHARMS INT	25MG/ML	A083329	001		Jul	CTEC
>A>	AP	!	25MG/ML	A083329	001		Jul	CTEC

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan	NEWA
AB			25MG	A213368	002	Jan 17, 2020	Jan	NEWA
AB			50MG	A213368	003	Jan 17, 2020	Jan	NEWA
AB			100MG	A213368	004	Jan 17, 2020	Jan	NEWA
AB			200MG	A213368	005	Jan 17, 2020	Jan	NEWA

CHLOROTHALIDONE

TABLET; ORAL

CHLOROTHALIDONE

AB	ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan	NEWA
AB		50MG	A213412	002	Feb 11, 2020	Jan	NEWA
AB	VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb	CAHN
AB		50MG	A211063	002	Feb 26, 2019	Feb	CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	AUROLIFE PHARMA LLC	500MG	A089853	001	May 04, 1988	Jun	CMFD
AB	GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020	May	NEWA
AB		750MG	A212185	002	May 26, 2020	May	NEWA
>A>	AB	MAYNE PHARMA	A211849	001	Jul 21, 2020	Jul	NEWA
>A>	AA		A211849	002	Jul 21, 2020	Jul	NEWA
>A>	AB		A211849	003	Jul 21, 2020	Jul	NEWA
AB	TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020	Jun	NEWA
AB		750MG	A212898	002	Jun 17, 2020	Jun	NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A211119	001	Apr 06, 2020	Mar	NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A211119	002	Apr 06, 2020	Mar	NEWA
	LOCHOLEST						
	@ ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb	CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb	CAHN
	@ INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan	CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan	CAHN
	LOCHOLEST LIGHT						
	@ ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb	CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	MICRO LABS	EQ 45MG FENOFIBRIC ACID	A213450	001	Jun 16, 2020	Jun	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A213450	002	Jun 16, 2020	Jun	NEWA
AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CMFD
AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CMFD

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

	@ DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	May	DISC
--	-------------------	-------------------	---------	-----	--------------	-----	------

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 30MG BASE	A211892	001	May 15, 2020	May	NEWA
AB		EQ 60MG BASE	A211892	002	May 15, 2020	May	NEWA
AB		EQ 90MG BASE	A211892	003	May 15, 2020	May	NEWA
AB	ACME LABS	EQ 30MG BASE	A213325	001	May 18, 2020	May	NEWA
AB		EQ 60MG BASE	A213325	002	May 18, 2020	May	NEWA
AB		EQ 90MG BASE	A213325	003	May 18, 2020	May	NEWA
	@ LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan	DISC
	@	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan	DISC
	@	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan	DISC

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPROFLOXACIN

>A>	@ CHARTWELL	250MG/5ML	A200563	001	Mar 05, 2014	Jul	CAHN
>A>	@	500MG/5ML	A200563	002	Mar 05, 2014	Jul	CAHN
>D>	@ LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Jul	CAHN
>D>	@	500MG/5ML	A200563	002	Mar 05, 2014	Jul	CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

>D>	+	NOVARTIS	0.3%;0.1%	N021537	001	Jul 18, 2003	Jul CFTG
>A>	AB	+	0.3%;0.1%	N021537	001	Jul 18, 2003	Jul CFTG
>A>		CIPROFLOXACIN AND DEXAMETHASONE					
>A>	AB	DR REDDYS LABS LTD	0.3%;0.1%	A205548	001	Aug 10, 2020	Jul NFTG

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Apr NEWA
AP		HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan CMFD
AP		PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190	001	May 04, 2020	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

	@	JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar DISC
	@		EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar DISC
	@		EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar DISC

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

PHEXXI

+	!	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020	May NEWA
---	---	------------	--------------	---------	-----	--------------	----------

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

>A>	!	GENUS	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	Jul CAHN
>D>	!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	Jul CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

	@	TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	May DISC
AT			1%	A210004	001	Mar 11, 2020	Feb NEWA

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

>A>	AB	SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Jul NEWA
-----	----	---------------------	------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

>D>	AP	ALVOGEN INC	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Jul DISC
>A>		@	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Jul DISC

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	AT	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jul DISC	
>A>		@	EQ 1% BASE	A062811	001	Sep 01, 1988	Jul DISC	
		@	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	Jun DISC

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB		HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb NEWA	
AB		LANNETT CO INC	2.5MG/ML	A213110	001	Apr 24, 2020	Apr NEWA	
		@	TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Apr DISC
AB			2.5MG/ML	A211032	001	Jan 31, 2020	Jan NEWA	

TABLET;ORAL

CLOBAZAM

AB		APOTEX	10MG	A209853	001	Jun 09, 2020	Jun NEWA
AB			20MG	A209853	002	Jun 09, 2020	Jun NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan NEWA
		CLOBETASOL PROPIONATE (EMOLLIENT)					
AB2		ANI PHARMS INC	0.05%	A075733	001	Aug 22, 2001	Jun CAHN
AB2		INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	May CAHN

	LOTION; TOPICAL						
	IMPEKLO						
	+!	MYLAN	0.05%	N213691	001	May 19, 2020	Jun CAHN
	+!	MYLAN LABS INC	0.05%	N213691	001	May 19, 2020	May NEWA
	SHAMPOO; TOPICAL						
	CLOBETASOL PROPIONATE						
AB		ALEOR DERMACEUTICALS	0.05%	A213290	001	May 18, 2020	May NEWA
	SPRAY; TOPICAL						
	CLOBETASOL PROPIONATE						
	@	ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Jan DISC
	<u>CLOCORTOLONE PIVALATE</u>						
	CREAM; TOPICAL						
	CLOCORTOLONE PIVALATE						
AB		TARO	0.1%	A206370	001	Apr 21, 2020	Apr NFTG
	CLODERM						
AB	+!	EPI HLTH	0.1%	N017765	001		Apr CFTG
	<u>CLOMIPHENE CITRATE</u>						
	TABLET; ORAL						
	MILOPHENE						
>A>	@	GRANATA BIO	50MG	A072196	001	Dec 20, 1988	Jul CAHN
>D>	@	MILEX	50MG	A072196	001	Dec 20, 1988	Jul CAHN
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>						
	CAPSULE; ORAL						
	CLOMIPRAMINE HYDROCHLORIDE						
AB		LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan NEWA
AB			50MG	A211364	002	Feb 07, 2020	Jan NEWA
AB			75MG	A211364	003	Feb 07, 2020	Jan NEWA
AB		MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan CMFD
AB			50MG	A211767	002	Apr 08, 2019	Jan CMFD
AB			75MG	A211767	003	Apr 08, 2019	Jan CMFD
AB		MICRO LABS	25MG	A213219	001	Jun 22, 2020	Jun NEWA
AB			50MG	A213219	002	Jun 22, 2020	Jun NEWA
AB			75MG	A213219	003	Jun 22, 2020	Jun NEWA
	@	TEVA	25MG	A074958	001	Aug 26, 1997	Feb DISC
	@		50MG	A074958	002	Aug 26, 1997	Feb DISC
	@		75MG	A074958	003	Aug 26, 1997	Feb DISC
AB		TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Mar NEWA
AB			50MG	A210653	002	Apr 03, 2020	Mar NEWA
AB			75MG	A210653	003	Apr 03, 2020	Mar NEWA
>A>	AB	UNIQUE PHARM LABS	25MG	A212285	001	Aug 07, 2020	Jul NEWA
>A>	AB		50MG	A212285	002	Aug 07, 2020	Jul NEWA
>A>	AB		75MG	A212285	003	Aug 07, 2020	Jul NEWA
AB		VGYAAN	25MG	A213221	001	Jun 22, 2020	Jun NEWA
AB			50MG	A213221	002	Jun 22, 2020	Jun NEWA
AB			75MG	A213221	003	Jun 22, 2020	Jun NEWA
	<u>CLONAZEPAM</u>						
	TABLET; ORAL						
	CLONAZEPAM						
	@	MYLAN	0.5MG	A075150	001	Oct 05, 1998	May DISC
	@		1MG	A075150	002	Oct 05, 1998	Jun DISC
	@		2MG	A075150	003	Oct 05, 1998	May DISC
	<u>CLONIDINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	CLONIDINE HYDROCHLORIDE						
AP		XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb CAHN
AP			5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb CAHN
	TABLET; ORAL						
	CLONIDINE HYDROCHLORIDE						
	@	AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May CAHN
	@		0.2MG	A070886	001	Aug 31, 1988	May CAHN
	@		0.3MG	A070886	003	Aug 31, 1988	May CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	CLONIDINE HYDROCHLORIDE						
AB1		UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	Feb CMFD

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	!	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	May	CHRS
		@ CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jun	DISC
		@	EQ 300MG BASE	A202266	002	Nov 20, 2012	Jun	DISC
AB		GRAVITI PHARMS	EQ 75MG BASE	A204359	001	Feb 02, 2017	Apr	CAHN
>A>	AB	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Jul	NEWA
>A>	AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Jul	NEWA
		PLAVIX						
AB	+	SANOFI AVENTIS US	EQ 300MG BASE	N020839	002	Sep 20, 2007	May	CHRS

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG
 @ 7.5MG

A072112 002 Aug 26, 1988 Feb CMS1
 A072112 003 Aug 26, 1988 Feb CMS1

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

NUMBRINO

CODY LABS INC 4%

N209575 001 Jan 10, 2020 Jan NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		PHARM ASSOC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Jun	CAHN
AA	!	NOSTRUM LABS INC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Jun	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE WITH CODEINE

@ PHARM ASSOC 10MG/5ML; 6.25MG/5ML
 @ VINTAGE 10MG/5ML; 6.25MG/5ML

A040650 001 Jan 31, 2006 Jun CAHN
 A040650 001 Jan 31, 2006 Apr DISC

COLCHICINE

TABLET;ORAL

COLCHICINE

AB		AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan	CMFD
AB		GRANULES PHARMS	0.6MG	A210425	001	Feb 05, 2020	Jan	NEWA
>A>		ZYDUS PHARMS	0.3MG	A211519	002	Nov 14, 2019	Jul	NEWA
>D>		@	0.6MG	A211519	001	Feb 19, 2019	Jul	CMFD
>A>	AB		0.6MG	A211519	001	Feb 19, 2019	Jul	CMFD

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL

WELCHOL

+ @ DAIICHI SANKYO INC 3.75GM

N210895 001 Apr 03, 2019 Jun DISC

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		INVAGEN PHARMS	625MG	A212602	001	Apr 20, 2020	Apr	NEWA
>A>	AB	ZHEJIANG JINGXIN	625MG	A209946	001	Jul 15, 2020	Jul	NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP XGEN PHARMS EQ 150MG BASE/VIAL

A064216 001 Feb 26, 1999 Feb CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

>A> SOLUTION;INTRAVENOUS

>A> TRALEMENT

>A> +! AM REGENT EQ 0.3MG COPPER/ML;EQ 55MCG
 BASE/ML;EQ 60MCG BASE/ML;EQ 3MG
 BASE/ML

N209376 001 Jul 02, 2020 Jul NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	10MG	A073144	001	May 30, 1991	Jun	CHRS
AB	! RUBICON	10MG	A208170	003	May 31, 2017	Jun	CHRS
>A>	AB UNICHEM LABS LTD	5MG	A213324	001	Jul 06, 2020	Jul	NEWA
>A>	AB	7.5MG	A213324	002	Jul 06, 2020	Jul	NEWA
>A>	AB	10MG	A213324	003	Jul 05, 2020	Jul	NEWA

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	ANI PHARMS INC	25MG	A207014	001	Mar 19, 2018	Jan	CAHN	
AB		50MG	A207014	002	Mar 19, 2018	Jan	CAHN	
SOLUTION; INTRAVENOUS								
CYCLOPHOSPHAMIDE								
>A>	+!	INGENUS PHARMS LLC	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jul	NEWA
>A>	+!		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jul	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	APPCO	4MG	A206553	001	Nov 29, 2016	Mar	CAHN
	@ PAR PHARM	4MG	A087129	001		May	DISC

CYSTEAMINE BITARTRATE

GRANULE; ORAL

PROCYSBI

>D>	+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Jul	CDFR
>D>	+		EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Feb	NEWA
>D>	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Jul	CDFR
>D>	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Feb	NEWA
GRANULE, DELAYED RELEASE; ORAL								
>A>								
>A>	+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Jul	CDFR
>A>	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Jul	CDFR

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

NOURESS

>D>	+	@ AVADEL LEGACY	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	Jul	CAHN
	+	@	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	May	CRLD
		@	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	May	DISC
>A>	+	@ EXELA PHARMA	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	Jul	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	HONG KONG	20MG/ML	A206189	001	Jun 26, 2020	Jun	NEWA
----	-----------	---------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	ALKEM LABS LTD	EQ 75MG BASE	A208040	001	Mar 11, 2020	Feb	NFTG	
AB		EQ 150MG BASE	A208040	002	Mar 11, 2020	Feb	NFTG	
AB	HETERO LABS LTD III	EQ 75MG BASE	A207961	001	May 06, 2020	Apr	NEWA	
AB		EQ 150MG BASE	A207961	002	May 06, 2020	Apr	NEWA	
PRADAXA								
AB	+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb	CFTG
AB	+!		EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb	CFTG

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP	XGEN PHARMS	0.5MG/VIAL	A203999	001	May 20, 2019	Feb	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
DALFAMPRIDINE

>A>	@ MYLAN	10MG	A206858	001	Jul 06, 2020	Jul	DISC
>A>	AB	10MG	A206858	001	Jul 06, 2020	Jul	NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION
REVONTO

AP	USWM	20MG/VIAL	A078378	001	Jul 24, 2007	Jun	CAHN
----	------	-----------	---------	-----	--------------	-----	------

DAPSONE

GEL; TOPICAL
ACZONE

AB	+! ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun	CTEC
AB	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Feb	NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

@	ALAN LABS INC	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Apr	DISC
@		EQ 15MG BASE	A209571	001	Oct 22, 2019	Apr	DISC
@	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb	DISC
@		EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb	DISC

DEFERASIROX

GRANULE; ORAL

>A>	DEFERASIROX							
>A>	AB	ALKEM LABS LTD	90MG	A213374	001	Jul 14, 2020	Jul	NFTG
>A>	AB		180MG	A213374	002	Jul 14, 2020	Jul	NFTG
>A>	AB		360MG	A213374	003	Jul 14, 2020	Jul	NFTG
>D>	+ NOVARTIS	90MG	N207968	001	May 18, 2017	Jul	CFTG	
>A>	AB	90MG	N207968	001	May 18, 2017	Jul	CFTG	
>D>	+ 180MG	180MG	N207968	002	May 18, 2017	Jul	CFTG	
>A>	AB	180MG	N207968	002	May 18, 2017	Jul	CFTG	
>D>	+! 360MG	360MG	N207968	003	May 18, 2017	Jul	CFTG	
>A>	AB	360MG	N207968	003	May 18, 2017	Jul	CFTG	

TABLET; ORAL

DEFERASIROX

AB	ALEMBIC PHARMS LTD	180MG	A211824	003	Jun 15, 2020	Jun	NEWA
AB	ALKEM LABS LTD	90MG	A210555	001	Mar 30, 2020	Mar	NEWA
>A>	AB	180MG	A210555	003	Jul 02, 2020	Jul	NEWA
AB		360MG	A210555	002	Mar 30, 2020	Mar	NEWA
AB	AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb	CAHN
AB		180MG	A210727	003	Jun 15, 2020	Jun	NEWA
AB		360MG	A210727	002	Dec 27, 2019	Feb	CAHN
AB	CIPLA	90MG	A211852	001	Feb 11, 2020	Jan	NEWA
AB		180MG	A211852	003	Jun 15, 2020	Jun	NEWA
AB		360MG	A211852	002	Feb 11, 2020	Jan	NEWA
AB	MSN	180MG	A210945	003	Jun 16, 2020	Jun	NEWA
AB	PIRAMAL HLTHCARE UK	180MG	A212995	003	Jun 15, 2020	Jun	NEWA
AB	SUN PHARM	180MG	A211641	003	Jun 15, 2020	Jun	NEWA
AB	TEVA PHARMS USA	180MG	A209223	003	Apr 24, 2020	Apr	NEWA
AB	ZYDUS PHARMS	180MG	A211383	003	Jun 15, 2020	Jun	NEWA

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB	ZYDUS PHARMS	125MG	A208882	001	May 05, 2020	Apr	NEWA
AB		250MG	A208882	002	May 05, 2020	Apr	NEWA
AB		500MG	A208882	003	May 05, 2020	Apr	NEWA

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

+	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Mar	CAHN
+	!	100MG/ML	N208030	001	Sep 09, 2015	Mar	CAHN

TABLET; ORAL

FERRIPROX

+	!	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CAHN
+			1GM	N021825	002	Jul 25, 2019	Mar	CAHN

		TABLET;ORAL							
		FERRIPROX							
		+!	1GM		N212269	001	May 19, 2020	May	NEWA
		<u>DEFEROXAMINE MESYLATE</u>							
		INJECTABLE;INJECTION							
		DEFEROXAMINE MESYLATE							
>D>	AP	HOSPIRA	2GM/VIAL		A076019	002	Mar 17, 2004	Jul	CHRS
>A>	AP	!	2GM/VIAL		A076019	002	Mar 17, 2004	Jul	CHRS
		DESFERAL							
>D>	AP	+! NOVARTIS	2GM/VIAL		N016267	002	May 25, 2000	Jul	DISC
>A>		+ @	2GM/VIAL		N016267	002	May 25, 2000	Jul	DISC
		<u>DELAVIRDINE MESYLATE</u>							
		TABLET;ORAL							
		RESCRIPTOR							
		+ @ VIIV HLHCARE	200MG		N020705	002	Jul 14, 1999	Mar	DISC
		<u>DESMOPRESSIN ACETATE</u>							
		INJECTABLE;INJECTION							
		DESMOPRESSIN ACETATE							
	AP	UBI	0.004MG/ML		A210218	001	Feb 14, 2020	Feb	NEWA
		TABLET;ORAL							
		DESMOPRESSIN ACETATE							
>D>	AB	MYLAN	0.1MG		A200653	001	Jun 27, 2014	Jul	DISC
>A>		@	0.1MG		A200653	001	Jun 27, 2014	Jul	DISC
>D>	AB		0.2MG		A200653	002	Jun 27, 2014	Jul	DISC
>A>		@	0.2MG		A200653	002	Jun 27, 2014	Jul	DISC
		<u>DESOGESTREL; ETHINYL ESTRADIOL</u>							
		TABLET;ORAL-28							
		DESOGESTREL AND ETHINYL ESTRADIOL							
	AB	NAARI PTE LTD	0.15MG,N/A;0.02MG,0.01MG		A209170	001	Jun 05, 2017	Jun	CAHN
		@	0.15MG;0.03MG		A207067	001	Sep 13, 2018	Jun	CAHN
		EMOQUETTE							
		@ VINTAGE PHARMS LLC	0.15MG;0.03MG		A076675	001	Feb 25, 2011	Apr	DISC
		SIMLIYA							
	AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG		A206853	001	Mar 22, 2017	Mar	CTNA
		<u>DESONIDE</u>							
		GEL;TOPICAL							
		DESONATE							
	AB	+! LEO PHARMA AS	0.05%		N021844	001	Oct 20, 2006	Apr	CFTG
		DESONIDE							
	AB	TERESINA	0.05%		A202470	001	May 11, 2020	Apr	NFTG
		<u>DESOXIMETASONE</u>							
		CREAM;TOPICAL							
		DESOXIMETASONE							
	AB	CADILA	0.25%		A205620	001	Sep 28, 2018	Mar	CMFD
	AB	COSETTE	0.25%		A209595	001	Mar 04, 2020	Feb	NEWA
		<u>DESVENLAFAXINE SUCCINATE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		DESVENLAFAXINE SUCCINATE							
		@ MYLAN	EQ 50MG BASE		A204095	001	Jun 29, 2015	Feb	DISC
	AB	YICHANG HUMANWELL	EQ 50MG BASE		A210014	001	Oct 01, 2018	Jun	CMFD
	AB		EQ 100MG BASE		A210014	002	Oct 01, 2018	Jun	CMFD
		<u>DEXAMETHASONE SODIUM PHOSPHATE</u>							
		INJECTABLE;INJECTION							
		DEXAMETHASONE SODIUM PHOSPHATE							
	AP	AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML		A210966	001	Jun 05, 2020	Jun	NEWA
		<u>DEXAMETHASONE; TOBRAMYCIN</u>							
		SUSPENSION/DROPS;OPHTHALMIC							
		TOBRADEX ST							
		+! EYEVANCE	0.05%;0.3%		N050818	001	Feb 13, 2009	Feb	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A207551	001	May 20, 2020	May	NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A207551	002	May 20, 2020	May	NEWA
AP	GLAND PHARMA LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209307	001	Jun 03, 2020	May	NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209307	002	Jun 03, 2020	May	NEWA
AP	HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan	NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan	NEWA
AP	JIANGSU HENGRUI MED	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A209065	002	Jun 12, 2020	Jun	NEWA
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun	CTNA
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan	CTNA
AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209065	003	Jun 12, 2020	Jun	NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209065	004	Jun 12, 2020	Jun	NEWA
	PRECEDEX						
+!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	Jun	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Mar	NEWA
AB		10MG	A209754	002	Mar 24, 2020	Mar	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

	@ PII	5MG	A205077	001	Jun 21, 2019	Jan	DISC
	@	10MG	A205077	002	Jun 21, 2019	Jan	DISC
	@	15MG	A205077	003	Jun 21, 2019	Jan	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA	! SLATE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Mar	CMFD
	@	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Feb	CAHN
		PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
AA	AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Mar	CMFD
	@ HI TECH PHARMA	15MG/5ML; 6.25MG/5ML	A040027	001	Jul 31, 1996	Mar	DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ FRESSENIUS KABI USA	2.5GM/100ML; 450MG/100ML	A211190	001	Dec 20, 2019	Jun	DISC
--	-----------------------	--------------------------	---------	-----	--------------	-----	------

DIAZEPAM

SPRAY; NASAL

VALTOCO

+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan	NEWA
+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan	NEWA
+!		10MG/SPRAY	N211635	003	Jan 10, 2020	Jan	NEWA

DIAZOXIDE

SUSPENSION; ORAL

DIAZOXIDE

>A>	AB	NOVITIUM PHARMA	50MG/ML	A210799	001	Jul 08, 2020	Jul	NEWA
-----	----	-----------------	---------	---------	-----	--------------	-----	------

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL

FLECTOR

+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb	CDFR
	LICART						
+!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Apr	CHRS
+		1.3%	N206976	001	Dec 19, 2018	Apr	CMFD

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

@ STRIDES PHARMA

25MG

A210078 001 Dec 03, 2019 Jun DISC

TABLET; ORAL

CATAFLAM

+	@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan	CRLD
---	------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

>D>	@ APOTEX INC	0.1%	A077600	001	Nov 13, 2008	Jul	CAHN
>A>	@ RUBICON	0.1%	A077600	001	Nov 13, 2008	Jul	CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

@ MICRO LABS USA

50MG

A074986 001 Feb 26, 1999 Mar CAHN

@

75MG

A074986 002 Feb 26, 1999 Mar CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	YUNG SHIN PHARM	50MG;0.2MG	A205143	001	Feb 19, 2020	Feb	NEWA
AB		75MG;0.2MG	A205143	002	Feb 19, 2020	Feb	NEWA

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

AA	!	GENERICS	10MG/5ML	A040169	001	Mar 24, 2005	May	CTEC
AA		HIKMA	10MG/5ML	A212286	001	May 22, 2020	May	NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

AUROBINDO PHARMA

125MG

A090094 001 Sep 24, 2008 Jun CTEC

200MG

A090094 002 Sep 24, 2008 Jun CTEC

250MG

A090094 003 Sep 24, 2008 Jun CTEC

!

400MG

A090094 004 Sep 24, 2008 Jun CHRS

400MG

A090094 004 Sep 24, 2008 Jun CTEC

VIDEX EC

+	@ BRISTOL MYERS SQUIBB	125MG	N021183	001	Oct 31, 2000	Jun	DISC
+	@	200MG	N021183	002	Oct 31, 2000	Jun	DISC
+	@	250MG	N021183	003	Oct 31, 2000	Jun	DISC
+	@	400MG	N021183	004	Oct 31, 2000	Jun	DISC

FOR SOLUTION; ORAL

VIDEX

+	@ BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991	Jun	DISC
---	------------------------	---------	---------	-----	--------------	-----	------

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

+	@ NOSTRUM LABS INC	25MG	N011722	002		Mar	CAHN
---	--------------------	------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

+	@ NOSTRUM LABS INC	75MG	N012546	001		Mar	CAHN
---	--------------------	------	---------	-----	--	-----	------

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

AB	CIPLA	0.5MG/SPRAY	A212907	001	May 20, 2020	May	NEWA	
AB	CUSTOPHARM INC	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Feb	NFTG	
	MIGRANAL							
AB	+!	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Feb	CFTG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	ACCORD HLTHCARE	120MG	A206997	001	Apr 28, 2020	Apr	NEWA
AB2		180MG	A206997	002	Apr 28, 2020	Apr	NEWA
AB2		240MG	A206997	003	Apr 28, 2020	Apr	NEWA
AB2	APOTEX	120MG	A074943	003	Dec 19, 2000	Apr	CTEC
	DILTZAC						
	@ APOTEX	120MG	A076395	001	Feb 01, 2006	Apr	DISC
	@	180MG	A076395	002	Feb 01, 2006	Apr	DISC
	@	240MG	A076395	003	Feb 01, 2006	Apr	DISC
	@	300MG	A076395	004	Feb 01, 2006	Apr	DISC
	@	360MG	A076395	005	Feb 01, 2006	Apr	DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL
NORPACE

>D>	AB	+	GD SEARLE LLC	EQ 100MG BASE	N017447	001	Jul	CAHN
>D>	AB	+	!	EQ 150MG BASE	N017447	002	Jul	CAHN
>A>	AB	+	PFIZER	EQ 100MG BASE	N017447	001	Jul	CAHN
>A>	AB	+	!	EQ 150MG BASE	N017447	002	Jul	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
NORPACE CR

>D>	+	GD SEARLE LLC	EQ 100MG BASE	N018655	001	Jul 20, 1982	Jul	CAHN
>D>	+	!	EQ 150MG BASE	N018655	002	Jul 20, 1982	Jul	CAHN
>A>	+	PFIZER	EQ 100MG BASE	N018655	001	Jul 20, 1982	Jul	CAHN
>A>	+	!	EQ 150MG BASE	N018655	002	Jul 20, 1982	Jul	CAHN

DISULFIRAM

TABLET;ORAL
DISULFIRAM

	@	HIKMA	250MG	A202652	001	Feb 05, 2014	Feb	DISC
	@		500MG	A202652	002	Feb 05, 2014	Feb	DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL
DIVALPROEX SODIUM

AB	AJANTA PHARMA LTD	EQ 125MG VALPROIC ACID	A213181	001	Mar 02, 2020	Feb	NEWA
	@ MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan	DISC

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

	@	MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan	DISC
	@		EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan	DISC
	@		EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

	@	LUPIN LTD	EQ 250MG VALPROIC ACID	A209286	001	Oct 18, 2019	Apr	DISC
	@		EQ 500MG VALPROIC ACID	A209286	002	Oct 18, 2019	Apr	DISC

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan	CMFD
AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan	CMFD
AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan	CMFD

DOFETILIDE

CAPSULE;ORAL
DOFETILIDE

AB	ACCORD HLTHCARE	0.125MG	A213338	001	Jun 19, 2020	Jun	NEWA
AB		0.25MG	A213338	002	Jun 19, 2020	Jun	NEWA
AB		0.5MG	A213338	003	Jun 19, 2020	Jun	NEWA
AB	MSN	0.125MG	A213220	001	Jan 29, 2020	Jan	NEWA
AB		0.25MG	A213220	002	Jan 29, 2020	Jan	NEWA
AB		0.5MG	A213220	003	Jan 29, 2020	Jan	NEWA

DOLUTEGRAVIR SODIUM

TABLET, FOR SUSPENSION;ORAL
TIVICAY PD

+! VIIV HLTHCARE EQ 5MG BASE N213983 001 Jun 12, 2020 Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB GRAVITI PHARMS 5MG A202114 001 Jul 05, 2013 Apr CAHN
 AB 10MG A202114 002 Jul 05, 2013 Apr CAHN
 >D> AB HERITAGE PHARMA 5MG A077344 001 May 31, 2011 Jul DISC
 >A> @ 5MG A077344 001 May 31, 2011 Jul DISC
 >D> AB 10MG A077344 002 May 31, 2011 Jul DISC
 >A> @ 10MG A077344 002 May 31, 2011 Jul DISC
 @ MYLAN PHARMS INC 5MG A090521 001 May 31, 2011 Mar DISC
 @ 10MG A090521 002 May 31, 2011 Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT MICRO LABS EQ 2.0% BASE;EQ 0.5% BASE A204777 001 May 28, 2020 May NEWA

DOXAZOSIN MESYLATE

TABLET;ORAL
CARDURA

AB +! UPJOHN EQ 1MG BASE N019668 001 Nov 02, 1990 Jun CAHN
 AB + EQ 2MG BASE N019668 002 Nov 02, 1990 Jun CAHN
 AB + EQ 4MG BASE N019668 003 Nov 02, 1990 Jun CAHN
 AB + EQ 8MG BASE N019668 004 Nov 02, 1990 Jun CAHN
 DOXAZOSIN MESYLATE
 @ ANI PHARMS INC EQ 1MG BASE A075432 001 Oct 18, 2000 Jan DISC
 @ EQ 2MG BASE A075432 002 Oct 18, 2000 Jan DISC
 @ EQ 4MG BASE A075432 003 Oct 18, 2000 Jan DISC
 @ EQ 8MG BASE A075432 004 Oct 18, 2000 Jan DISC
 >D> AB DAVA PHARMS INC EQ 1MG BASE A076161 001 Jun 10, 2004 Jul DISC
 >A> @ EQ 1MG BASE A076161 001 Jun 10, 2004 Jul DISC
 >D> AB EQ 2MG BASE A076161 002 Jun 10, 2004 Jul DISC
 >A> @ EQ 2MG BASE A076161 002 Jun 10, 2004 Jul DISC
 >D> AB EQ 4MG BASE A076161 003 Jun 10, 2004 Jul DISC
 >A> @ EQ 4MG BASE A076161 003 Jun 10, 2004 Jul DISC
 >D> AB EQ 8MG BASE A076161 004 Jun 10, 2004 Jul DISC
 >A> @ EQ 8MG BASE A076161 004 Jun 10, 2004 Jul DISC
 TABLET, EXTENDED RELEASE;ORAL
 CARDURA XL
 + UPJOHN EQ 4MG BASE N021269 001 Feb 22, 2005 Jun CAHN
 +! EQ 8MG BASE N021269 002 Feb 22, 2005 Jun CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

>A> AB CONTRACT PHARMACAL EQ 10MG BASE A213474 001 Jul 28, 2020 Jul NEWA
 >A> AB EQ 25MG BASE A213474 002 Jul 28, 2020 Jul NEWA
 >A> AB EQ 50MG BASE A213474 003 Jul 28, 2020 Jul NEWA
 >A> AB EQ 75MG BASE A213474 004 Jul 28, 2020 Jul NEWA
 >A> AB EQ 100MG BASE A213474 005 Jul 28, 2020 Jul NEWA
 >A> AB LANNETT CO INC EQ 10MG BASE A212997 001 Jul 24, 2020 Jul NEWA
 >A> AB EQ 25MG BASE A212997 002 Jul 24, 2020 Jul NEWA
 >A> AB EQ 50MG BASE A212997 003 Jul 24, 2020 Jul NEWA
 >A> AB EQ 75MG BASE A212997 004 Jul 24, 2020 Jul NEWA
 >A> AB EQ 100MG BASE A212997 005 Jul 24, 2020 Jul NEWA
 AB TARO PHARM INDS LTD EQ 10MG BASE A213063 001 Jul 01, 2020 Jun NEWA
 AB EQ 25MG BASE A213063 002 Jul 01, 2020 Jun NEWA
 AB EQ 50MG BASE A213063 003 Jul 01, 2020 Jun NEWA
 AB EQ 75MG BASE A213063 004 Jul 01, 2020 Jun NEWA
 AB EQ 100MG BASE A213063 005 Jul 01, 2020 Jun NEWA
 CONCENTRATE;ORAL
 DOXEPIIN HYDROCHLORIDE
 AA ! LANNETT CO INC EQ 10MG BASE/ML A074721 001 Dec 29, 1998 May CHRS
 @ TEVA PHARMS EQ 10MG BASE/ML A071609 001 Nov 09, 1987 May DISC

TABLET;ORAL

DOXEPIH HYDROCHLORIDE

>A>	AB	PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jul NEWA
>A>	AB		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jul NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb CAHN
AP		NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

		@ MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan DISC
		MONODOX					
>D>	+	@ ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jul CAHN
>D>	+	@	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jul CAHN
>D>	+	@	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jul CAHN
>A>	+	@ CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jul CAHN
>A>	+	@	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jul CAHN
>A>	+	@	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jul CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020	Mar NEWA
AB			EQ 100MG BASE	A212610	002	Mar 31, 2020	Mar NEWA

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

>A>	+	!	DEN-MAT	50MG	N050751	001	Sep 03, 1998	Jul CAHN
>D>	+	!	TOLMAR	50MG	N050751	001	Sep 03, 1998	Jul CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB		AJANTA PHARMA LTD	EQ 75MG BASE	A211584	001	Jun 01, 2020	May NEWA	
AB			EQ 150MG BASE	A211584	002	Jun 01, 2020	May NEWA	
AB		ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb NEWA	
AB			EQ 75MG BASE	A211744	001	Jun 30, 2020	Jun NEWA	
AB			EQ 100MG BASE	A210536	001	May 14, 2020	May NEWA	
AB			EQ 150MG BASE	A211744	002	Jun 30, 2020	Jun NEWA	
>D>	AB	CARIBE HOLDINGS	EQ 100MG BASE	A062269	002	Nov 08, 1982	Jul CHRS	
>A>	AB	!	EQ 100MG BASE	A062269	002	Nov 08, 1982	Jul CHRS	
>D>	AB	HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	Jul DISC	
>A>	AB	@	EQ 20MG BASE	A065163	001	May 13, 2005	Jul DISC	
>D>	AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	Jul CHRS
>A>	AB		EQ 100MG BASE	A065095	001	Jul 02, 2003	Jul CHRS	
AB		OAKLOCK LLC	EQ 100MG BASE	A210664	001	Mar 16, 2020	Mar NEWA	

TABLET, DELAYED RELEASE;ORAL

DORYX

>D>	+		MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Jul DISC
>A>	+	@		EQ 80MG BASE	N050795	004	Apr 11, 2013	Jul DISC
	+			EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar CMFD

DOXYCYCLINE HYCLATE

AB		PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb NEWA
----	--	--------------	--------------	---------	-----	--------------	----------

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	10MG;10MG	A207825	001	Jul 06, 2020	Jul NEWA
-----	----	------------------	-----------	---------	-----	--------------	----------

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan NEWA
AB			5MG	A207421	002	Feb 07, 2020	Jan NEWA
AB			10MG	A207421	003	Feb 07, 2020	Jan NEWA

MARINOL

AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan CAHN
AB	+	!	5MG	N018651	002	May 31, 1985	Jan CAHN
AB	+		10MG	N018651	003	May 31, 1985	Jan CAHN

SOLUTION;ORAL
SYNDROS

+!	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Feb CAHN
----	---------	--------	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan CAHN
----	--------	------------	---------	-----	--------------	----------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

>D>	AB	APOTEX	3MG;0.03MG	A205876	001	Sep 21, 2016	Jul DISC
>A>		@	3MG;0.03MG	A205876	001	Sep 21, 2016	Jul DISC
	AB	HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan NEWA
	AB	NAARI PTE LTD	3MG;0.03MG	A207245	001	Nov 22, 2016	Jun CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

@	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	May DISC
@		EQ 30MG BASE	A210599	002	Apr 17, 2019	May DISC
@		EQ 60MG BASE	A210599	003	Apr 17, 2019	May DISC
@	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Mar DISC
@		EQ 30MG BASE	A207219	002	Aug 16, 2019	Mar DISC
@		EQ 60MG BASE	A207219	003	Aug 16, 2019	Mar DISC

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

>A>	AB	ACELLA	0.5MG	A206373	001	Mar 17, 2016	Jul CAHN
		@ ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan DISC
		@ APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Feb DISC
	AB	AUROBINDO PHARMA LTD	0.5MG	A202660	001	Nov 20, 2015	May CAHN
		@ HIKMA	0.5MG	A202204	001	Nov 23, 2015	Feb DISC
>D>	AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Jul CAHN
		@ STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018	Mar CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	Laurus Labs Ltd	400MG;300MG;300MG	A213038	001	May 14, 2020	May NFTG	
AB		600MG;300MG;300MG	A212786	001	May 14, 2020	May NFTG	
		SYMFI					
AB	+!	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	May CFTG
		SYMFI LO					
AB	+!	MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018	May CFTG

ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE;ORAL

ORIAHNN (COPACKAGED)

+!	ABBVIE INC	EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	N213388	001	May 29, 2020	May NEWA
----	------------	--	---------	-----	--------------	----------

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

>A>	AB	YUNG SHIN PHARM	EQ 20MG BASE	A209680	001	Jul 13, 2020	Jul NEWA
>A>	AB		EQ 40MG BASE	A209680	002	Jul 13, 2020	Jul NEWA
		RELPAK					
>D>	AB	+ PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jul CAHN
>D>	AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jul CAHN
>A>	AB	+ UPJOHN	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jul CAHN
>A>	AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jul CAHN

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIJARDY XR

+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan NEWA
+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan NEWA
+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan NEWA
+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	May	NEWA
	@ MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb	DISC
AB	ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb	NEWA

ENALAPRIL MALEATE

SOLUTION; ORAL

EPANED

+!	AZURITY	1MG/ML	N208686	001	Sep 20, 2016	May	CAHN
----	---------	--------	---------	-----	--------------	-----	------

ENTECAVIR

TABLET; ORAL

ENTECAVIR

	@ MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan	DISC	
	@	1MG	A206226	002	Mar 26, 2019	Jan	DISC	
>A>	AB	PHARMADAX INC	0.5MG	A212106	001	Aug 10, 2020	Jul	NEWA
>A>	AB		1MG	A212106	002	Aug 10, 2020	Jul	NEWA
	AB	SUNSHINE LAKE	0.5MG	A211978	001	May 20, 2020	May	NEWA
	AB		1MG	A211978	002	May 20, 2020	May	NEWA
	@ YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Apr	DISC	
	@	1MG	A212201	002	Nov 04, 2019	Apr	DISC	

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

>D>	AP	+!	AVADEL LEGACY	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Jul	CAHN
>A>	AP	+!	EXELA PHARMA	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Jul	CAHN
			EMERPHED						
		+!	NEXUS PHARMS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Apr	NEWA
			EPHEDRINE SULFATE						
>A>	AP		ANDERSEN	50MG/ML (50MG/ML)	A209646	001	Aug 04, 2020	Jul	NEWA

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP	+!	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Apr	CFTG
		EPINEPHRINE						
AP		INTL MEDICATION SYS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A211880	001	Apr 24, 2020	Apr	NFTG

EPLERENONE

TABLET; ORAL

EPLERENONE

AB	COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb	CAHN	
AB		50MG	A078482	002	Jul 30, 2008	Feb	CAHN	
>A>	AB	PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Jul	NEWA
>A>	AB		50MG	A212765	002	Aug 10, 2020	Jul	NEWA

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

	@ MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011	Apr	DISC
	@	EQ 600MG BASE	A202012	002	Nov 16, 2011	Apr	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP	HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Mar	NEWA
AP		75MG/100ML	A207864	002	Mar 20, 2020	Mar	NEWA

ERAVACYCLINE DIHYDROCHLORIDE

POWDER; INTRAVENOUS

XERAVA

+!	TETRAPHASE PHARMS	EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020	Jun	NEWA
----	-------------------	--------------------	---------	-----	--------------	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	EQ 25MG BASE	A211083	001	Jul 02, 2020	Jul	NEWA
>A>	AB		EQ 100MG BASE	A211083	002	Jul 02, 2020	Jul	NEWA
>A>	AB		EQ 150MG BASE	A211083	003	Jul 02, 2020	Jul	NEWA
	AB	ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020	Apr	NEWA
	AB		EQ 100MG BASE	A213065	002	Apr 16, 2020	Apr	NEWA
	AB		EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr	NEWA

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

>A>	AB	TORRENT	250MG	A212015	001	Jul 06, 2020	Jul	NEWA
>A>	AB		500MG	A212015	002	Jul 06, 2020	Jul	NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA		ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan	CAHN
AA	!	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr	CHRS
		LEXAPRO						
+	@	ALLERGAN	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr	DISC

TABLET;ORAL

ESCITALOPRAM OXALATE

	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	May	DISC
	@		EQ 10MG BASE	A202210	002	Sep 11, 2012	May	DISC
	@		EQ 20MG BASE	A202210	003	Sep 11, 2012	May	DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		HETERO LABS LTD III	EQ 20MG BASE	A211977	001	Jun 02, 2020	May	NEWA
AB			EQ 40MG BASE	A211977	002	Jun 02, 2020	May	NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar	NFTG
AB			EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar	NFTG
AB			EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar	NFTG
		NEXIUM						
AB	+	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar	CFTG
AB	+		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar	CFTG
AB	+	!	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar	CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A204206	001	Feb 18, 2020	Feb	NEWA
AB			EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Feb	NEWA
		VIMOVO						
AB	+	HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Feb	CTEC
AB	+	!	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Feb	CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar	NEWA
AP			EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar	NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

+	@	BELCHER	24.65MG	N202342	001	Aug 06, 2013	Mar	CAHN
+	@		49.3MG	N202342	002	Aug 06, 2013	Mar	CAHN

ESTAZOLAMTABLET; ORAL
ESTAZOLAM

>A>	AB	NOVITIUM PHARMA	1MG	A074826	001	Jul 03, 1997	Jul	CAHN
>A>	AB		2MG	A074826	002	Jul 03, 1997	Jul	CAHN
>D>	AB	PAR PHARM	1MG	A074826	001	Jul 03, 1997	Jul	CAHN
>D>	AB		2MG	A074826	002	Jul 03, 1997	Jul	CAHN

ESTRADIOL VALERATEINJECTABLE; INJECTION
DELESTROGEN

AO	+!	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr	CTEC
		ESTRADIOL VALERATE						
AO		HIKMA	10MG/ML	A203723	001	Apr 21, 2020	Apr	NEWA
AO			20MG/ML	A203723	002	Apr 21, 2020	Apr	NEWA
AO			40MG/ML	A203723	003	Apr 21, 2020	Apr	NEWA

ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

	@	NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018	Jun	CAHN
	@	TEVA PHARMS USA	0.5MG; 0.1MG	A200747	001	Mar 08, 2012	Jan	DISC

ESTROPIPATETABLET; ORAL
ESTROPIPATE

	@	MYLAN	0.75MG	A040359	001	Aug 26, 1999	Jan	DISC
	@		1.5MG	A040359	002	Aug 26, 1999	Jan	DISC

ESZOPICLONETABLET; ORAL
ESZOPICLONE

	@	HIKMA	1MG	A091153	001	Apr 15, 2014	Feb	DISC
	@		2MG	A091153	002	Apr 15, 2014	Feb	DISC
	@		3MG	A091153	003	Apr 15, 2014	Feb	DISC

ETHACRYNATE SODIUMINJECTABLE; INJECTION
ETHACRYNATE SODIUM

AP		VPI PHARMS INC	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Jun	NEWA
----	--	----------------	-------------------	---------	-----	--------------	-----	------

ETHACRYNIC ACIDTABLET; ORAL
ETHACRYNIC ACID

AB		UPSHER SMITH LABS	25MG	A212417	001	Feb 19, 2020	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONETABLET; ORAL-28
NORQUEST FE

>D>	@	GD SEARLE LLC	0.035MG; 75MG; 1MG	N018926	001	Jul 18, 1986	Jul	CAHN
>A>	@	PFIZER	0.035MG; 75MG; 1MG	N018926	001	Jul 18, 1986	Jul	CAHN

ETHINYL ESTRADIOL; LEVONORGESTRELSYSTEM; TRANSDERMAL
TWIRLA

+!	AGILE	0.03MG/24HR; 0.12MG/24HR	N204017	001	Feb 14, 2020	Feb	NEWA
----	-------	--------------------------	---------	-----	--------------	-----	------

TABLET; ORAL
BALCOLTRA

+!	AVION PHARMS	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan	CHRS
+		0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan	CRLD

TABLET; ORAL-28
ELIFEMME

@	XIROMED	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Mar	DISC
---	---------	--	---------	-----	--------------	-----	------

LEVONORGESTREL AND ETHINYL ESTRADIOL

@	MYLAN LABS LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	Feb	DISC
---	----------------	--	---------	-----	--------------	-----	------

ORSYTHIA

@	VINTAGE PHARMS LLC	0.02MG; 0.1MG	A077099	001	May 11, 2011	Jun	DISC
---	--------------------	---------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL
TYBLUME

+!	EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020	Jun CTNA
+!		0.02MG;0.1MG	N209405	001	Mar 30, 2020	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

AB	NORETHINDRONE AND ETHINYL ESTRADIOL NAARI PTE LTD	0.035MG;1MG	A206864	001	Apr 28, 2017	Jun CAHN
AB	TABLET, CHEWABLE;ORAL NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	Jun CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

AB	LOESTRIN 24 FE + TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE @ MYLAN LABS LTD	0.02MG;1MG	A202742	001	Oct 30, 2014	Jun DISC

TABLET;ORAL-21

	GILDESS 1.5/30 @ VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Jun DISC
AB	LOESTRIN 21 1.5/30 + TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jan CAHN
AB	LOESTRIN 21 1/20 + TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jan CAHN
AB	LOESTRIN FE 1.5/30 +! TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jan CAHN

TABLET;ORAL-28

AB	CHABELINA FE NOVAST LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020	Mar NEWA
	GILDESS FE 1.5/30 @ VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jun DISC
AB	LOESTRIN FE 1/20 + TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jan CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL @ MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb DISC
>D>	TABLET, CHEWABLE;ORAL FINZALA TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jul DISC
>A>	@	0.02MG;1MG	A210087	001	Apr 07, 2020	Jul DISC
AB		0.02MG;1MG	A210087	001	Apr 07, 2020	Mar NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

>D>	AB	NORGESTIMATE AND ETHINYL ESTRADIOL GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A204057	001	Feb 23, 2016	Jul CHRS
>A>	AB	!	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A204057	001	Feb 23, 2016	Jul CHRS
>D>		ORTHO TRI-CYCLEN LO					
>D>	AB	+! JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	N021241	001	Aug 22, 2002	Jul DISC
>A>		+ @	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	N021241	001	Aug 22, 2002	Jul DISC
		TRI-PREVIFEM @ VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.2 15MG,0.25MG	A076335	001	Mar 26, 2004	Jun DISC

ETHOSUXIMIDE

CAPSULE;ORAL

AB	ETHOSUXIMIDE PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Mar NEWA
----	-----------------------------------	-------	---------	-----	--------------	----------

ETODOLAC

TABLET;ORAL

	ETODOLAC @ TEVA	400MG	A075009	001	Nov 26, 1997	Feb DISC
	@	500MG	A075009	002	Dec 28, 1999	Feb DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

@ MYLAN LABS LTD

2MG/ML

A078289 001 Jan 02, 2009 Feb DISC

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

AB HIKMA

2.5MG

A207486 001 Jun 08, 2020 Jun NEWA

AB

5MG

A207486 002 Jun 08, 2020 Jun NEWA

AB

7.5MG

A207486 003 Jun 08, 2020 Jun NEWA

AB MYLAN

2.5MG

A212936 001 Jun 08, 2020 Jun NEWA

AB

5MG

A212936 002 Jun 08, 2020 Jun NEWA

AB

7.5MG

A212936 003 Jun 08, 2020 Jun NEWA

AB

10MG

A212936 004 Jun 08, 2020 Jun NEWA

AB

TEVA PHARMS USA

2.5MG

A210050 001 Dec 09, 2019 Jun CMFD

@

2.5MG

A210050 001 Dec 09, 2019 Jun DISC

AB

5MG

A210050 002 Dec 09, 2019 Jun CMFD

@

5MG

A210050 002 Dec 09, 2019 Jun DISC

AB

@

7.5MG

A210050 003 Dec 09, 2019 Jun CMFD

@

7.5MG

A210050 003 Dec 09, 2019 Jun DISC

@

10MG

A210050 004 Dec 09, 2019 Jun DISC

ZORTRESS

>D> AB +! NOVARTIS

0.75MG

N021560 003 Apr 20, 2010 Jul CHRS

>A> AB

+

0.75MG

N021560 003 Apr 20, 2010 Jul CHRS

>D>

+

1MG

N021560 004 Aug 10, 2018 Jul CHRS

>A>

+!

1MG

N021560 004 Aug 10, 2018 Jul CHRS

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ MAYNE PHARMA INC

25MG

A208764 001 Aug 08, 2019 Jan DISC

AB

QILU

25MG

A213547 001 Apr 13, 2020 Mar NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

@ MYLAN

10MG

A201790 001 Apr 26, 2019 Feb DISC

@ TEVA PHARMS USA

10MG

A078724 001 Jun 12, 2017 Mar DISC

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AB ! AUROBINDO PHARMA LTD

40MG

A206530 002 Dec 22, 2015 Jan CHRS

@ MYLAN

20MG

A075704 001 Apr 16, 2001 Feb DISC

@ TEVA

20MG

A075311 001 Apr 16, 2001 Mar DISC

@

40MG

A075311 002 Apr 16, 2001 Mar DISC

PEPCID

+ @ VALEANT PHARMS NORTH

20MG

N019462 001 Oct 15, 1986 Jan DISC

+ @

40MG

N019462 002 Oct 15, 1986 Jan DISC

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB SUNSHINE LAKE

40MG

A213069 001 Jun 02, 2020 May NEWA

AB

80MG

A213069 002 Jun 02, 2020 May NEWA

FENFLURAMINE HYDROCHLORIDE

SOLUTION; ORAL

FINTEPLA

+! ZOGENIX INC

EQ 2.2MG BASE/ML

N212102 001 Jun 25, 2020 Jun NEWA

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB ANI PHARMS INC

67MG

A209504 001 Apr 30, 2018 Jan CAHN

AB

134MG

A209504 002 Apr 30, 2018 Jan CAHN

AB

200MG

A209504 003 Apr 30, 2018 Jan CAHN

@ MYLAN PHARMS INC

43MG

A202579 001 Jan 10, 2013 Mar DISC

@

130MG

A202579 002 Jan 10, 2013 Mar DISC

TABLET;ORALFENOFIBRATE

AB	ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan NEWA
AB		160MG	A213252	002	Jan 17, 2020	Jan NEWA
AB	APPCO	54MG	A210670	001	Sep 06, 2019	Jan CAHN
AB		160MG	A210670	002	Sep 06, 2019	Jan CAHN
AB	GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar NEWA
AB		54MG	A210606	001	Aug 17, 2018	Jan CMFD
AB		145MG	A211122	002	Mar 18, 2020	Mar NEWA
AB		160MG	A210606	002	Aug 17, 2018	Jan CMFD
AB	MANKIND PHARMA	54MG	A213864	001	Jun 12, 2020	Jun NEWA
AB		160MG	A213864	002	Jun 12, 2020	Jun NEWA

FENOFIBRIC ACIDTABLET;ORALFIBRICOR

>D>	+ ATHENA	35MG	N022418	001	Aug 14, 2009	Jul DISC
>A>	+ @	35MG	N022418	001	Aug 14, 2009	Jul DISC

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMALFENTANYL-37

>A>	AB	SPECGX LLC	37.5MCG/HR	A077154	006	Jan 14, 2020	Jul NEWA
		FENTANYL-62					
>D>		MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014	Jul CTEC
>A>	AB		62.5MCG/HR	A076258	007	Dec 29, 2014	Jul CTEC
>A>	AB	SPECGX LLC	62.5MCG/HR	A077154	007	Jan 14, 2020	Jul NEWA
		FENTANYL-87					
>D>		MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Jul CTEC
>A>	AB		87.5MCG/HR	A076258	008	Dec 29, 2014	Jul CTEC

FENTANYL CITRATEINJECTABLE;INJECTIONFENTANYL CITRATE PRESERVATIVE FREE

AP	+!	HIKMA	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
----	----	-------	-------------------	---------	-----	--------------	----------

FERRIC DERISOMALTOSESOLUTION;INTRAVENOUSMONOFERRIC

	+ @	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jun DISC
	+!		100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan NEWA
	+ @		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jun DISC
	+!		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan NEWA
	+!		1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan NEWA

FERRIC PYROPHOSPHATE CITRATESOLUTION;INTRAVENOUSTRIFERIC AVNU

	+!	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Mar NEWA
--	----	----------------------	-----------------------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE;ORALFESOTERODINE FUMARATE

	@	DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Feb DISC
	@		8MG	A204975	002	Aug 13, 2019	Feb DISC

FEXOFENADINE HYDROCHLORIDETABLET;ORALFEXOFENADINE HYDROCHLORIDE

	@	BARR	30MG	A076191	001	Aug 31, 2005	Mar DISC
	@		60MG	A076191	002	Aug 31, 2005	Mar DISC
	@		180MG	A076191	003	Aug 31, 2005	Mar DISC

FIDAXOMICINFOR SUSPENSION;ORALDIFICID

	+!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020	Jan NEWA
--	----	-------------------	---------	---------	-----	--------------	----------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

@ TEVA	1MG	A 076905	001	Nov 05, 2013	Mar	DISC
--------	-----	----------	-----	--------------	-----	------

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

@ BIOCON LTD	EQ 0.5MG BASE	A 207979	001	Dec 04, 2019	Jun	DISC
AB GLENMARK PHARMS LTD	EQ 0.5MG BASE	A 207985	001	Jun 18, 2020	Jun	NEWA
AB HETERO LABS LTD V	EQ 0.5MG BASE	A 207933	001	May 18, 2020	May	NEWA
AB STRIDES PHARMA	EQ 0.5MG BASE	A 207971	001	Jun 29, 2020	Jun	NEWA
>A> AB TEVA PHARMS USA	EQ 0.5MG BASE	A 208008	001	Jul 02, 2020	Jul	NEWA

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS

TAUVID

+! AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N 212123	001	May 28, 2020	May	NEWA
+!	50ML (8.1-51mCi/ML)	N 212123	002	May 28, 2020	May	NEWA

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

@ HIKMA	50MG/5ML	A 076246	001	Jul 29, 2004	Feb	DISC
@	200MG/5ML	A 076246	002	Jul 29, 2004	Feb	DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A 078764	001	Jan 30, 2012	Mar	DISC
@	400MG/200ML (2MG/ML)	A 078764	002	Jan 30, 2012	Mar	DISC
@ HOSPIRA	200MG/100ML (2MG/ML)	A 076304	001	Jul 29, 2004	Mar	DISC
@	400MG/200ML (2MG/ML)	A 076304	002	Jul 29, 2004	Mar	DISC
@ WOODWARD	200MG/100ML (2MG/ML)	A 077988	001	May 26, 2010	Mar	DISC
@	400MG/200ML (2MG/ML)	A 077988	002	May 26, 2010	Mar	DISC

TABLET; ORAL

FLUCONAZOLE

>A> AB ANI PHARMS INC	50MG	A 078423	001	Mar 07, 2011	Jul	CAHN
>A> AB	100MG	A 078423	002	Mar 07, 2011	Jul	CAHN
>A> AB	150MG	A 078423	003	Mar 07, 2011	Jul	CAHN
>A> AB	200MG	A 078423	004	Mar 07, 2011	Jul	CAHN
>D> AB HARRIS PHARM	50MG	A 078423	001	Mar 07, 2011	Jul	CAHN
>D> AB	100MG	A 078423	002	Mar 07, 2011	Jul	CAHN
>D> AB	150MG	A 078423	003	Mar 07, 2011	Jul	CAHN
>D> AB	200MG	A 078423	004	Mar 07, 2011	Jul	CAHN
@ MYLAN	50MG	A 076351	001	Jul 29, 2004	Jan	DISC
@	100MG	A 076351	002	Jul 29, 2004	Jan	DISC
@	150MG	A 076351	003	Jul 29, 2004	Jan	DISC
@	200MG	A 076351	004	Jul 29, 2004	Jan	DISC
@ TEVA	50MG	A 074681	001	Jul 29, 2004	Mar	DISC
@	100MG	A 074681	002	Jul 29, 2004	Mar	DISC
@	150MG	A 074681	003	Jul 29, 2004	Mar	DISC
@	200MG	A 074681	004	Jul 29, 2004	Mar	DISC

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

AB AUROBINDO PHARMA LTD	250MG	A 213665	001	May 01, 2020	Apr	NEWA
AB	500MG	A 213665	002	May 01, 2020	Apr	NEWA
AB STRIDES PHARMA	250MG	A 212632	001	Apr 17, 2020	Apr	NEWA
AB	500MG	A 212632	002	Apr 17, 2020	Apr	NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

@ UNIV TX SW MEDCTR	20-200mCi/ML	A 210265	001	Feb 06, 2020	May	DISC
AP	20-200mCi/ML	A 210265	001	Feb 06, 2020	Jan	NEWA

FLUNISOLIDESPRAY, METERED;NASAL
FLUNISOLIDE

!	APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Mar	CHRS
		0.029MG/SPRAY	A077436	001	Aug 09, 2007	Mar	CMFD

FLUOCINONIDECREAM;TOPICAL
FLUOCINONIDE

AB1	AMNEAL	0.05%	A210554	001	Aug 21, 2018	Apr	CMFD
AB	CADILA	0.1%	A208989	001	Feb 10, 2020	Feb	CAHN
AB	ZYDUS PHARMS	0.1%	A208989	001	Feb 10, 2020	Jan	NEWA

SOLUTION;TOPICAL
FLUOCINONIDE

@	TEVA	0.05%	A072511	001	Feb 07, 1989	Mar	DISC
---	------	-------	---------	-----	--------------	-----	------

FLUOROESTRADIOL F-18SOLUTION;INTRAVENOUS
CERIANNA

+	!	ZIONEXA	50ML (4-100mCi/ML)	N212155	001	May 20, 2020	May	NEWA
---	---	---------	--------------------	---------	-----	--------------	-----	------

FLUOROURACILINJECTABLE;INJECTION
FLUOROURACIL

@	INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019	Apr	DISC
@		500MG/10ML (50MG/ML)	A209271	001	Dec 11, 2019	Apr	DISC
@		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019	Apr	DISC
@		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019	Apr	DISC

SOLUTION;TOPICAL
FLUOROURACIL

AT	!	TARO	5%	A076526	002	Nov 05, 2003	Mar	CHRS
----	---	------	----	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDECAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE

@	BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002	Mar	DISC
@		EQ 20MG BASE	A074803	001	Aug 02, 2001	Mar	DISC
@	SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002	May	DISC
@		EQ 20MG BASE	A075658	002	Jan 29, 2002	May	DISC

SOLUTION;ORAL
FLUOXETINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Mar	CMFD
		@ SPECGX LLC	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	May	DISC

TABLET;ORAL
FLUOXETINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020	Mar	NEWA
AB			EQ 20MG BASE	A213286	002	Apr 08, 2020	Mar	NEWA
AB			EQ 60MG BASE	A213265	001	Jun 10, 2020	Jun	NEWA

SARAFEM

>D>	+	APIL	EQ 15MG BASE	N021860	002	May 19, 2006	Jul	DISC
>A>	+	@	EQ 15MG BASE	N021860	002	May 19, 2006	Jul	DISC
	+		EQ 15MG BASE	N021860	002	May 19, 2006	Apr	CTEC

SELFEMRA

@	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Apr	DISC
@		EQ 15MG BASE	A200151	002	Feb 03, 2014	Apr	DISC
@		EQ 20MG BASE	A200151	003	Feb 03, 2014	Apr	DISC

FLUPHENAZINE HYDROCHLORIDETABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

>A>	AB	AMNEAL	1MG	A213647	001	Jul 09, 2020	Jul	NEWA
>A>	AB		2.5MG	A213647	002	Jul 09, 2020	Jul	NEWA
>A>	AB		5MG	A213647	003	Jul 09, 2020	Jul	NEWA
>A>	AB		10MG	A213647	004	Jul 09, 2020	Jul	NEWA
>D>	AB	MYLAN	1MG	A089804	002	Aug 12, 1988	Jul	DISC
>A>		@	1MG	A089804	002	Aug 12, 1988	Jul	DISC
		@ SANDOZ	1MG	A089586	002	Oct 16, 1987	Mar	DISC
		@	2.5MG	A089586	003	Oct 16, 1987	Mar	DISC
		@	5MG	A089586	004	Oct 16, 1987	Mar	DISC
		@	10MG	A089586	001	Oct 16, 1987	Mar	DISC

FLUTICASONE PROPIONATEPOWDER; INHALATION
ARMONAIR DIGIHALER

+	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Mar	NEWA
+		0.113MG/INH	N208798	005	Feb 20, 2020	Mar	NEWA
+	!	0.232MG/INH	N208798	006	Feb 20, 2020	Mar	NEWA

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE; ORAL
FLUVOXAMINE MALEATE

AB	BIONPHARMA INC	150MG	A212182	001	May 11, 2020	Apr	NEWA
	TABLET; ORAL						
	FLUVOXAMINE MALEATE						
	@ TEVA	25MG	A075893	001	Sep 10, 2002	Mar	DISC
	@	50MG	A075893	002	Sep 10, 2002	Mar	DISC
	@	100MG	A075893	003	Sep 10, 2002	Mar	DISC

FOLIC ACIDINJECTABLE; INJECTION
FOLIC ACID

AP	X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019	Jan	CAHN
AP	XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019	Feb	CAHN
	TABLET; ORAL						
	FOLIC ACID						
	@ VINTAGE	1MG	A040756	001	Jun 04, 2010	Jun	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	!	AUROBINDO PHARMA	20MG;12.5MG	A079245	002	Jul 09, 2009	Apr	CHRS
	@	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Apr	DISC
	@		20MG;12.5MG	A079025	002	Sep 17, 2010	Apr	DISC

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER; INTRAVENOUS

AKYNZEO

+	!	HEL SINN HLTHCARE	EQ 235MG BASE/VIAL; EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018	May	CMS1
---	---	-------------------	---	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS
AKYNZEO

+	!	HEL SINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML); EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020	May	NEWA
---	---	-------------------	--	---------	-----	--------------	-----	------

>A> FOSTEMSAVIR TROMETHAMINE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> RUKOBIA

>A>	+	!	VIIV HLTHCARE	EQ 600MG BASE	N212950	001	Jul 02, 2020	Jul	NEWA
-----	---	---	---------------	---------------	---------	-----	--------------	-----	------

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FULVESTRANT

AO		CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020	Jan	NEWA
>A>	AO	DR REDDYS	50MG/ML	A209246	001	Aug 07, 2020	Jul	NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		GLAND PHARMA LTD	10MG/ML	A213902	001	Jul 01, 2020	Jun	NEWA
	TABLET; ORAL							
	FUROSEMIDE							
	@	AVET	20MG	N018413	001	Nov 30, 1983	Jan	DISC
	@		40MG	N018413	002	Nov 30, 1983	Jan	DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		CSPC OUYI	100MG	A075477	001	Mar 23, 2005	Jan	CMFD
AB			300MG	A075477	002	Mar 23, 2005	Jan	CMFD
AB			400MG	A075477	003	Mar 23, 2005	Jan	CMFD
	@	JIANGSU HENGRUI MED	100MG	A091008	001	Oct 26, 2017	May	DISC

	CAPSULE;ORAL								
	GABAPENTIN								
	@	300MG	A091008	002	Oct 26, 2017	May	DISC		
	@	400MG	A091008	003	Oct 26, 2017	May	DISC		
	@	TEVA PHARMS	100MG	A075435	001	Oct 08, 2004	Mar	DISC	
	@	300MG	A075435	002	Oct 08, 2004	Mar	DISC		
	@	400MG	A075435	003	Oct 08, 2004	Mar	DISC		
	NEURONTIN								
AB	+	UPJOHN	100MG	N020235	001	Dec 30, 1993	Jun	CAHN	
AB	+		300MG	N020235	002	Dec 30, 1993	Jun	CAHN	
AB	+	!	400MG	N020235	003	Dec 30, 1993	Jun	CAHN	
	SOLUTION;ORAL								
	GABAPENTIN								
	@	VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	May	DISC	
	NEURONTIN								
AA	+	!	UPJOHN	250MG/5ML	N021129	001	Mar 02, 2000	Jun	CAHN
	TABLET;ORAL								
	GABAPENTIN								
	@	MYLAN PHARMS INC	600MG	A090335	001	Jun 01, 2010	Mar	DISC	
	@		800MG	A090335	002	Jun 01, 2010	Mar	DISC	
	@	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Mar	DISC	
	@		800MG	A205807	002	Mar 10, 2017	Mar	DISC	
	GRALISE								
BX	+	!	ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan	CAHN
BX	+	!		600MG	N022544	002	Jan 28, 2011	Jan	CAHN
	NEURONTIN								
AB	+	UPJOHN	600MG	N020882	001	Oct 09, 1998	Jun	CAHN	
AB	+	!	800MG	N020882	002	Oct 09, 1998	Jun	CAHN	
	<u>GALANTAMINE HYDROBROMIDE</u>								
	TABLET;ORAL								
	GALANTAMINE HYDROBROMIDE								
	@	HIKMA	EQ 4MG BASE	A077608	001	Feb 11, 2009	Feb	DISC	
	@		EQ 8MG BASE	A077608	002	Feb 11, 2009	Feb	DISC	
	@		EQ 12MG BASE	A077608	003	Feb 11, 2009	Feb	DISC	
	<u>GEMCITABINE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	GEMCITABINE HYDROCHLORIDE								
	@	APOTEX	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	Feb	DISC	
	@		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	Feb	DISC	
	@		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	Feb	DISC	
>D>	AP	MYLAN LABS LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	DISC	
>A>	@		EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	Jul	DISC	
	@		EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	May	DISC	
	@		EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	Mar	DISC	
AP		SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Jan	CMFD	
AP			EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Jan	CMFD	
	@	TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Mar	DISC	
	@		EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Mar	DISC	
	<u>GEMFIBROZIL</u>								
	TABLET;ORAL								
	GEMFIBROZIL								
AB		CADILA	600MG	A204189	001	Aug 28, 2018	Feb	CAHN	
	@	TEVA	600MG	A074256	001	Oct 31, 1993	Feb	DISC	
	<u>GLIMEPIRIDE</u>								
	TABLET;ORAL								
	GLIMEPIRIDE								
	@	MYLAN	1MG	A077624	001	Nov 28, 2005	Apr	DISC	
	@		2MG	A077624	002	Nov 28, 2005	Apr	DISC	
	@		4MG	A077624	003	Nov 28, 2005	Apr	DISC	
	<u>GLYBURIDE</u>								
	TABLET;ORAL								
	GLYBURIDE								
AB1		ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	May	CMFD	
AB1			2.5MG	A206483	002	Feb 22, 2019	May	CMFD	
AB1			5MG	A206483	003	Feb 22, 2019	May	CMFD	
	GLYBURIDE (MICRONIZED)								
	@	MYLAN	1.5MG	A074792	001	Jun 26, 1998	Jan	DISC	

TABLET;ORAL

GLYBURIDE (MICRONIZED)

@	3MG	A074792	002	Jun 26, 1998	Jan DISC
@	6MG	A074792	003	Aug 17, 1999	Jan DISC

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>A>	AP	ACCORD HLTHCARE	0.2MG/ML	A213238	001	Jul 08, 2020	Jul NEWA
	AP	RICONPHARMA LLC	0.2MG/ML	A210083	001	Feb 21, 2020	Feb NEWA

POWDER; INHALATION

SEEBRI

+	@	NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar CAHN
+	@	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Mar DISC

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

		EXELA PHARMA	1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020	Apr NEWA
--	--	--------------	--------------------	---------	-----	--------------	----------

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+	@	NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar CAHN
+	@	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Mar DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

	@	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Apr DISC
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Apr DISC
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Mar DISC
AP		PUNISKA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN
	@	YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Apr DISC
AP			EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Feb NEWA
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020	Jun NEWA

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

@	MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan DISC
---	-------	-------------	---------	-----	--------------	----------

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

AB		COSETTE	125MG/5ML	A065438	001	Oct 08, 2010	May CAHN
----	--	---------	-----------	---------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROSIZED

TABLET;ORAL

GRIS-PEG

>D>	AB	+	VALEANT PHARMS INC	250MG	N050475	002	Jul CHRS
>A>	AB	+		250MG	N050475	002	Jul CHRS

GRISEOFULVIN, ULTRAMICROSIZED

>D>	AB		MOUNTAIN	250MG	A204371	002	Jan 09, 2014	Jul CHRS
>A>	AB	!		250MG	A204371	002	Jan 09, 2014	Jul CHRS

HALCINONIDE

SOLUTION; TOPICAL

HALOG

!	SUN PHARM INDS INC	0.1%	N017823	001		Mar CMFD
---	--------------------	------	---------	-----	--	----------

HALOBETASOL PROPIONATE

LOTION; TOPICAL

HALOBETASOL PROPIONATE

	@	PERRIGO ISRAEL	0.05%	A211464	001	Jun 03, 2020	Jun DISC
AB			0.05%	A211464	001	Jun 03, 2020	May NFTG

ULTRAVATE

	+	!	SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	Jun CTEC
AB		+	!	0.05%	N208183	001	Nov 06, 2015	May CFTG

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	UPSHER SMITH LABS	0.5MG	A211061	001	Jan 08, 2020	Jun	CAHN
AB		1MG	A211061	002	Jan 08, 2020	Jun	CAHN
AB		2MG	A211061	003	Jan 08, 2020	Jun	CAHN
AB		5MG	A211061	004	Jan 08, 2020	Jun	CAHN
AB		10MG	A211061	005	Jan 08, 2020	Jun	CAHN
AB		20MG	A211061	006	Jan 08, 2020	Jun	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@	TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Mar	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	GLAND PHARMA LTD	1,000 UNITS/ML	A205323	002	Nov 18, 2019	Apr	NEWA	
>A>	AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Jul	NEWA
AP		20,000 UNITS/ML	A211004	001	Feb 24, 2020	Feb	NEWA	
	+ @	PFIZER	10,000 UNITS/ML	N201370	003	Jul 21, 2011	Jun	DISC
		HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>	AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020	Jul	NEWA
		HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020	Apr	NEWA
		HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>A>	AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020	Jul	NEWA
		HEPARIN SODIUM PRESERVATIVE FREE						
AP	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	CTEC
AP		NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Mar	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

@	NOSTRUM LABS INC	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN
---	------------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	!	NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011	Jan	CHRS	
		TUSSIGON							
		@	KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Jan	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	XGEN PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
----	-------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Jan	DISC
---	----------------	------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@	IVAX SUB TEVA PHARMS	12.5MG	A077005	001	Jul 13, 2005	Mar	DISC
---	----------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007	Jan	DISC
@		50MG	A040735	003	Jan 23, 2007	Jan	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

@	COREPHARMA	12.5MG; 10MG	A076674	001	Oct 05, 2004	Feb	CAHN
@		12.5MG; 20MG	A076674	002	Oct 05, 2004	Feb	CAHN
@		25MG; 20MG	A076674	003	Oct 05, 2004	Feb	CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	HERITAGE PHARMS INC	12.5MG; 7.5MG	A202150	001	Mar 07, 2014	Apr	DISC
@		12.5MG; 15MG	A202150	002	Mar 07, 2014	Apr	DISC
@		25MG; 15MG	A202150	003	Mar 07, 2014	Apr	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>D>	@	ACCORD HLTHCARE	12.5MG; 20MG	A209281	001	Feb 07, 2019	Jul	CMFD
>A>	AB		12.5MG; 20MG	A209281	001	Feb 07, 2019	Jul	CMFD
>D>	@		12.5MG; 40MG	A209281	002	Feb 07, 2019	Jul	CMFD
>A>	AB		12.5MG; 40MG	A209281	002	Feb 07, 2019	Jul	CMFD
>D>	@		25MG; 40MG	A209281	003	Feb 07, 2019	Jul	CMFD
>A>	AB		25MG; 40MG	A209281	003	Feb 07, 2019	Jul	CMFD
	AB	UMEDICA LABS PVT LTD	12.5MG; 20MG	A208847	001	Sep 17, 2019	May	CMFD
	@		12.5MG; 20MG	A208847	001	Sep 17, 2019	Mar	DISC
	AB		12.5MG; 40MG	A208847	003	Sep 17, 2019	May	CMFD
	@		12.5MG; 40MG	A208847	003	Sep 17, 2019	Mar	DISC
	AB		25MG; 40MG	A208847	002	Sep 17, 2019	May	CMFD
	@		25MG; 40MG	A208847	002	Sep 17, 2019	Mar	DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

>D>	AB	+	GD SEARLE LLC	25MG; 25MG	N012616	004	Dec 30, 1982	Jul	CAHN
>D>		+		50MG; 50MG	N012616	005	Dec 30, 1982	Jul	CAHN
>A>	AB	+	PFIZER	25MG; 25MG	N012616	004	Dec 30, 1982	Jul	CAHN
>A>		+		50MG; 50MG	N012616	005	Dec 30, 1982	Jul	CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

@	MACLEODS PHARMS LTD	12.5MG; 40MG	A204169	001	Nov 02, 2015	May	DISC
@		12.5MG; 80MG	A204169	002	Nov 02, 2015	May	DISC
@		25MG; 80MG	A204169	003	Nov 02, 2015	May	DISC
@	MYLAN	12.5MG; 40MG	A091648	001	Feb 25, 2014	Apr	DISC
@		12.5MG; 80MG	A091648	002	Feb 25, 2014	Apr	DISC
@		25MG; 80MG	A091648	003	Feb 25, 2014	Apr	DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	CADILA	25MG; 37.5MG	A208358	001	Feb 11, 2019	Feb	CAHN	
	@	DURAMED PHARMS BARR	25MG; 37.5MG	A075052	001	Jun 18, 1999	Mar	DISC

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@	PLIVA	25MG; 37.5MG	A074026	001	Apr 26, 1996	Mar	DISC
---	-------	--------------	---------	-----	--------------	-----	------

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

AB	ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan	NFTG	
AB		15MG	A206986	002	Jan 21, 2020	Jan	NFTG	
AB		20MG	A206986	003	Jan 21, 2020	Jan	NFTG	
AB		30MG	A206986	004	Jan 21, 2020	Jan	NFTG	
AB		40MG	A206986	005	Jan 21, 2020	Jan	NFTG	
AB		50MG	A206986	006	Jan 21, 2020	Jan	NFTG	
	ZOHYDRO ER							
AB	+	PERSION	10MG	N202880	001	Oct 25, 2013	Jan	CFTG
AB	+		15MG	N202880	002	Oct 25, 2013	Jan	CFTG
AB	+		20MG	N202880	003	Oct 25, 2013	Jan	CFTG
AB	+		30MG	N202880	004	Oct 25, 2013	Jan	CFTG
AB	+		40MG	N202880	005	Oct 25, 2013	Jan	CFTG
AB	+		50MG	N202880	006	Oct 25, 2013	Jan	CFTG

<u>HYDROCORTISONE</u>									
	ENEMA;RECTAL								
	HYDROCORTISONE								
	@ TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994	Mar	DISC		
	LOTION;TOPICAL								
	HYDROCORTISONE								
	@ FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Apr	DISC		
AT	!	PERRIGO CO	A089074	001	Nov 26, 1985	Apr	CHRS		
	OINTMENT;TOPICAL								
	HYDROCORTISONE								
	@ ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982	Mar	DISC		
	TABLET;ORAL								
	HYDROCORTISONE								
AB	STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017	Feb	CAHN		
AB		10MG	A207029	002	Apr 27, 2017	Feb	CAHN		
AB		20MG	A207029	003	Apr 27, 2017	Feb	CAHN		
<u>HYDROCORTISONE ACETATE</u>									
	CREAM;TOPICAL								
	HYDROCORTISONE ACETATE								
	@ IMPERIUM	2.5%	A040259	001	Jul 29, 1999	Jun	CAHN		
<u>HYDROCORTISONE VALERATE</u>									
	OINTMENT;TOPICAL								
	HYDROCORTISONE VALERATE								
AB	COSETTE	0.2%	A211764	001	Mar 04, 2020	Feb	NEWA		
<u>HYDROMORPHONE HYDROCHLORIDE</u>									
	INJECTABLE;INJECTION								
	DILAUDID								
	+!	FRESENIUS KABI USA	N019034	006	Jan 16, 2020	Jan	NEWA		
	HYDROMORPHONE HYDROCHLORIDE								
	@ BARR	10MG/ML	A076444	001	Apr 25, 2003	Mar	DISC		
	SOLUTION;ORAL								
	HYDROMORPHONE HYDROCHLORIDE								
AA	LANNETT CO INC	5MG/5ML	A207108	001	Apr 22, 2020	Apr	NEWA		
	TABLET;ORAL								
	HYDROMORPHONE HYDROCHLORIDE								
AB	NOSTRUM LABS INC	8MG	A076723	001	Oct 18, 2005	Feb	CAHN		
<u>HYDROXYCHLOROQUINE SULFATE</u>									
	TABLET;ORAL								
	HYDROXYCHLOROQUINE SULFATE								
AB	ACCORD HLTHCARE	200MG	A213342	001	Apr 07, 2020	Mar	NEWA		
AB	APPCO	200MG	A210441	001	May 01, 2018	Mar	CAHN		
AB	HAVIX	200MG	A212902	001	May 14, 2020	May	NEWA		
AB	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Mar	CMFD		
AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Mar	CMFD		
<u>HYDROXYPROGESTERONE CAPROATE</u>									
	SOLUTION;INTRAMUSCULAR								
	HYDROXYPROGESTERONE CAPROATE								
	@ AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC		
AP1		1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan	CMS1		
<u>HYDROXYUREA</u>									
	CAPSULE;ORAL								
	HYDROXYUREA								
AB	LEADING PHARMA LLC	500MG	A213438	001	Apr 08, 2020	Mar	NEWA		
<u>HYDROXYZINE HYDROCHLORIDE</u>									
	SYRUP;ORAL								
	HYDROXYZINE HYDROCHLORIDE								
	@ VINTAGE PHARMS	10MG/5ML	A040391	001	Apr 10, 2002	May	DISC		
	TABLET;ORAL								
	HYDROXYZINE HYDROCHLORIDE								
	@ AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May	CAHN		
	@	25MG	A087871	003	Dec 20, 1982	May	CAHN		
	@	50MG	A087871	001	Dec 20, 1982	May	CAHN		

HYDROXYZINE PAMOATECAPSULE; ORAL
VISTARIL

>D>	+	@ PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002		Jul	CMFD
>A>	AB	+	EQ 25MG HYDROCHLORIDE	N011459	002		Jul	CMFD
>D>	+	@	EQ 50MG HYDROCHLORIDE	N011459	004		Jul	CMFD
>A>	AB	+	EQ 50MG HYDROCHLORIDE	N011459	004		Jul	CMFD

IBUPROFENTABLET; ORAL
IBUPROFEN

AB		AUROBINDO PHARMA LTD	400MG	A213794	001	May 08, 2020	Apr	NEWA
AB			600MG	A213794	002	May 08, 2020	Apr	NEWA
AB			800MG	A213794	003	May 08, 2020	Apr	NEWA

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
IBUPROFEN LYSINE

AP		XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN
----	--	-------------	------------------------------------	---------	-----	--------------	-----	------

IBUPROFEN; OXYCODONE HYDROCHLORIDETABLET; ORAL
COMBUNOX

+	@	FOREST LABS	400MG; 5MG	N021378	001	Nov 26, 2004	Apr	CRLD
		OXYCODONE HYDROCHLORIDE AND IBUPROFEN						
		ACTAVIS ELIZABETH	400MG; 5MG	A078769	001	Jan 04, 2008	Apr	CTEC
	@	BARR LABS INC	400MG; 5MG	A078316	001	Nov 29, 2007	Apr	DISC

ICATIBANT ACETATEINJECTABLE; SUBCUTANEOUS
ICATIBANT ACETATE

>A>	AP	CIPLA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A212446	001	Jul 13, 2020	Jul	NEWA
	AP	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A208317	001	Jun 18, 2020	Jun	NEWA
	AP	JIANGSU HANSOH PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211021	001	Mar 09, 2020	Feb	NEWA

ICOSAPENT ETHYLCAPSULE; ORAL
ICOSAPENT ETHYL

>A>	AB	DR REDDYS	1GM	A209499	001	Aug 07, 2020	Jul	NEWA
	AB	HIKMA	1GM	A209457	001	May 21, 2020	May	NFTG
		VASCEPA						
	AB	+! AMARIN PHARMS	1GM	N202057	001	Jul 26, 2012	May	CFTG

IMATINIB MESYLATETABLET; ORAL
IMATINIB MESYLATE

>A>	AB	EUGIA PHARMA	EQ 100MG BASE	A212773	001	Jul 23, 2020	Jul	NEWA
>A>	AB		EQ 400MG BASE	A212773	002	Jul 23, 2020	Jul	NEWA
	AB	ZYDUS PHARMS	EQ 100MG BASE	A210658	001	Apr 08, 2020	Mar	NEWA
	AB		EQ 400MG BASE	A210658	002	Apr 08, 2020	Mar	NEWA

IMIPRAMINE HYDROCHLORIDETABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

>A>		@ CHARTWELL	10MG	A090441	002	Mar 11, 2010	Jul	CAHN
>A>		@	25MG	A090441	003	Mar 11, 2010	Jul	CAHN
>A>		@	50MG	A090441	001	Mar 11, 2010	Jul	CAHN
>D>		@ LUPIN LTD	10MG	A090441	002	Mar 11, 2010	Jul	CAHN
>D>		@	25MG	A090441	003	Mar 11, 2010	Jul	CAHN
>D>		@	50MG	A090441	001	Mar 11, 2010	Jul	CAHN
	AB	OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Apr	CMFD
	AB		25MG	A040751	002	Feb 28, 2008	Apr	CMFD
	AB		50MG	A040751	001	Feb 28, 2008	Apr	CMFD

INDACATEROL MALEATEPOWDER; INHALATION
ARCAPTA NEOHALER

+	@	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	CAHN
+	@	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	DISC

INDAPAMIDETABLET; ORAL
INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A075201	001	Dec 04, 1998	Jan	CAHN
AB		2.5MG	A075201	002	Dec 04, 1998	Jan	CAHN

INDINAVIR SULFATECAPSULE; ORAL
CRIXIVAN

+ @	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996	Mar	DISC
-----	-------------------	---------------	---------	-----	--------------	-----	------

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

>D>	AB	HERITAGE	25MG	N018851	001	May 18, 1984	Jul	DISC
>A>		@	25MG	N018851	001	May 18, 1984	Jul	DISC
	AB		25MG	N018851	001	May 18, 1984	Jan	CAHN
>D>	AB		50MG	N018851	002	May 18, 1984	Jul	DISC
>A>		@	50MG	N018851	002	May 18, 1984	Jul	DISC
	AB		50MG	N018851	002	May 18, 1984	Jan	CAHN
		@ HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Apr	DISC
		@	50MG	A070756	001	Feb 12, 1986	Mar	DISC

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

@	MYLAN	75MG	A202139	001	Mar 20, 2014	May	DISC
---	-------	------	---------	-----	--------------	-----	------

SUPPOSITORY; RECTAL
INDOMETHACIN

>D>	!	ACP NIMBLE	50MG	A073314	001	Aug 31, 1992	Jul	CAHN
>A>	!	COSETTE	50MG	A073314	001	Aug 31, 1992	Jul	CAHN

INGENOL MEBUTATEGEL; TOPICAL
INGENOL MEBUTATE

@	PERRIGO UK FINCO	0.015%	A209018	001	Jan 07, 2019	Jun	DISC	
@		0.05%	A209019	001	Jan 09, 2019	Jun	DISC	
+	!	LEO LABS	0.015%	N202833	001	Jan 23, 2012	Jun	CTEC
+	!		0.05%	N202833	002	Jan 23, 2012	Jun	CTEC

IPRATROPIUM BROMIDESOLUTION; INHALATION
IPRATROPIUM BROMIDE

@	WATSON LABS	0.02%	A076291	001	May 09, 2005	Apr	DISC
---	-------------	-------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

AB	APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD
----	------------	---------------	---------	-----	--------------	-----	------

IRBESARTANTABLET; ORAL
IRBESARTAN

@	HIKMA	75MG	A090201	001	Oct 15, 2012	Feb	DISC
@		150MG	A090201	002	Oct 15, 2012	Feb	DISC
@		300MG	A090201	003	Oct 15, 2012	Feb	DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

@	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Apr	DISC
@		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Apr	DISC
@	PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008	Apr	DISC
@		100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008	Apr	DISC

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

@	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Feb	DISC
@		60MG	A076813	001	Jan 07, 2005	Feb	DISC

ISOTRETINOINCAPSULE; ORAL
ABSORICA LD+ @ SUN PHARM
+ @20MG
28MGN211913 003 Nov 05, 2019 Jun DISC
N211913 005 Nov 05, 2019 Jun DISCITRACONAZOLESOLUTION; ORAL
ITRACONAZOLE

@ APOTEX

10MG/ML

A208481 001 Aug 02, 2019 Feb DISC

IVACAFTORTABLET; ORAL
KALYDECO

+ @ VERTEX PHARMS

75MG

N203188 002 May 20, 2019 Jun DISC

IVERMECTINCREAM; TOPICAL
IVERMECTIN>D> AB PERRIGO UK FINCO
>A> @1%
1%
1%A210225 001 Apr 13, 2020 Jul DISC
A210225 001 Apr 13, 2020 Jul DISC
A210225 001 Apr 13, 2020 Mar NEWALOTION; TOPICAL
IVERMECTINAB TARO
SKLICE0.5%
0.5%A210720 001 May 06, 2020 Apr NFTG
N202736 001 Feb 07, 2012 Apr CFTG

AB +! ARBOR PHARMS LLC

KETOCONAZOLETABLET; ORAL
KETOCONAZOLE

AB HAVIX

200MG

A075912 001 Jan 10, 2002 Apr CMFD

KETOROLAC TROMETHAMINETABLET; ORAL
KETOROLAC TROMETHAMINEAB MYLAN
@ PLIVA10MG
10MG
10MGA074761 001 May 16, 1997 Feb CHRS
A075284 001 Jun 23, 1999 Apr DISC
A074754 001 May 16, 1997 Feb CHRS

AB ! TEVA

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
NORMODYNE

+ @ SCHERING

5MG/ML

N018686 001 Aug 01, 1984 Jan CRLD

TABLET; ORAL
LABETALOL HYDROCHLORIDEAB HERITAGE PHARMA
AB100MG
200MGA074787 001 Aug 03, 1998 Feb CMFD
A074787 002 Aug 03, 1998 Feb CMFDLACTITOLFOR SOLUTION; ORAL
PIZENSY+! BRAINTREE LABS
+10GM
10GM/PACKETN211281 001 Feb 12, 2020 Feb NEWA
N211281 001 Feb 12, 2020 Feb NEWALACTULOSESOLUTION; ORAL, RECTAL
ENULOSE>D> AA ! ACTAVIS MID ATLANTIC
>A> @10GM/15ML
10GM/15MLA071548 001 Aug 15, 1988 Jul DISC
A071548 001 Aug 15, 1988 Jul DISC

LACTULOSE

>D> AA FRESENIUS KABI
>A> AA !10GM/15ML
10GM/15MLA090502 001 Jan 25, 2012 Jul CHRS
A090502 001 Jan 25, 2012 Jul CHRSLAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TEMIXYS+! CELLTRION
+300MG; 300MG
300MG; 300MGN211284 001 Nov 16, 2018 May CHRS
N211284 001 Nov 16, 2018 May CRLD

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

@ MYLAN LABS LTD	150MG;300MG	A079079	001	Aug 12, 2019	Apr	CAHN
------------------	-------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ MYLAN	25MG	A077420	001	Jan 27, 2009	Mar	DISC
@	100MG	A077420	002	Jan 27, 2009	Mar	DISC
@	150MG	A077420	003	Jan 27, 2009	Mar	DISC
@	200MG	A077420	004	Jan 27, 2009	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	DR REDDYS LABS LTD	250MG	A202383	006	Sep 06, 2018	Mar	NEWA
AB	ZYDUS PHARMS	25MG	A207763	001	Apr 01, 2020	Mar	NEWA
AB		50MG	A207763	002	Apr 01, 2020	Mar	NEWA
AB		100MG	A207763	003	Apr 01, 2020	Mar	NEWA
AB		200MG	A207763	004	Apr 01, 2020	Mar	NEWA
AB		250MG	A207763	005	Apr 01, 2020	Mar	NEWA
AB		300MG	A207763	006	Apr 01, 2020	Mar	NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	HETERO LABS LTD III	15MG	A203083	001	May 18, 2020	May	NEWA
AB		30MG	A203083	002	May 18, 2020	May	NEWA

LANTHANUM CARBONATE

POWDER; ORAL

FOSRENOL

>D>	+	SHIRE DEV LLC	EQ 750MG BASE	N204734	001	Sep 24, 2014	Jul	CAHN
>D>	+	!	EQ 1GM BASE	N204734	002	Sep 24, 2014	Jul	CAHN
>A>	+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001	Sep 24, 2014	Jul	CAHN
>A>	+	!	EQ 1GM BASE	N204734	002	Sep 24, 2014	Jul	CAHN

TABLET, CHEWABLE; ORAL

FOSRENOL

>D>	@	SHIRE LLC	EQ 250MG BASE	N021468	001	Oct 26, 2004	Jul	CAHN	
>D>	AB	+	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul	CAHN	
>D>	AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul	CAHN	
>D>	AB	+	!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul	CAHN
>A>	@	TAKEDA PHARMS USA	EQ 250MG BASE	N021468	001	Oct 26, 2004	Jul	CAHN	
>A>	AB	+	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul	CAHN	
>A>	AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul	CAHN	
>A>	AB	+	!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul	CAHN

LASMIDITAN SUCCINATE

TABLET; ORAL

REYVOW

+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA
+	!	100MG	N211280	002	Jan 31, 2020	Jan	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

@ AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Mar	DISC		
XALATAN								
AT	+	UPJOHN	0.005%	N020597	001	Jun 05, 1996	Jun	CAHN

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

@ BARR	10MG	A077083	001	Sep 13, 2005	Apr	DISC	
@	20MG	A077083	002	Sep 13, 2005	Apr	DISC	
AB	LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA
AB		20MG	A211863	002	Feb 04, 2020	Jan	NEWA
@ TEVA PHARMS	10MG	A077084	001	Sep 13, 2005	Apr	DISC	
@	20MG	A077084	002	Sep 13, 2005	Apr	DISC	

LEMBOREXANT

TABLET; ORAL
DAYVIGO

+	EISAI INC	5MG	N212028	001	Apr 07, 2020	Apr	NEWA
+	!	10MG	N212028	002	Apr 07, 2020	Apr	NEWA

LETROZOLE

TABLET; ORAL
LETROZOLE

	@	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	May	DISC
>D>	AB	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Jul	DISC
>A>		@	2.5MG	A090789	001	Jun 03, 2011	Jul	DISC

LEUCOVORIN CALCIUM

TABLET; ORAL
LEUCOVORIN CALCIUM

AB		EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	Mar	CMFD
AB			EQ 25MG BASE	A074544	002	Aug 28, 1997	Mar	CMFD
>D>		HIKMA	EQ 10MG BASE	A072734	001	Feb 22, 1993	Jul	CTEC
>A>	AB		EQ 10MG BASE	A072734	001	Feb 22, 1993	Jul	CTEC
>D>			EQ 15MG BASE	A072735	001	Feb 22, 1993	Jul	CTEC
>A>	AB		EQ 15MG BASE	A072735	001	Feb 22, 1993	Jul	CTEC
>A>	AB	RICONPHARMA LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Jul	NEWA
>A>	AB		EQ 10MG BASE	A211132	002	Jul 30, 2020	Jul	NEWA
>A>	AB		EQ 15MG BASE	A211132	003	Jul 30, 2020	Jul	NEWA
>A>	AB		EQ 25MG BASE	A211132	004	Jul 30, 2020	Jul	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-PED KIT

+	@	ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CTNA
+	@		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CTNA
+	!		7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CTNA
+	!		11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CTNA
+	!		11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CTNA
+	!		15MG/VIAL	N020263	006	Jan 21, 1994	May	CTNA
+	!		30MG/VIAL	N020263	008	Aug 15, 2011	May	CTNA

INJECTABLE; SUBCUTANEOUS
ELIGARD KIT

+	!	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CTNA
+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CTNA
+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May	CTNA
+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May	CTNA

POWDER; INTRAMUSCULAR
LUPRON DEPOT-PED KIT

+	@	ABBVIE ENDOCRINE INC	3.75MG, 7.5MG	N020263	003	Apr 16, 1993	May	CPOT
+	@		3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CDFR
+	!		7.5MG	N020263	002	Apr 16, 1993	May	CPOT
+	!		7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CDFR
+	@		7.5MG, 7.5MG	N020263	004	Apr 16, 1993	May	CPOT
+	@		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CDFR
+	!		11.25MG	N020263	005	Jan 21, 1994	May	CPOT
+	!		11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CDFR
+	!		11.25MG	N020263	007	Aug 15, 2011	May	CPOT
+	!		11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CDFR
+	!		15MG	N020263	006	Jan 21, 1994	May	CPOT
+	!		15MG/VIAL	N020263	006	Jan 21, 1994	May	CDFR
+	!		30MG	N020263	008	Aug 15, 2011	May	CPOT
+	!		30MG/VIAL	N020263	008	Aug 15, 2011	May	CDFR

POWDER; SUBCUTANEOUS
ELIGARD KIT

+	!	TOLMAR THERAP	7.5MG	N021343	001	Jan 23, 2002	May	CPOT
+	!		7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CDFR
+	!		22.5MG	N021379	001	Jul 24, 2002	May	CPOT
+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CDFR
+	!		30MG	N021488	001	Feb 13, 2003	May	CPOT
+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May	CDFR
+	!		45MG	N021731	001	Dec 14, 2004	May	CPOT
+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May	CDFR

FENSOLVI KIT

+	!	TOLMAR	45MG	N213150	001	May 01, 2020	May	NEWA
---	---	--------	------	---------	-----	--------------	-----	------

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ @ CSPC OUYI EQ 1.25MG BASE N212895 001 Dec 19, 2019 May DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

>D>	AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A 090813	001	May 26, 2010	Jul	DISC
>A>		@	500MG/5ML (100MG/ML)	A 090813	001	May 26, 2010	Jul	DISC
	AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A 091485	001	Aug 05, 2011	Feb	CAHN
			LEVETIRACETAM IN SODIUM CHLORIDE					
>A>	AP	NEXUS PHARMS	500MG/100ML (5MG/ML)	A 213532	001	Jul 06, 2020	Jul	NEWA
>A>	AP		1000MG/100ML (10MG/ML)	A 213532	002	Jul 06, 2020	Jul	NEWA
>A>	AP		1500MG/100ML (15MG/ML)	A 213532	003	Jul 06, 2020	Jul	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA ACI HEALTHCARE LTD 100MG/ML A 078582 001 Jan 15, 2009 Jun CMFD

TABLET; ORAL

LEVETIRACETAM

>D>	AB	ACIC PHARMS	250MG	A 090767	001	Jul 28, 2010	Jul	CAHN
>D>	AB		500MG	A 090767	002	Jul 28, 2010	Jul	CAHN
>D>	AB		750MG	A 090767	003	Jul 28, 2010	Jul	CAHN
>D>	AB		1GM	A 090767	004	Jul 28, 2010	Jul	CAHN
		@ TEVA PHARMS	250MG	A 078101	001	Jan 15, 2009	Apr	DISC
		@	500MG	A 078101	002	Jan 15, 2009	Apr	DISC
		@	750MG	A 078101	003	Jan 15, 2009	Apr	DISC
		@	1GM	A 078101	004	Jan 15, 2009	Apr	DISC
	AB	VIWIT PHARM	250MG	A 078869	001	Mar 13, 2009	Mar	CAHN
	AB		250MG	A 078869	001	Mar 13, 2009	Mar	CAHN
	AB		500MG	A 078869	002	Mar 13, 2009	Mar	CAHN
	AB		500MG	A 078869	002	Mar 13, 2009	Mar	CAHN
	AB		750MG	A 078869	003	Mar 13, 2009	Mar	CAHN
	AB		750MG	A 078869	003	Mar 13, 2009	Mar	CAHN
	AB		1GM	A 078869	004	Mar 13, 2009	Mar	CAHN
	AB		1GM	A 078869	004	Mar 13, 2009	Mar	CAHN
>A>	AB	VKT PHARMA	250MG	A 090767	001	Jul 28, 2010	Jul	CAHN
>A>	AB		500MG	A 090767	002	Jul 28, 2010	Jul	CAHN
>A>	AB		750MG	A 090767	003	Jul 28, 2010	Jul	CAHN
>A>	AB		1GM	A 090767	004	Jul 28, 2010	Jul	CAHN
	AB	ZHEJIANG JINGXIN	250MG	A 091491	001	Dec 14, 2010	Jun	CAHN
	AB		500MG	A 091491	002	Dec 14, 2010	Jun	CAHN
	AB		750MG	A 091491	003	Dec 14, 2010	Jun	CAHN
	AB		1GM	A 091491	004	Dec 14, 2010	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

		@ ACTAVIS ELIZABETH	500MG	A 091557	001	Sep 12, 2011	Apr	DISC
		@	750MG	A 091557	002	Sep 12, 2011	Apr	DISC
AB		OVERSEAS	750MG	A 212688	001	Jun 11, 2020	Jun	NEWA
		@ TEVA PHARMS	500MG	A 091430	001	Sep 12, 2011	Apr	DISC
		@	750MG	A 091430	002	Sep 12, 2011	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 2.5MG/5ML A 202915 001 Aug 21, 2014 Feb DISC

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 5MG A 203027 001 Feb 13, 2015 Feb DISC

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP		GLAND PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A 205540	001	Apr 22, 2020	Apr	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A 205540	002	Apr 22, 2020	Apr	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

>D>		@ APOTEX INC	0.5%	A 078282	001	Dec 20, 2010	Jul	CAHN
>A>		@ RUBICON	0.5%	A 078282	001	Dec 20, 2010	Jul	CAHN

LEVOLEUCOVORIN CALCIUMSOLUTION;INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

AP	!	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr	CHRS
AP	!		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr	CHRS
	@	SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Apr	DISC

LEVORPHANOL TARTRATETABLET;ORAL
LEVORPHANOL TARTRATE

AB		NOVITIUM PHARMA	2MG	A213479	001	Jul 01, 2020	Jun	NEWA
----	--	-----------------	-----	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUMPOWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Mar	NEWA
----	--	-----------	-------------	---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL
THYRO-TABS

AB2, AB4	+	ALVOGEN	0.3MG	N021116	009	Oct 24, 2002	Jan	CHRS
-------------	---	---------	-------	---------	-----	--------------	-----	------

LIDOCAINEOINTMENT;TOPICAL
LIDOCAINE

AT		MACLEODS PHARMS LTD	5%	A211697	001	Mar 16, 2020	Mar	NEWA
	@	SUNGEN PHARMA	5%	A212486	001	Oct 17, 2019	Mar	DISC
AT			5%	A212486	001	Oct 17, 2019	Mar	CPOT
	@	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Apr	DISC

PATCH;TOPICAL
LIDOCAINE

AB		RHODES PHARMS	5%	A209190	001	Apr 30, 2020	Apr	NEWA
----	--	---------------	----	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP		HUONS	1%	A212821	001	May 07, 2020	Apr	NEWA
AP		WEST-WARD PHARMS INT	1%	A080407	001		Mar	CMFD
AP			2%	A080407	002		Mar	CMFD
		LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE					
AP		WEST-WARD PHARMS INT	1%	A084625	001		Mar	CMFD
AP			2%	A084625	002		Mar	CMFD

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

AT		WOCKHARDT BIO AG	4%	A087881	001	Nov 18, 1982	Jun	CMFD
----	--	------------------	----	---------	-----	--------------	-----	------

LINCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION
LINCOMYCIN

AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

LINEZOLIDTABLET;ORAL
LINEZOLID

	@	GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Apr	DISC
	@	TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May	DISC

LIOthyRONINE SODIUMINJECTABLE;INJECTION
LIOthyRONINE SODIUM

AP		XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb	CAHN
----	--	-------------	-------------------	---------	-----	--------------	-----	------

TABLET;ORAL
LIOthyRONINE SODIUM

AB		SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
AB			EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
AB			EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD

TABLET;ORAL

LIOTHYRONINE SODIUM

>D>	@ TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Jul	CMFD
>A>	AB	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Jul	CMFD
>D>	@	EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Jul	CMFD
>A>	AB	EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Jul	CMFD
>D>	@	EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Jul	CMFD
>A>	AB	EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Jul	CMFD

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

VYVANSE

>D>	+ SHIRE DEVELOPMENT	10MG	N021977	007	Oct 30, 2014	Jul	CAHN
>D>	+	20MG	N021977	004	Dec 10, 2007	Jul	CAHN
>D>	+	30MG	N021977	001	Feb 23, 2007	Jul	CAHN
>D>	+	40MG	N021977	005	Dec 10, 2007	Jul	CAHN
>D>	+	50MG	N021977	002	Feb 23, 2007	Jul	CAHN
>D>	+	60MG	N021977	006	Dec 10, 2007	Jul	CAHN
>D>	+!	70MG	N021977	003	Feb 23, 2007	Jul	CAHN
>A>	+ TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014	Jul	CAHN
>A>	+	20MG	N021977	004	Dec 10, 2007	Jul	CAHN
>A>	+	30MG	N021977	001	Feb 23, 2007	Jul	CAHN
>A>	+	40MG	N021977	005	Dec 10, 2007	Jul	CAHN
>A>	+	50MG	N021977	002	Feb 23, 2007	Jul	CAHN
>A>	+	60MG	N021977	006	Dec 10, 2007	Jul	CAHN
>A>	+!	70MG	N021977	003	Feb 23, 2007	Jul	CAHN

TABLET, CHEWABLE;ORAL

VYVANSE

>D>	+ SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jul	CAHN
>D>	+	20MG	N208510	002	Jan 28, 2017	Jul	CAHN
>D>	+	30MG	N208510	003	Jan 28, 2017	Jul	CAHN
>D>	+	40MG	N208510	004	Jan 28, 2017	Jul	CAHN
>D>	+	50MG	N208510	005	Jan 28, 2017	Jul	CAHN
>D>	+!	60MG	N208510	006	Jan 28, 2017	Jul	CAHN
>A>	+ TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017	Jul	CAHN
>A>	+	20MG	N208510	002	Jan 28, 2017	Jul	CAHN
>A>	+	30MG	N208510	003	Jan 28, 2017	Jul	CAHN
>A>	+	40MG	N208510	004	Jan 28, 2017	Jul	CAHN
>A>	+	50MG	N208510	005	Jan 28, 2017	Jul	CAHN
>A>	+!	60MG	N208510	006	Jan 28, 2017	Jul	CAHN

LISINAPRIL

SOLUTION;ORAL

QBRELIS

+!	AZURITY	1MG/ML	N208401	001	Jul 29, 2016	May	CAHN
----	---------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

LISINAPRIL

>A>	@ ASCENT PHARMS INC	2.5MG	A075903	001	Jul 01, 2002	Jul	CAHN
>A>	@	5MG	A075903	002	Jul 01, 2002	Jul	CAHN
>A>	@	10MG	A075903	003	Jul 01, 2002	Jul	CAHN
>A>	@	20MG	A075903	004	Jul 01, 2002	Jul	CAHN
>A>	@	30MG	A075903	005	Jul 01, 2002	Jul	CAHN
>A>	@	40MG	A075903	006	Jul 01, 2002	Jul	CAHN
AB	COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb	CAHN
AB		5MG	A076102	002	Sep 30, 2002	Feb	CAHN
AB		10MG	A076102	003	Sep 30, 2002	Feb	CAHN
AB		20MG	A076102	004	Sep 30, 2002	Feb	CAHN
AB		30MG	A076102	005	Sep 30, 2002	Feb	CAHN
AB		40MG	A076102	006	Sep 30, 2002	Feb	CAHN
>D>	@ INVATECH	2.5MG	A075903	001	Jul 01, 2002	Jul	CAHN
>D>	@	5MG	A075903	002	Jul 01, 2002	Jul	CAHN
>D>	@	10MG	A075903	003	Jul 01, 2002	Jul	CAHN
>D>	@	20MG	A075903	004	Jul 01, 2002	Jul	CAHN
>D>	@	30MG	A075903	005	Jul 01, 2002	Jul	CAHN
>D>	@	40MG	A075903	006	Jul 01, 2002	Jul	CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	+ HIKMA	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
AB	+	300MG	N017812	001		Jan	CAHN
AB	+!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN
	@ MYLAN	150MG	A076243	002	Feb 24, 2003	Jan	DISC

	CAPSULE;ORAL								
	LITHIUM CARBONATE								
	@	300MG		A076243	001	Jun 27, 2002		Jan	DISC
	<u>LITHIUM CITRATE</u>								
	SYRUP;ORAL								
	LITHIUM CITRATE								
AA	+! HIKMA	EQ 300MG CARBONATE/5ML		N018421	001			Jan	CAHN
	<u>LOFEXIDINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	LUCEMYRA								
	+! USWM	EQ 0.18MG BASE		N209229	001	May 16, 2018		Jun	CAHN
	<u>LOMITAPIDE MESYLATE</u>								
	CAPSULE;ORAL								
	JUXTAPID								
	+ AMRYT	EQ 5MG BASE		N203858	001	Dec 21, 2012		May	CAHN
	+	EQ 10MG BASE		N203858	002	Dec 21, 2012		May	CAHN
	+	EQ 20MG BASE		N203858	003	Dec 21, 2012		May	CAHN
	+	EQ 30MG BASE		N203858	004	Apr 23, 2015		May	CAHN
	+	EQ 40MG BASE		N203858	005	Apr 23, 2015		May	CAHN
	+!	EQ 60MG BASE		N203858	006	Apr 23, 2015		May	CAHN
	<u>LORAZEPAM</u>								
	TABLET;ORAL								
	LORAZEPAM								
	@ MYLAN	0.5MG		A077657	001	Mar 16, 2006		Mar	DISC
	@	1MG		A077657	002	Mar 16, 2006		Mar	DISC
	@	2MG		A077657	003	Mar 16, 2006		Mar	DISC
	<u>LORCASERIN HYDROCHLORIDE</u>								
	TABLET;ORAL								
	BELVIQ								
	+ @ EISAI INC	10MG		N022529	001	Jun 27, 2012		Feb	DISC
	TABLET, EXTENDED RELEASE;ORAL								
	BELVIQ XR								
	+ @ EISAI INC	20MG		N208524	001	Jul 15, 2016		Feb	DISC
	<u>LOSARTAN POTASSIUM</u>								
	TABLET;ORAL								
	LOSARTAN POTASSIUM								
	@ HIKMA	25MG		A077459	001	Oct 06, 2010		Feb	DISC
	@	50MG		A077459	002	Oct 06, 2010		Feb	DISC
	@	100MG		A077459	003	Oct 06, 2010		Feb	DISC
	<u>LOVASTATIN</u>								
	TABLET;ORAL								
	LOVASTATIN								
AB	COREPHARMA	10MG		A077748	001	Feb 28, 2007		Feb	CAHN
AB		20MG		A077748	002	Feb 28, 2007		Feb	CAHN
AB		40MG		A077748	003	Feb 28, 2007		Feb	CAHN
	<u>LURBINECTEDIN</u>								
	POWDER; INTRAVENOUS								
	ZEPZELCA								
	+! JAZZ	4MG/VIAL		N213702	001	Jun 15, 2020		Jun	NEWA
	<u>MAFENIDE ACETATE</u>								
	CREAM; TOPICAL								
	SULFAMYLON								
	+! RISING	EQ 85MG BASE/GM		N016763	001			May	CAHN
	<u>MAGNESIUM SULFATE</u>								
	INJECTABLE; INJECTION								
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER								
>A>	AP	BAXTER HLTHCARE CORP 1GM/100ML		A211965	001	Aug 11, 2020		Jul	NEWA
		MAGNESIUM SULFATE IN PLASTIC CONTAINER							
	AP	BAXTER HLTHCARE CORP 2GM/50ML (40MG/ML)		A211966	001	Jun 01, 2020		May	NEWA
	AP	4GM/50ML (80MG/ML)		A211966	002	Jun 01, 2020		May	NEWA
	AP	4GM/100ML (40MG/ML)		A211966	003	Jun 01, 2020		May	NEWA
>A>	AP	GLAND PHARMA LTD 2GM/50ML (40MG/ML)		A213917	001	Jul 10, 2020		Jul	NEWA

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

>A>	AP		4GM/100ML (40MG/ML)		A213917	002	Jul 10, 2020	Jul	NEWA
-----	----	--	---------------------	--	---------	-----	--------------	-----	------

MAZINDOL

TABLET; ORAL

SANOREX

	+ @	NOVARTIS	1MG		N017247	001		Jan	CAHN
	+ @		2MG		N017247	002		Jan	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA		INDICUS PHARMA	50MG		A205136	003	Feb 22, 2019	Jun	CTEC
	@	MYLAN PHARMS INC	12.5MG		A202640	001	Sep 17, 2012	Jan	DISC
	@		25MG		A202640	002	Sep 17, 2012	Jan	DISC
AA		ZYDUS	12.5MG		A213957	001	Jun 23, 2020	Jun	NEWA
AA			25MG		A213957	002	Jun 23, 2020	Jun	NEWA

MEFENAMIC ACID

CAPSULE; ORAL

PONSTEL

>A>	AB	+!	AVION PHARMS	250MG	N015034	003		Jul	CAHN
>D>	AB	+!	SHIONOGI INC	250MG	N015034	003		Jul	CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

	!	BARR	250MG		A076392	001	Dec 29, 2003	Feb	CTEC
	@	HIKMA	250MG		A076523	001	Oct 01, 2004	Feb	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

	@	HIKMA	40MG/ML		A075997	001	Feb 15, 2002	Feb	DISC
AB	!	PAR PHARM	40MG/ML		A075671	001	Jul 25, 2001	Feb	CHRS
	@	TEVA PHARMS	40MG/ML		A075681	001	May 05, 2003	Apr	DISC

MELOXICAM

CAPSULE; ORAL

MELOXICAM

AB		LUPIN LTD	5MG		A209487	001	Jun 01, 2020	May	NFTG
AB			10MG		A209487	002	Jun 01, 2020	May	NFTG
		VIVLODEX							
AB	+	ZYLA	5MG		N207233	001	Oct 22, 2015	May	CFTG
AB	+!		10MG		N207233	002	Oct 22, 2015	May	CFTG

SOLUTION; INTRAVENOUS

ANJESO

	+!	BAUDAX	30MG/ML (30MG/ML)		N210583	001	Feb 20, 2020	Feb	NEWA
--	----	--------	-------------------	--	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

QMITZ ODT

	+ @	TERSERA THERAPS LLC	7.5MG		N211210	001	Oct 19, 2018	Apr	DISC
	+ @		15MG		N211210	002	Oct 19, 2018	Apr	DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

	@	ALVOGEN INC	EQ 50MG BASE/VIAL		A204817	001	May 17, 2019	May	DISC
AP		BPI LABS LLC	EQ 50MG BASE/VIAL		A209197	001	May 08, 2020	Apr	NEWA
AP		INGENUS PHARMS LLC	EQ 50MG BASE/VIAL		A210947	001	Feb 18, 2020	Feb	NEWA
	@	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL		A204773	001	Aug 22, 2016	Feb	DISC
	@	TWI PHARMS	EQ 50MG BASE/VIAL		A211463	001	Sep 13, 2019	Jan	DISC
	@	USWM	EQ 50MG BASE/VIAL		A207032	001	May 03, 2019	Jun	CAHN

POWDER; INTRAVENOUS

EVOMELA

	+!	ACROTECH	EQ 50MG BASE/VIAL		N207155	001	Mar 10, 2016	Mar	CTEC
AP	+!		EQ 50MG BASE/VIAL		N207155	001	Mar 10, 2016	Feb	CFTG

MELPHALAN HYDROCHLORIDE

	@	ACTAVIS LLC	EQ 50MG BASE/VIAL		A209323	001	Mar 06, 2020	Mar	DISC
AP			EQ 50MG BASE/VIAL		A209323	001	Mar 06, 2020	Feb	NFTG

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB	ANI PHARMS INC	7MG	A205365	001	Feb 28, 2020	Feb	NEWA
AB		14MG	A205365	002	Feb 28, 2020	Feb	NEWA
AB		21MG	A205365	003	Feb 28, 2020	Feb	NEWA
AB		28MG	A205365	004	Feb 28, 2020	Feb	NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	@ CHARTWELL	5MG	A090244	001	Jul 11, 2018	Mar	CAHN
	@	10MG	A090244	002	Jul 11, 2018	Mar	CAHN
AB	HIKMA	5MG	A208173	001	Feb 28, 2020	Feb	NEWA
AB		10MG	A208173	002	Feb 28, 2020	Feb	NEWA
AB	NINGBO	5MG	A212947	001	Apr 03, 2020	Apr	CAHN
AB		5MG	A212947	001	Apr 03, 2020	Mar	NEWA
AB		10MG	A212947	002	Apr 03, 2020	Apr	CAHN
AB		10MG	A212947	002	Apr 03, 2020	Mar	NEWA
	@ TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	Apr	DISC
	@	10MG	A090052	002	Oct 25, 2011	Apr	DISC

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

AA	! EPIC PHARMA	50MG	A040331	001	May 28, 1999	Feb	CHRS
AA	!	100MG	A040331	002	May 28, 1999	Feb	CHRS
	@ HIKMA	50MG	A040110	001	Mar 12, 1997	Feb	DISC
	@	100MG	A040110	002	Mar 12, 1997	Feb	DISC

MESALAMINE

SUPPOSITORY;RECTAL

MESALAMINE

AB	ANNORA PHARMA	1GM	A213377	001	Mar 19, 2020	Mar	NEWA
AB	ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan	NEWA

METAXALONE

TABLET;ORAL

METAXALONE

>D>	AB	APPCO	800MG	A208774	001	Sep 24, 2018	Jul	CAHN
	AB	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Mar	CTEC
>A>	AB	RISING	800MG	A208774	001	Sep 24, 2018	Jul	CAHN
	AB	SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020	Mar	NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb	NFTG
	RIOMET						
AB	+! RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb	CFTG
	+!	500MG/5ML	N021591	001	Sep 11, 2003	Jan	CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

	@ HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Mar	DISC
	@	850MG	A075978	002	Jan 25, 2002	Mar	DISC
	@	1GM	A075978	003	Nov 05, 2002	Mar	DISC
	@ MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	May	DISC
	@	850MG	A205330	002	Oct 31, 2017	May	DISC
	@	1GM	A205330	003	Oct 31, 2017	May	DISC
	@ MYLAN	500MG	A075976	001	Jan 24, 2002	Jan	DISC
	@	850MG	A075976	002	Jan 24, 2002	Jan	DISC
	@	1GM	A075976	003	Jan 24, 2002	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB2	AJANTA PHARMA LTD	500MG	A213651	001	Apr 09, 2020	Mar	NEWA
AB2		1GM	A213651	002	Apr 09, 2020	Mar	NEWA
	@ APOTEX	750MG	A076706	002	Dec 29, 2005	May	DISC
	@ BARR	750MG	A076863	001	Oct 14, 2004	Apr	DISC
	@ MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	May	DISC
	@	750MG	A206955	002	Dec 07, 2016	May	DISC
AB1	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Jun	CMFD
AB		750MG	A211052	002	Sep 24, 2018	Jun	CMFD

METHADONE HYDROCHLORIDE

	CONCENTRATE;ORAL						
	METHADONE HYDROCHLORIDE						
AA	SPECGX LLC	10MG/ML	A207368	001	Aug 22, 2019	May	CAHN
	SOLUTION;ORAL						
	METHADONE HYDROCHLORIDE						
AA	SPECGX LLC	5MG/5ML	A207537	001	Oct 02, 2019	May	CAHN
AA		10MG/5ML	A207537	002	Oct 01, 2019	May	CAHN
	TABLET;ORAL						
	DOLOPHINE HYDROCHLORIDE						
	+ @ HIKMA	5MG	N006134	002		Jun	DISC
	+ @	10MG	N006134	010		Jun	DISC
	METHADONE HYDROCHLORIDE						
AA	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Mar	CAHN
AA		5MG	A210484	001	Aug 02, 2018	Mar	CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar	CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar	CAHN
AA	ROXANE	5MG	A088108	001	Mar 08, 1983	May	CMFD
AA		10MG	A088109	001	Mar 08, 1983	May	CMFD
AA	! SPECGX LLC	5MG	A040517	001	Apr 27, 2004	Jun	CHRS
AA	!	10MG	A040517	002	Apr 27, 2004	Jun	CHRS
AA	VISTAPHARM	10MG	A204166	001	Mar 16, 2020	Mar	NEWA
	METHADOSE						
	@ SPECGX LLC	5MG	A040050	001	Apr 15, 1993	May	DISC
	@	10MG	A040050	002	Apr 15, 1993	May	DISC

METHAZOLAMIDE

	TABLET;ORAL						
	METHAZOLAMIDE						
>A>	@ BAUSCH	25MG	A207438	001	Oct 05, 2018	Jul	CAHN
>A>	@	50MG	A207438	002	Oct 05, 2018	Jul	CAHN
>D>	@ MICRO LABS	25MG	A207438	001	Oct 05, 2018	Jul	CAHN
>D>	@	50MG	A207438	002	Oct 05, 2018	Jul	CAHN

METHENAMINE HIPPURATE

	TABLET;ORAL						
	METHENAMINE HIPPURATE						
>D> AB	IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Jul	DISC
>A>	@	1GM	A076411	001	Jun 20, 2003	Jul	DISC

METHOCARBAMOL

	TABLET;ORAL						
	METHOCARBAMOL						
>A> AA	AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020	Jul	NEWA
	@ HIKMA INTL PHARMS	500MG	A085159	001		Feb	DISC
	@	750MG	A085123	001		Feb	DISC

METHOHEXITAL SODIUM

	INJECTABLE;INJECTION						
	BREVITAL SODIUM						
>D>	+! PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Jul	DISC
>A>	+ @	2.5GM/VIAL	N011559	002		Jul	DISC

METHOTREXATE SODIUM

	INJECTABLE;INJECTION						
	METHOTREXATE SODIUM PRESERVATIVE FREE						
	@ MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Jan	DISC
	@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Jan	DISC
	@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Jan	DISC
	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Jan	CTEC
	SOLUTION;ORAL						
	XATMEP						
>D>	+! AZURITY	EQ 2MG BASE/ML	N208400	001	Apr 25, 2017	Jul	CPOT
	+!	EQ 2MG BASE/ML	N208400	001	Apr 25, 2017	May	CAHN
>A>	+!	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Jul	CPOT
	TABLET;ORAL						
	METHOTREXATE SODIUM						
AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A213343	001	Jan 24, 2020	Jan	NEWA

TABLET;ORAL

METHOTREXATE SODIUM							
	+ @	DAVA PHARMS INC	EQ 2.5MG BASE	N008085	002		Mar DISC
AB		EUGIA PHARMA	EQ 2.5MG BASE	A210454	001	Jan 30, 2020	Jan NEWA
AB	!	HIKMA	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Mar CHRS

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE							
AA		BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Apr CTEC
AA	!		5MG	A200602	002	Sep 24, 2012	Apr CTEC
AA		BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Apr CMFD
AA			5MG	A040642	002	Dec 06, 2011	Apr CMFD

METHYLDOPA

TABLET;ORAL

METHYLDOPA							
	@	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Apr DISC
	@		500MG	A070343	001	Feb 20, 1986	Apr DISC
	@	WATSON LABS	500MG	A070625	001	Jun 06, 1986	Apr DISC

METHYLENE BLUE

SOLUTION;INTRAVENOUS

PROVAYBLUE							
	+!	PROVEPHARM SAS	10MG/2ML (5MG/ML)	N204630	002	Jul 18, 2019	Jun NEWA

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE							
AB		TULEX PHARMS INC	0.2MG	A212233	001	May 01, 2020	Apr NEWA

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

>D>	AB	+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jul CTEC
>A>		+		8.6MG	N205489	001	Jun 19, 2017	Jul CTEC
	AB	+		8.6MG	N205489	001	Jun 19, 2017	Jun CFTG
>D>	AB	+		17.3MG	N205489	002	Jun 19, 2017	Jul CTEC
>A>		+		17.3MG	N205489	002	Jun 19, 2017	Jul CTEC
	AB	+		17.3MG	N205489	002	Jun 19, 2017	Jun CFTG
>D>	AB	+!		25.9MG	N205489	003	Jun 19, 2017	Jul CTEC
>A>		+!		25.9MG	N205489	003	Jun 19, 2017	Jul CTEC
	AB	+!		25.9MG	N205489	003	Jun 19, 2017	Jun CFTG
		+!		25.9MG	N205489	003	Jun 19, 2017	Jun CHRS
>D>			METHYLPHENIDATE					
>D>	AB		ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020	Jul DISC
>A>		@		8.6MG	A210924	001	Jun 19, 2020	Jul DISC
	AB			8.6MG	A210924	001	Jun 19, 2020	Jun NFTG
>D>	AB			17.3MG	A210924	002	Jun 19, 2020	Jul DISC
>A>		@		17.3MG	A210924	002	Jun 19, 2020	Jul DISC
	AB			17.3MG	A210924	002	Jun 19, 2020	Jun NFTG
>D>	AB			25.9MG	A210924	003	Jun 19, 2020	Jul DISC
>A>		@		25.9MG	A210924	003	Jun 19, 2020	Jul DISC
	AB			25.9MG	A210924	003	Jun 19, 2020	Jun NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE							
	@	BARR LABS INC	10MG	A079031	004	Oct 15, 2014	Apr DISC
	@		20MG	A079031	001	Jul 13, 2012	Apr DISC
	@		30MG	A079031	002	Jul 13, 2012	Apr DISC
	@		40MG	A079031	003	Jul 13, 2012	Apr DISC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE							
AA		ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020	Mar NEWA
AA			10MG/5ML	A211647	002	Mar 30, 2020	Mar NEWA
>A>	AA		5MG/5ML	A210764	001	Apr 10, 2020	Jul CAHN
>A>	AA		10MG/5ML	A210764	002	Apr 10, 2020	Jul CAHN
>D>	AA		5MG/5ML	A210764	001	Apr 10, 2020	Jul CAHN
	AA		5MG/5ML	A210764	001	Apr 10, 2020	Mar NEWA
>D>	AA		10MG/5ML	A210764	002	Apr 10, 2020	Jul CAHN
	AA		10MG/5ML	A210764	002	Apr 10, 2020	Mar NEWA

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	QUAGEN	5MG/5ML	A213567	001	Jun 04, 2020	Jun	NEWA
AA		10MG/5ML	A213567	002	Jun 04, 2020	Jun	NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	PRINSTON INC	5MG	A212697	001	Jul 23, 2020	Jul	NEWA
>A>	AB		10MG	A212697	002	Jul 23, 2020	Jul	NEWA
>A>	AB		20MG	A212697	003	Jul 23, 2020	Jul	NEWA
		@ WATSON LABS	5MG	A040220	001	Aug 29, 1997	Apr	DISC
		@	10MG	A040220	002	Aug 29, 1997	Apr	DISC
		@	20MG	A040220	003	Aug 29, 1997	Apr	DISC

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>D>		@ ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018	Jul	CMFD
>A>	AB		18MG	A076772	001	Mar 22, 2018	Jul	CMFD
		@	18MG	A076772	001	Mar 22, 2018	Mar	DISC
>D>		@	27MG	A076772	002	Mar 22, 2018	Jul	CMFD
>A>	AB		27MG	A076772	002	Mar 22, 2018	Jul	CMFD
		@	27MG	A076772	002	Mar 22, 2018	Mar	DISC
>D>		@	36MG	A076772	003	Mar 22, 2018	Jul	CMFD
>A>	AB		36MG	A076772	003	Mar 22, 2018	Jul	CMFD
		@	36MG	A076772	003	Mar 22, 2018	Mar	DISC
>D>		@	54MG	A076655	001	Mar 21, 2018	Jul	CMFD
>A>	AB		54MG	A076655	001	Mar 21, 2018	Jul	CMFD
		@	54MG	A076655	001	Mar 21, 2018	Mar	DISC
>A>	AB	DR REDDYS	18MG	A213473	001	Jul 29, 2020	Jul	NEWA
>A>	AB		27MG	A213473	002	Jul 29, 2020	Jul	NEWA
>A>	AB		36MG	A213473	003	Jul 29, 2020	Jul	NEWA
>A>	AB		54MG	A213473	004	Jul 29, 2020	Jul	NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

		@ DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar	DISC
--	--	-----------------------	-----	---------	-----	--------------	-----	------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

>D>		@ AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul	CMFD
>A>	AB		40MG/ML	A210043	001	May 20, 2019	Jul	CMFD
>D>		@	80MG/ML	A210043	002	May 20, 2019	Jul	CMFD
>A>	AB		80MG/ML	A210043	002	May 20, 2019	Jul	CMFD

METOCLOPRAMIDE HYDROCHLORIDE

SPRAY, METERED;NASAL

GIMOTI

+	!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Jun	NEWA
---	---	------------------	--------------------	---------	-----	--------------	-----	------

METOLAZONE

TABLET;ORAL

METOLAZONE

		@ ANI PHARMS INC	2.5MG	A075543	001	Jan 06, 2004	May	CMS1
		@	5MG	A075543	002	Mar 01, 2004	May	CMS1

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

		@ ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar	DISC
		@	EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar	DISC
		@	EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar	DISC
		@	EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar	DISC
		@ ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan	DISC
		@	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan	DISC
		@	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan	DISC
AB		PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar	NEWA
AB			EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar	NEWA
AB			EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar	NEWA
AB			EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar	NEWA

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE						
	@ HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb	DISC
	@	100MG	A074141	002	Jan 31, 1995	Feb	DISC
AB	YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	NEWA
AB		50MG	A208955	002	Feb 05, 2020	Jan	NEWA
AB		100MG	A208955	003	Feb 05, 2020	Jan	NEWA

METRONIDAZOLE

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

>A>	AP	GLAND PHARMA LTD	500MG/100ML	A212435	001	Aug 03, 2020	Jul	NEWA
		@ MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Jun	DISC

METYROSINE

CAPSULE; ORAL

DEMSEER

>D>	+	BAUSCH	250MG	N017871	001		Jul	CFTG
>A>	AB	+	250MG	N017871	001		Jul	CFTG
>A>		METYROSINE						
>A>	AB	AMNEAL	250MG	A213734	001	Jul 24, 2020	Jul	NFTG

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB		ANI PHARMS INC	150MG	A074450	001	May 16, 1996	Jun	CMFD
AB			200MG	A074450	002	May 16, 1996	Jun	CMFD
AB			250MG	A074450	003	May 16, 1996	Jun	CMFD
>A>	AB	CROSSMEDIKA SA	150MG	A213500	001	Jul 22, 2020	Jul	NEWA
>A>	AB		200MG	A213500	002	Jul 22, 2020	Jul	NEWA
>A>	AB		250MG	A213500	003	Jul 22, 2020	Jul	NEWA
AB		TEVA	150MG	A074377	001	May 16, 1995	Jun	CTEC
AB			200MG	A074377	002	May 16, 1995	Jun	CTEC
AB	!		250MG	A074377	003	May 16, 1995	Jun	CTEC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

	@ MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan	DISC
	@	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan	DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	2.5MG	A212774	001	Aug 10, 2020	Jul	NEWA
>A>	AB		5MG	A212774	002	Aug 10, 2020	Jul	NEWA
>A>	AB		10MG	A212774	003	Aug 10, 2020	Jul	NEWA

MIFEPRISTONE

TABLET; ORAL

KORLYM

>D>	+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Jul	CFTG
>A>	AB	+	300MG	N202107	001	Feb 17, 2012	Jul	CFTG
>A>		MIFEPRISTONE						
>A>	AB	TEVA PHARMS USA INC	300MG	A211436	001	Aug 03, 2020	Jul	NFTG

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

>A>	AB	EDENBRIDGE PHARMS	100MG	A209821	001	Aug 06, 2020	Jul	NEWA
-----	----	-------------------	-------	---------	-----	--------------	-----	------

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP		MEITHEAL	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Apr	CAHN
AP		NANJING KING-FRIEND	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Mar	NEWA
>A>	AP	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
>A>	AP	GLAND PHARMA LTD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A213585	001	Jul 16, 2020	Jul	NEWA
>A>	AP		EQ 40MG BASE/200ML (EQ 0.2MG	A213585	002	Jul 16, 2020	Jul	NEWA

INJECTABLE; INJECTION
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER
(BASE/ML)

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL
ZILXI

+! FOAMIX EQ 1.5% BASE N213690 001 May 28, 2020 May NEWA

CAPSULE, EXTENDED RELEASE; ORAL
XIMINO

JOURNEY EQ 45MG BASE N201922 001 Jul 11, 2012 Feb CAHN
@ EQ 67.5MG BASE N201922 002 Jul 11, 2012 Feb CAHN
EQ 90MG BASE N201922 003 Jul 11, 2012 Feb CAHN
@ EQ 112.5MG BASE N201922 004 Jul 11, 2012 Feb CAHN
EQ 135MG BASE N201922 005 Jul 11, 2012 Feb CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 50MG BASE A213662 001 May 01, 2020 Apr NEWA
AB EQ 75MG BASE A213662 002 May 01, 2020 Apr NEWA
AB EQ 100MG BASE A213662 003 May 01, 2020 Apr NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MIRABEGRON

@ SAWAI USA 25MG A209446 001 Dec 27, 2019 Jan DISC
MYRBETRIQ
+! APGDI 25MG N202611 001 Jun 28, 2012 Jan CTEC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

>D> AB IMPAX LABS INC 15MG A076901 001 Jun 28, 2005 Jul DISC
>A> @ 15MG A076901 001 Jun 28, 2005 Jul DISC
>D> AB 30MG A076901 002 Jun 28, 2005 Jul DISC
>A> @ 30MG A076901 002 Jun 28, 2005 Jul DISC
>D> AB 45MG A076901 003 Jun 28, 2005 Jul DISC
>A> @ 45MG A076901 003 Jun 28, 2005 Jul DISC

MITOMYCIN

POWDER; PYELOALYCEAL
JELMYTO

+! UROGEN PHARMA 40MG/VIAL N211728 001 Apr 15, 2020 Apr NEWA

MOMETASONE FUROATE

SPRAY, METERED; NASAL
MOMETASONE FUROATE

AB AMNEAL PHARMS 0.05MG/SPRAY A207989 001 Apr 03, 2017 Mar CPOT
AB APOTEX INC 0.05MG/SPRAY A091161 001 Mar 22, 2016 Mar CPOT
NASONEX
AB +! MERCK SHARP DOHME 0.05MG/SPRAY N020762 001 Oct 01, 1997 Mar CPOT

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL
BAFIERTAM

+! BANNER LIFE SCIENCES 95MG N210296 001 Apr 28, 2020 Apr NEWA

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB AUROBINDO PHARMA LTD EQ 4MG BASE/PACKET A213471 001 Feb 18, 2020 Feb NEWA

TABLET; ORAL

MONTELUKAST SODIUM

AB GRAVITI PHARMS EQ 10MG BASE A209012 001 Apr 24, 2017 May CAHN
@ HIKMA EQ 10MG BASE A090655 001 Aug 03, 2012 Feb DISC

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB GRAVITI PHARMS EQ 4MG BASE A209011 001 Apr 18, 2017 Apr CAHN
AB EQ 5MG BASE A209011 002 Apr 18, 2017 Apr CAHN
@ JUBILANT GENERICS EQ 4MG BASE A203795 001 Feb 27, 2015 Jan DISC
@ EQ 5MG BASE A203795 002 Feb 27, 2015 Jan DISC

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

	+	ALLERGAN	70MG	N020616	010	Jul 09, 2012	Apr	CTEC
		MORPHINE SULFATE						
		@ TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Apr	DISC
		@	30MG	A202718	002	Dec 29, 2014	Apr	DISC
		@	40MG	A202718	007	Jun 03, 2015	Apr	DISC
		@	50MG	A202718	003	Dec 29, 2014	Apr	DISC
		@	60MG	A202718	004	Dec 29, 2014	Apr	DISC
		@	70MG	A202718	008	Jun 03, 2015	Apr	DISC
		@	80MG	A202718	005	Dec 29, 2014	Apr	DISC
		@	100MG	A202718	006	Dec 29, 2014	Apr	DISC

INJECTABLE;INJECTION
DURAMORPH PF

AP	+	HIKMA	0.5MG/ML	N018565	001	Sep 18, 1984	Feb	CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Feb	CAHN
		INFUMORPH						
AP	+	HIKMA	10MG/ML	N018565	003	Jul 19, 1991	Feb	CAHN
AP	+		25MG/ML	N018565	004	Jul 19, 1991	Feb	CAHN
		MORPHINE SULFATE						
AP		HIKMA	4MG/ML	A205758	001	May 21, 2015	Feb	CAHN
AP			8MG/ML	A205758	002	May 21, 2015	Feb	CAHN
AP			10MG/ML	A205758	003	May 21, 2015	Feb	CAHN
		@ HOSPIRA	1MG/ML	A071850	001	May 11, 1988	May	DISC
	+	@ ICU MEDICAL INC	1MG/ML	N019916	001	Oct 30, 1992	May	DISC

SOLUTION;INTRAMUSCULAR

MORPHINE SULFATE (AUTOINJECTOR)

	+	MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990	Jun	CPOT
	+		15MG/ML	N019999	001	Jul 12, 1990	Jun	CTNA
	+		15MG/ML	N019999	001	Jul 12, 1990	Jun	CDFR

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

		@ NESHER PHARMS	15MG	A076733	001	May 19, 2004	Mar	DISC
		@	100MG	A077855	001	Sep 27, 2007	Mar	DISC
		@	200MG	A077855	002	Sep 27, 2007	Mar	DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		GLAND PHARMA LTD	EQ 0.5% BASE	A208778	001	Mar 30, 2020	Mar	NEWA
AT1		MYLAN	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Mar	NEWA

TABLET;ORAL

AVELOX

	+	@ BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Apr	DISC
		MOXIFLOXACIN HYDROCHLORIDE						
AB	!	DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Apr	CHRS

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CTEC
AB		TARO	EQ 2% BASE	A207116	001	Apr 27, 2020	Apr	NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

		@ VINTAGE PHARMS LLC	250MG	A090111	001	Dec 22, 2009	Jun	DISC
--	--	----------------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	CONCORD BIOTECH LTD	500MG	A212087	001	Jul 31, 2020	Jul	NEWA
-----	----	---------------------	-------	---------	-----	--------------	-----	------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

		@ TEVA PHARMS USA	180MG	A202720	001	Oct 30, 2014	Mar	DISC
		@	360MG	A202720	002	Oct 30, 2014	Mar	DISC

NABILONECAPSULE;ORAL
CESAMET

+! BAUSCH 1MG N018677 001 Dec 26, 1985 Mar CAHN

NABUMETONETABLET;ORAL
NABUMETONE

>D>	AB	!	IMPAX LABS INC	750MG	A 075189	002	Sep 24, 2001	Jul	CHRS
>A>	AB			750MG	A 075189	002	Sep 24, 2001	Jul	CHRS
>D>	AB		INVAGEN PHARMS	750MG	A 078671	002	Mar 07, 2008	Jul	CHRS
>A>	AB	!		750MG	A 078671	002	Mar 07, 2008	Jul	CHRS

NADOLOLTABLET;ORAL
CORCARD

AB	+		USWM	20MG	N018063	005	Oct 28, 1986	Jun	CAHN
AB	+			40MG	N018063	001		Jun	CAHN
AB	+!			80MG	N018063	002		Jun	CAHN
		@		120MG	N018063	003		Jun	CAHN
		@		160MG	N018063	004		Jun	CAHN
			NADOLOL						
		@	VGYAAN	20MG	A212856	001	Sep 13, 2019	Mar	DISC
		@		40MG	A212856	002	Sep 13, 2019	Mar	DISC
		@		80MG	A212856	003	Sep 13, 2019	Mar	DISC

NAFARELIN ACETATESPRAY, METERED;NASAL
SYNAREL

>D>		+!	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990	Jul	CAHN
>A>		+!	PFIZER	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990	Jul	CAHN

NAFCILLIN SODIUMINJECTABLE;INJECTION
NAFCILLIN SODIUM

>D>	AP		FRESENIUS	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019	Jul	DISC
>A>		@		EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019	Jul	DISC
>D>	AP			EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019	Jul	DISC
>A>		@		EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019	Jul	DISC
	AP			EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	May	NEWA

NALBUPHINE HYDROCHLORIDEINJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

		@	MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Feb	DISC
		@		10MG/ML	A207595	001	Jan 11, 2019	Feb	DISC
		@		20MG/ML	A206506	002	Feb 06, 2019	Feb	DISC
		@		20MG/ML	A207595	002	Jan 11, 2019	Feb	DISC

NALOXEGOL OXALATETABLET;ORAL
MOVANTIK

>D>		+	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Jul	CAHN
>D>		+!		EQ 25MG BASE	N204760	002	Sep 16, 2014	Jul	CAHN
>A>		+	REDHILL	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Jul	CAHN
>A>		+!		EQ 25MG BASE	N204760	002	Sep 16, 2014	Jul	CAHN

NALOXONE HYDROCHLORIDEINJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

	AP		DR REDDYS	1MG/ML	A213209	001	Mar 16, 2020	Mar	NEWA
	AP	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Mar	CTEC
>D>	AP		PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jul	DISC
>A>		@		0.4MG/ML	A211286	001	Jan 17, 2020	Jul	DISC
	AP			0.4MG/ML	A211286	001	Jan 17, 2020	Jan	NEWA

NAPROXEN

		SUSPENSION;ORAL							
		NAPROXEN							
>A>	AB	AMNEAL	25MG/ML	A212705	001	Jul 31, 2020	Jul	NEWA	
		TABLET;ORAL							
		NAPROXEN							
		@ MYLAN	250MG	A074121	001	Dec 21, 1993	Jan	DISC	
		@	375MG	A074121	002	Dec 21, 1993	Jan	DISC	
		@	500MG	A074121	003	Dec 21, 1993	Jan	DISC	
AB		SCIEGEN PHARMS INC	250MG	A212517	001	Feb 21, 2020	Feb	NEWA	
AB			375MG	A212517	002	Feb 21, 2020	Feb	NEWA	
AB			500MG	A212517	003	Feb 21, 2020	Feb	NEWA	
		TABLET, DELAYED RELEASE;ORAL							
		NAPROXEN							
		@ PLIVA	375MG	A075337	001	May 26, 1999	Mar	DISC	
		@	500MG	A075337	002	May 26, 1999	Mar	DISC	

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ TEVA

EQ 250MG BASE

A074198 001 Dec 21, 1993 Mar DISC

@

EQ 500MG BASE

A074198 002 Dec 21, 1993 Mar DISC

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

@ ALVOGEN

60MG

A205055 001 Dec 11, 2015 Mar DISC

@

120MG

A205055 002 Dec 11, 2015 Mar DISC

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

@ BRECKENRIDGE

500MG

A065468 001 Mar 29, 2010 Jul CAHN

@

500MG

A065468 001 Mar 29, 2010 Apr DISC

>A> @ NOSTRUM LABS INC

500MG

A065468 001 Mar 29, 2010 Jul CAHN

AA XGEN PHARMS

500MG

A065220 001 Jul 28, 2006 Feb CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT WATSON LABS

EQ 40MG BASE/ML;200,000 UNITS/ML

A062664 001 Apr 08, 1986 Mar CMFD

AT XGEN PHARMS

EQ 40MG BASE/ML;200,000 UNITS/ML

A065106 001 Jan 31, 2006 Feb CAHN

AT

EQ 40MG BASE/ML;200,000 UNITS/ML

A065108 001 Jan 31, 2006 Feb CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

>D> AP +! AVADEL LEGACY

5MG/10ML (0.5MG/ML)

N204078 001 May 31, 2013 Jul CAHN

>D> AP +!

10MG/10ML (1MG/ML)

N204078 002 May 31, 2013 Jul CAHN

>A> AP +! EXELA PHARMA

5MG/10ML (0.5MG/ML)

N204078 001 May 31, 2013 Jul CAHN

>A> AP +!

10MG/10ML (1MG/ML)

N204078 002 May 31, 2013 Jul CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

+! AERIE PHARMS INC

EQ 0.02% BASE

N208254 001 Dec 18, 2017 Feb CAIN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

@ MYLAN

500MG

A203742 001 Feb 22, 2019 Jan DISC

@

750MG

A203742 002 Feb 22, 2019 Jan DISC

@

1GM

A203742 003 Feb 22, 2019 Jan DISC

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AM REGENT

25MG/10ML (2.5MG/ML)

A090534 001 Nov 17, 2009 May CMFD

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML)
40MG/200ML (0.2MG/ML)

N022276 002 Apr 07, 2016 May CMFD
N022276 003 Apr 07, 2016 May CMFD

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

>A> AB ACELLA 10MG A072781 001 Jul 30, 1993 Jul CAHN
>D> AB INTERGEL PHARM 10MG A072781 001 Jul 30, 1993 Jul CAHN

NIMODIPINE

SOLUTION; ORAL

NYMALIZE

+ @ ARBOR PHARMS LLC 3MG/ML N203340 001 May 10, 2013 Apr DISC
+! 3MG/ML N203340 001 May 10, 2013 Apr CPOT
+! 6MG/ML N203340 002 Apr 08, 2020 Apr NEWA

NIRAPARIB TOSYLATE

CAPSULE; ORAL

ZEJULA

+! GLAXOSMITHKLINE EQ 100MG BASE N208447 001 Mar 27, 2017 Jan CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

BX +! USPHARMA 0.1MG/HR N020145 001 Apr 04, 1995 Mar CTEC
BX +! 0.2MG/HR N020145 002 Apr 04, 1995 Mar CTEC
BX +! 0.4MG/HR N020145 004 Apr 04, 1995 Mar CTEC
BX +! 0.6MG/HR N020145 005 Apr 04, 1995 Mar CTEC

TABLET; SUBLINGUAL

NITROGLYCERIN

@ ACTAVIS LABS FL INC 0.3MG

@ 0.4MG

@ 0.6MG

A203693 001 Oct 16, 2017 Mar DISC
A203693 002 Oct 16, 2017 Mar DISC
A203693 003 Oct 16, 2017 Mar DISC

NITROSTAT

>D> AB + PFIZER PHARMS 0.3MG N021134 001 May 01, 2000 Jul CAHN
>D> AB + 0.4MG N021134 002 May 01, 2000 Jul CAHN
>D> AB +! 0.6MG N021134 003 May 01, 2000 Jul CAHN
>A> AB + UPJOHN 0.3MG N021134 001 May 01, 2000 Jul CAHN
>A> AB + 0.4MG N021134 002 May 01, 2000 Jul CAHN
>A> AB +! 0.6MG N021134 003 May 01, 2000 Jul CAHN

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

@ MYLAN PHARMS INC 150MG

@ 300MG

AB ! WATSON LABS 300MG

A075806 001 Jul 05, 2002 May DISC
A075806 002 Jul 05, 2002 May DISC
A075616 002 Jul 09, 2002 May CHRS

NORETHINDRONE

TABLET; ORAL-28

NOR-QD

AB1 +! TEVA BRANDED PHARM 0.35MG N017060 001 Jan CAHN

NORETHINDRONE

AB1 NAARI PTE LTD 0.35MG A206807 001 Dec 13, 2016 Jun CAHN

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL

SPINRAZA

+! BIOGEN IDEC EQ 12MG BASE/5ML (EQ 2.4MG
BASE/ML) N209531 001 Dec 23, 2016 Jun CPOT

NYSTATIN

CREAM; TOPICAL

NYSTATIN

>D> AT VINTAGE 100,000 UNITS/GM A065315 001 May 31, 2006 Jul DISC
>A> @ 100,000 UNITS/GM A065315 001 May 31, 2006 Jul DISC

POWDER; TOPICAL

NYSTATIN

AT XGEN PHARMS 100,000 UNITS/GM A065175 001 Dec 17, 2004 Feb CAHN

		SUSPENSION;ORAL							
		NYSTATIN							
AA		SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991	May	CMFD	
		<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>							
		CREAM;TOPICAL							
		NYSTATIN AND TRIAMCINOLONE ACETONIDE							
>A>	AT	TORRENT	100,000 UNITS/GM;0.1%	A213142	001	Jul 14, 2020	Jul	NEWA	
		OINTMENT;TOPICAL							
		NYSTATIN AND TRIAMCINOLONE ACETONIDE							
AT		CADILA	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Jun	CAHN	
		@ VITRUVIAS THERAP	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	CPOT	
		@	100000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	DISC	
AT		ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	CMFD	
		<u>OCTREOTIDE ACETATE</u>							
		CAPSULE, DELAYED RELEASE;ORAL							
		MYCAPSSA							
		+! CHIASSMA	EQ 20MG BASE	N208232	001	Jun 26, 2020	Jun	NEWA	
		INJECTABLE;INJECTION							
		OCTREOTIDE ACETATE							
		@ HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Feb	DISC	
		@	EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Feb	DISC	
		@	EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Feb	DISC	
		SANDOSTATIN							
		+ @ NOVARTIS	EQ 0.2MG BASE/ML	N019667	004	Jun 12, 1991	May	DISC	
		+ @	EQ 1MG BASE/ML	N019667	005	Jun 12, 1991	May	DISC	
		SOLUTION;SUBCUTANEOUS							
		BYNFEZIA PEN							
		+! SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N213224	001	Jan 28, 2020	Jan	NEWA	
		<u>OLANZAPINE</u>							
		TABLET;ORAL							
		OLANZAPINE							
>A>	AB	INDOCO	2.5MG	A206155	001	Jul 31, 2020	Jul	NEWA	
>A>	AB		5MG	A206155	002	Jul 31, 2020	Jul	NEWA	
>A>	AB		7.5MG	A206155	003	Jul 31, 2020	Jul	NEWA	
>A>	AB		10MG	A206155	004	Jul 31, 2020	Jul	NEWA	
>A>	AB		15MG	A206155	005	Jul 31, 2020	Jul	NEWA	
>A>	AB		20MG	A206155	006	Jul 31, 2020	Jul	NEWA	
		@ IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Mar	DISC	
		@ JIANGSU HANSOH PHARM	2.5MG	A209399	001	Sep 24, 2018	May	DISC	
		@	5MG	A209399	002	Sep 24, 2018	May	DISC	
		@	10MG	A209399	003	Sep 24, 2018	May	DISC	
		@ TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC	
		@	5MG	A076000	002	Oct 24, 2011	Jan	DISC	
		@	7.5MG	A076000	003	Oct 24, 2011	Jan	DISC	
		@	10MG	A076000	004	Oct 24, 2011	Jan	DISC	
		@	15MG	A076000	005	Oct 24, 2011	Jan	DISC	
		<u>OLMESARTAN MEDOXOMIL</u>							
		TABLET;ORAL							
		OLMESARTAN MEDOXOMIL							
AB		INVENTIA	5MG	A208659	001	May 18, 2020	May	NEWA	
AB			20MG	A208659	002	May 18, 2020	May	NEWA	
AB			40MG	A208659	003	May 18, 2020	May	NEWA	
		@ JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC	
		@	20MG	A205482	002	Apr 24, 2017	Feb	DISC	
		@	40MG	A205482	003	Apr 24, 2017	Feb	DISC	
AB		SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar	NEWA	
AB			20MG	A090237	002	Apr 13, 2020	Mar	NEWA	
AB			40MG	A090237	003	Apr 13, 2020	Mar	NEWA	
		<u>OLOPATADINE HYDROCHLORIDE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		OLOPATADINE HYDROCHLORIDE							
		@ CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC	
		@	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC	
>D>	AT	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul	CMS1	
		@ WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC	
AT			EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb	NFTG	

	SOLUTION/DROPS;OPHTHALMIC					
>D>	PAZEO					
>D>	+!	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015 Jul CMS1
	+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015 Mar CTEC
AT	+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015 Feb CFTG
	SPRAY, METERED;NASAL					
	OLOPATADINE HYDROCHLORIDE					
AB		AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020 Jan NEWA
	<u>OMEGA-3-ACID ETHYL ESTERS</u>					
	CAPSULE;ORAL					
	OMEGA-3-ACID ETHYL ESTERS					
AB		CSPC NBP PHARM CO	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211979	001	May 12, 2020 Apr NEWA
AB		PURACAP PHARM LLC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210093	001	Jun 15, 2020 Jun NEWA
AB		SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019 Feb CMFD
	<u>OMEPRAZOLE</u>					
	CAPSULE, DELAYED REL PELLETS;ORAL					
	OMEPRAZOLE					
	@	MYLAN	10MG	A205070	001	Jun 29, 2018 Feb DISC
	@		20MG	A075876	002	May 29, 2003 Jan DISC
	@		20MG	A205070	002	Jun 29, 2018 Feb DISC
	@		40MG	A205070	003	Jun 29, 2018 Feb DISC
	@	TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017 May DISC
	<u>OMEPRAZOLE; SODIUM BICARBONATE</u>					
	CAPSULE;ORAL					
	OMEPRAZOLE AND SODIUM BICARBONATE					
AB		GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020 Apr NEWA
AB			40MG;1.1GM	A212587	002	Apr 30, 2020 Apr NEWA
	<u>ONDANSETRON</u>					
	FILM;ORAL					
	ZUPLENZ					
	+	FORTOVIA	4MG	N022524	001	Jul 02, 2010 May CAHN
	+!		8MG	N022524	002	Jul 02, 2010 May CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL					
	ONDANSETRON					
	@	BARR	4MG	A076693	001	Jun 25, 2007 Mar DISC
	@		8MG	A076693	002	Jun 25, 2007 Mar DISC
	@	TEVA	4MG	A076810	001	Jun 25, 2007 Mar DISC
	@		8MG	A076810	002	Jun 25, 2007 Mar DISC
	<u>ONDANSETRON HYDROCHLORIDE</u>					
	INJECTABLE; INJECTION					
	ONDANSETRON HYDROCHLORIDE					
	@	EMCURE PHARMS	EQ 2MG BASE/ML	A090424	001	Apr 16, 2010 May DISC
AP	!	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648	001	Jun 15, 2012 Jun CHRS
AP	!	QILU	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014 Mar CHRS
	TABLET;ORAL					
	ONDANSETRON HYDROCHLORIDE					
	@	MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007 Jan DISC
	@		EQ 8MG BASE	A076930	002	Jun 25, 2007 Jan DISC
	@	PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112	001	Jun 25, 2007 Mar DISC
	@		EQ 8MG BASE	A077112	002	Jun 25, 2007 Mar DISC
	@		EQ 24MG BASE	A077112	003	Jun 25, 2007 Mar DISC
	<u>OPICAPONE</u>					
	CAPSULE;ORAL					
	ONGENTYS					
	+	NEUROCRINE	25MG	N212489	001	Apr 24, 2020 Apr NEWA
	+!		50MG	N212489	002	Apr 24, 2020 Apr NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	MSN	EQ 30MG BASE	A212544	001	May 20, 2020	May NEWA
AB		EQ 45MG BASE	A212544	002	May 20, 2020	May NEWA
AB		EQ 75MG BASE	A212544	003	May 20, 2020	May NEWA
AB	SUNSHINE LAKE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Feb NEWA
AB		EQ 45MG BASE	A212739	002	Mar 04, 2020	Feb NEWA
AB		EQ 75MG BASE	A212739	003	Mar 04, 2020	Feb NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AJANTA PHARMA LTD	EQ 6MG BASE/ML	A212784	001	May 27, 2020	May NEWA
----	-------------------	----------------	---------	-----	--------------	----------

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+	RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020	Mar NEWA
+		EQ 5MG BASE	N212801	002	Mar 06, 2020	Mar NEWA
+	!	EQ 10MG BASE	N212801	003	Mar 06, 2020	Mar NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>A>	AP	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A206198	001	Jul 20, 2020	Jul NEWA
>A>	AP		EQ 2GM BASE/VIAL	A206198	002	Jul 20, 2020	Jul NEWA
>A>	AP		EQ 10GM BASE/VIAL	A206199	001	Jul 27, 2020	Jul NEWA

OXAPROZIN

TABLET;ORAL

DAYPRO

>D>	AB	+	GD SEARLE	600MG	N018841	004	Oct 29, 1992	Jul CAHN
>A>	AB	+	PFIZER	600MG	N018841	004	Oct 29, 1992	Jul CAHN
			OXAPROZIN					
	AB		CHARTWELL	600MG	A075987	001	Sep 02, 2004	Mar CAHN
		@	IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002	Mar DISC

OXAPROZIN POTASSIUM

TABLET;ORAL

DAYPRO ALTA

>D>		@	GD SEARLE	600MG	N020776	001	Oct 17, 2002	Jul CAHN
>A>		@	PFIZER	600MG	N020776	001	Oct 17, 2002	Jul CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Mar CMFD
AB		15MG	A071026	003	Aug 10, 1987	Mar CMFD
AB		30MG	A071026	001	Aug 10, 1987	Mar CMFD

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@	HIKMA	150MG	A077795	001	Oct 09, 2007	Feb DISC
@		300MG	A077795	002	Oct 09, 2007	Feb DISC
@		600MG	A077795	003	Oct 09, 2007	Feb DISC

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	LEADING PHARMA LLC	5MG	A212798	001	Apr 06, 2020	Mar NEWA
----	--------------------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

>D>	AB		IMPAX PHARMS	5MG	A076745	002	May 09, 2007	Jul DISC
>A>		@		5MG	A076745	002	May 09, 2007	Jul DISC
>D>	AB			10MG	A076745	003	May 09, 2007	Jul DISC
>A>		@		10MG	A076745	003	May 09, 2007	Jul DISC
>D>	AB			15MG	A076745	001	Nov 09, 2006	Jul DISC
>A>		@		15MG	A076745	001	Nov 09, 2006	Jul DISC
		@	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan DISC
		@		15MG	A076644	002	May 10, 2007	Jan DISC

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE							
	@ ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan	DISC
AA	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan	NEWA
AA		100MG/5ML	A212429	002	Jan 27, 2020	Jan	NEWA
	@ HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb	DISC
AA	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020	Apr	NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE							
	@ NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar	DISC
	@	10MG	A077290	002	Dec 08, 2005	Mar	DISC
	@	15MG	A077290	003	Dec 08, 2005	Mar	DISC
	@	20MG	A077290	004	Dec 08, 2005	Mar	DISC
	@	30MG	A077290	005	Dec 08, 2005	Mar	DISC
	ROXYBOND						
	@ OHEMO LIFE	5MG	N209777	001	Apr 20, 2017	May	CAHN
	@	15MG	N209777	002	Apr 20, 2017	May	CAHN
	@	30MG	N209777	003	Apr 20, 2017	May	CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
>A>	UPNEEQ						
>A>	+! RVL PHARMS	0.1%	N212520	001	Jul 08, 2020	Jul	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE							
	@ ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar	DISC
	@	7.5MG	A079046	001	Dec 13, 2010	Mar	DISC
	@	10MG	A079046	004	Jul 11, 2013	Mar	DISC
	@	15MG	A079046	002	Dec 13, 2010	Mar	DISC
	@	20MG	A079046	005	Jul 11, 2013	Mar	DISC
	@	30MG	A079046	006	Jul 11, 2013	Mar	DISC
	@	40MG	A079046	007	Jul 11, 2013	Mar	DISC
	@ SPECGX LLC	5MG	A202946	001	Jun 27, 2014	May	DISC
	@	7.5MG	A202946	002	Jun 27, 2014	May	DISC
	@	10MG	A202946	003	Jun 27, 2014	May	DISC
	@	15MG	A202946	004	Jun 27, 2014	May	DISC
	@	20MG	A202946	005	Jun 27, 2014	May	DISC
	@	30MG	A202946	006	Jun 27, 2014	May	DISC
	@	40MG	A202946	007	Jun 27, 2014	May	DISC

OZANIMOD HYDROCHLORIDE

CAPSULE; ORAL

ZEPOSIA							
	+ CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar	NEWA
	+	0.46MG	N209899	002	Mar 25, 2020	Mar	NEWA
	+!	0.92MG	N209899	003	Mar 25, 2020	Mar	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE							
AP	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM							
	@ TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar	DISC
	@	90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar	DISC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM							
AB	SUN PHARM	EQ 40MG BASE	A213725	001	Jun 30, 2020	Jun	NFTG
AB	PROTONIX						
AB	+! WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jun	CFTG
	TABLET, DELAYED RELEASE; ORAL						
	PANTOPRAZOLE SODIUM						
	@ MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	May	DISC

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

@	EQ 40MG BASE	A200821	002	Feb 16, 2012	May	DISC
@ TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007	May	DISC
@	EQ 40MG BASE	A077056	002	Aug 02, 2007	May	DISC

PAROXETINE HYDROCHLORIDE

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

@ JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan	DISC
@	EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan	DISC
@	EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan	DISC
@	EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan	DISC

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS
SIGNIFOR

+ RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb	CAHN
+	EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb	CAHN
+!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb	CAHN

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT

+ RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb	CAHN
+	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb	CAHN
+	EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb	CAHN
+	EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb	CAHN
+!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+ @ NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan	CRLD
--------------	---------------	---------	-----	--------------	-----	------

PEMETREXED

SOLUTION;INTRAVENOUS
PEMFEXY

+! EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020	Feb	NEWA
-----------------	----------------------	---------	-----	--------------	-----	------

PEMIGATINIB

TABLET;ORAL
PEMAZYRE

+ INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020	Apr	NEWA
+	9MG	N213736	002	Apr 17, 2020	Apr	NEWA
+!	13.5MG	N213736	003	Apr 17, 2020	Apr	NEWA

PENICILLAMINE

CAPSULE;ORAL
PENICILLAMINE

AB	ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan	CAHN
AB	APOTEX	250MG	A213310	001	Apr 28, 2020	Apr	NEWA
>A> AB	DR REDDYS	250MG	A211867	001	Aug 04, 2020	Jul	NEWA

TABLET;ORAL
PENICILLAMINE

AB	TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020	Feb	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

PERMETHRIN

CREAM;TOPICAL
ELIMITE

+ @ MYLAN	5%	N019855	001	Aug 25, 1989	Feb	DISC	
AB !	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	Feb	CHRS

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	ZYDUS PHARMS	2MG	A205232	001	Apr 06, 2020	Mar	NEWA
AB		4MG	A205232	002	Apr 06, 2020	Mar	NEWA
AB		8MG	A205232	003	Apr 06, 2020	Mar	NEWA
AB		16MG	A205232	004	Apr 06, 2020	Mar	NEWA

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017	Mar	CAHN
AA		35MG	A203600	001	Dec 27, 2017	Mar	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+ CONCORDIA	10MG	N008708	001		Jun	CMFD
----	-------------	------	---------	-----	--	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR 15MG

A090591 001 Mar 18, 2010 Mar DISC

@ 30MG

A090591 002 Mar 18, 2010 Mar DISC

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR 37.5MG

A090470 001 Aug 31, 2009 Mar DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Jun	NEWA
AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Jun	NEWA
>A>	AP1 APOLLO	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jul	NEWA
>A>	AP1	50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jul	NEWA
>A>	AP1	100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jul	NEWA
AP1	CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jun	NEWA
AP1		50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jun	NEWA
AP1	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A211920	001	Jun 05, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A211920	002	Jun 05, 2020	Jun	NEWA
AP1	RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan	NEWA
AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan	NEWA
AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan	NEWA
AP1	SAGENT PHARMS INC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jun	CAHN
AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jun	CAHN
AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jun	CAHN
	VAZCULEP						
>D>	AP1 +!	AVADEL LEGACY 10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jul	CAHN
>D>	AP1 +!	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jul	CAHN
>D>	AP1 +!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jul	CAHN
>A>	AP1 +!	EXELA PHARMA 10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jul	CAHN
>A>	AP1 +!	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jul	CAHN
>A>	AP1 +!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jul	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	! PHARM ASSOC	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	Jun	CAHN
----	---------------	---------------------	---------	-----	--------------	-----	------

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

>D>	AB +!	PARKE DAVIS 125MG/5ML	N008762	001		Jul	CAHN
>A>	AB +!	UPJOHN 125MG/5ML	N008762	001		Jul	CAHN
		DILANTIN-30					
>D>	@	PARKE DAVIS 30MG/5ML	N008762	002		Jul	CAHN
>A>	@	UPJOHN 30MG/5ML	N008762	002		Jul	CAHN

TABLET, CHEWABLE; ORAL

DILANTIN

>D>	AB	!	PFIZER	50MG	A084427	001		Jul	CAHN
>A>	AB	!	UPJOHN	50MG	A084427	001		Jul	CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

>D>		!	PARKE-DAVIS	30MG EXTENDED	A084349	001		Jul	CAHN
>D>	AB	!		100MG EXTENDED	A084349	002		Jul	CAHN
>A>		!	UPJOHN	30MG EXTENDED	A084349	001		Jul	CAHN
>A>	AB	!		100MG EXTENDED	A084349	002		Jul	CAHN
			EXTENDED PHENYTOIN SODIUM						
		@	LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Apr	DISC

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB			AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Mar	CMFD
		@		5MG	A212377	001	Aug 13, 2019	Feb	DISC
AB				7.5MG	A212377	002	Aug 13, 2019	Mar	CMFD
		@		7.5MG	A212377	002	Aug 13, 2019	Feb	DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

>D>	AB		BRECKENRIDGE	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jul	CAHN
>D>	AB			EQ 30MG BASE	A078472	002	Feb 13, 2013	Jul	CAHN
>D>	AB			EQ 45MG BASE	A078472	003	Feb 13, 2013	Jul	CAHN
		@	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan	DISC
		@		EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan	DISC
		@		EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan	DISC
>A>	AB		NOSTRUM LABS INC	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jul	CAHN
>A>	AB			EQ 30MG BASE	A078472	002	Feb 13, 2013	Jul	CAHN
>A>	AB			EQ 45MG BASE	A078472	003	Feb 13, 2013	Jul	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP			ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Apr	CMFD
AP				EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Apr	CMFD
AP				EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Apr	CMFD

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB			STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Mar	CAHN
AB				20MG	A206136	002	Jun 20, 2017	Mar	CAHN

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT	+	!	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan	CAHN
----	---	---	--------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

>D>	AA		BRECKENRIDGE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Jul	CAHN
>A>	AA		NOSTRUM LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Jul	CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

		@	GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036	001		Jan	CMS1
			POLYMYXIN B SULFATE						
AP			XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN

POSACONAZOLE

SUSPENSION;ORAL

NOXAFIL

AB	+	!	SCHERING	40MG/ML	N022003	001	Sep 15, 2006	May	CFTG
AB			POSACONAZOLE		A208773	001	May 15, 2020	May	NFTG

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MICRO-K

	+	@	NESHER PHARMS	8MEQ	N018238	001		May	DISC
	+	@	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	May	DISC
AB			STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015	Mar	CAHN
AB				10MEQ	A205549	002	Dec 08, 2015	Mar	CAHN

FOR SUSPENSION, EXTENDED RELEASE;ORAL
MICRO-K LS

	+	@	KV PHARM	20MEQ/PACKET	N019561	003	Aug 26, 1988	Feb	CRLD
AB1			AMNEAL	10MEQ	A212861	001	May 08, 2020	Apr	NEWA
AB1				20MEQ	A212861	003	May 08, 2020	Apr	NEWA
AB2			GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb	NEWA
AB2				10MEQ	A211797	002	Mar 04, 2020	Feb	NEWA
	@		STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019	Feb	CAHN
	@			10MEQ	A206881	002	Jan 22, 2019	Feb	CAHN
	@			10MEQ	A210097	001	Jun 17, 2019	Feb	CAHN
	@			20MEQ	A210098	001	Apr 26, 2019	Feb	CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB			BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Jun	NEWA
AB				15MEQ	A212799	002	Jun 29, 2020	Jun	NEWA
AB			RISING	5MEQ	A077440	001	Jun 09, 2006	Apr	CAHN
AB				10MEQ	A077440	002	Jun 09, 2006	Apr	CAHN

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PRALIDOXIME CHLORIDE (AUTOINJECTOR)

	+	!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun	CTNA
			SOLUTION;INTRAMUSCULAR						
	+	!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun	CDFR
	+	!		600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983	Jun	CPTO

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB			GRAVITI PHARMS	0.25MG	A211088	001	Oct 03, 2018	May	CAHN
AB				0.5MG	A211088	002	Oct 03, 2018	May	CAHN
AB				0.75MG	A211088	003	Oct 03, 2018	May	CAHN
AB				1MG	A211088	004	Oct 03, 2018	May	CAHN
AB				1.5MG	A211088	005	Oct 03, 2018	May	CAHN
	@		HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	Apr	DISC
	@			0.25MG	A077724	002	Feb 19, 2008	Apr	DISC
	@			0.5MG	A077724	003	Feb 19, 2008	Apr	DISC
	@			1MG	A077724	004	Feb 19, 2008	Apr	DISC
	@			1.5MG	A077724	005	Feb 19, 2008	Apr	DISC
	@		MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012	Jun	DISC
	@			0.25MG	A202164	002	Sep 20, 2012	Jun	DISC
	@			0.5MG	A202164	003	Sep 20, 2012	Jun	DISC
	@			1MG	A202164	004	Sep 20, 2012	Jun	DISC
	@			1.5MG	A202164	005	Sep 20, 2012	Jun	DISC
	@		MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan	DISC
	@			0.25MG	A077854	002	Oct 08, 2010	Jan	DISC
	@			0.5MG	A077854	003	Oct 08, 2010	Jan	DISC
	@			0.75MG	A090764	001	Apr 09, 2010	Jan	DISC
	@			1MG	A077854	004	Oct 08, 2010	Jan	DISC
	@			1.5MG	A077854	005	Oct 08, 2010	Jan	DISC

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ZENNOVA	0.125MG	A090151	001	Apr 30, 2012	Feb	CAHN
AB		0.25MG	A090151	002	Apr 30, 2012	Feb	CAHN
AB		0.5MG	A090151	003	Apr 30, 2012	Feb	CAHN
AB		0.75MG	A090151	006	Apr 30, 2012	Feb	CAHN
AB		1MG	A090151	004	Apr 30, 2012	Feb	CAHN
AB		1.5MG	A090151	005	Apr 30, 2012	Feb	CAHN

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016	Jun	CAHN
----	-----------	-------	---------	-----	--------------	-----	------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

>A>	AB	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jul	NEWA
>A>	AB		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jul	NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A>	AB	APPCO	10MG	A209869	001	Apr 13, 2018	Jul	CAHN
>A>	AB		20MG	A209869	002	Apr 13, 2018	Jul	CAHN
>A>	AB		40MG	A209869	003	Apr 13, 2018	Jul	CAHN
>A>	AB		80MG	A209869	004	Apr 13, 2018	Jul	CAHN
>D>	AB	CHARTWELL RX	10MG	A209869	001	Apr 13, 2018	Jul	CAHN
>D>	AB		20MG	A209869	002	Apr 13, 2018	Jul	CAHN
>D>	AB		40MG	A209869	003	Apr 13, 2018	Jul	CAHN
>D>	AB		80MG	A209869	004	Apr 13, 2018	Jul	CAHN

PREDNICARBATE

CREAM;TOPICAL

DERMATOP E EMOLLIENT

+	@	VALEANT BERMUDA	0.1%	N020279	001	Oct 29, 1993	Apr	DISC
---	---	-----------------	------	---------	-----	--------------	-----	------

PREDNICARBATE

@	FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Apr	DISC
---	----------------	------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DERMATOP

+	@	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Feb	DISC
---	---	----------------------	------	---------	-----	--------------	-----	------

PREDNICARBATE

!	FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Feb	CTEC
---	----------------	------	---------	-----	--------------	-----	------

AB	!		0.1%	A077236	001	Mar 09, 2007	Feb	CHRS
----	---	--	------	---------	-----	--------------	-----	------

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

AB	+!	NOVARTIS	1%	N017469	001		Jan	CHRS
----	----	----------	----	---------	-----	--	-----	------

AB	+		1%	N017469	001		Jan	CRLD
----	---	--	----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Feb	NEWA
-------------	------------------	---------	-----	--------------	-----	------

@ VINTAGE	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	Jun	DISC
-----------	------------------	---------	-----	--------------	-----	------

PREDNISON

TABLET, DELAYED RELEASE;ORAL

PREDNISON

@	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr	DISC
---	---------------------	-----	---------	-----	--------------	-----	------

@		2MG	A204867	002	Apr 25, 2017	Apr	DISC
---	--	-----	---------	-----	--------------	-----	------

@		5MG	A204867	003	Apr 25, 2017	Apr	DISC
---	--	-----	---------	-----	--------------	-----	------

RAYOS

+	HORIZON PHARMA USA	1MG	N202020	001	Jul 26, 2012	Apr	CTEC
---	--------------------	-----	---------	-----	--------------	-----	------

+		2MG	N202020	002	Jul 26, 2012	Apr	CTEC
---	--	-----	---------	-----	--------------	-----	------

+!		5MG	N202020	003	Jul 26, 2012	Apr	CTEC
----	--	-----	---------	-----	--------------	-----	------

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	PFIZER	25MG	N021446	001	Dec 30, 2004	Jun CAHN
AB	+		50MG	N021446	002	Dec 30, 2004	Jun CAHN
AB	+		75MG	N021446	003	Dec 30, 2004	Jun CAHN
AB	+		100MG	N021446	004	Dec 30, 2004	Jun CAHN
AB	+		150MG	N021446	005	Dec 30, 2004	Jun CAHN
AB	+		200MG	N021446	006	Dec 30, 2004	Jun CAHN
AB	+		225MG	N021446	007	Dec 30, 2004	Jun CAHN
AB	+		300MG	N021446	008	Dec 30, 2004	Jun CAHN

PREGABALIN

>A>	AB	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Jul NEWA
>A>	AB		50MG	A091025	002	Jul 09, 2020	Jul NEWA
>A>	AB		75MG	A091025	003	Jul 09, 2020	Jul NEWA
>A>	AB		100MG	A091025	004	Jul 09, 2020	Jul NEWA
>A>	AB		150MG	A091025	005	Jul 09, 2020	Jul NEWA
>A>	AB		200MG	A091025	006	Jul 09, 2020	Jul NEWA
>A>	AB		225MG	A091025	007	Jul 09, 2020	Jul NEWA
>A>	AB		300MG	A091025	008	Jul 09, 2020	Jul NEWA
AB		CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar NEWA
AB			75MG	A212865	002	Mar 20, 2020	Mar NEWA
AB			100MG	A212865	003	Mar 20, 2020	Mar NEWA
AB			150MG	A212865	004	Mar 20, 2020	Mar NEWA
AB		HIKAL	25MG	A213423	001	Mar 23, 2020	Mar NEWA
AB			50MG	A213423	002	Mar 23, 2020	Mar NEWA
AB			75MG	A213423	003	Mar 23, 2020	Mar NEWA
AB			100MG	A213423	004	Mar 23, 2020	Mar NEWA
AB			150MG	A213423	005	Mar 23, 2020	Mar NEWA
AB			200MG	A213423	006	Mar 23, 2020	Mar NEWA
AB			225MG	A213423	007	Mar 23, 2020	Mar NEWA
AB			300MG	A213423	008	Mar 23, 2020	Mar NEWA
	@	MYLAN	25MG	A091228	001	Sep 20, 2019	Feb DISC
	@		50MG	A091228	002	Sep 20, 2019	Feb DISC
	@		75MG	A091228	003	Sep 20, 2019	Feb DISC
	@		100MG	A091228	004	Sep 20, 2019	Feb DISC
	@		150MG	A091228	005	Sep 20, 2019	Feb DISC
	@		200MG	A091228	006	Sep 20, 2019	Feb DISC
	@		225MG	A091228	007	Sep 20, 2019	Feb DISC
	@		300MG	A091228	008	Sep 20, 2019	Feb DISC

SOLUTION;ORAL

LYRICA

AA	+	PFIZER	20MG/ML	N022488	001	Jan 04, 2010	Jun CAHN
----	---	--------	---------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

+		PFIZER	82.5MG	N209501	001	Oct 11, 2017	Jun CAHN
+			165MG	N209501	002	Oct 11, 2017	Jun CAHN
+	!		330MG	N209501	003	Oct 11, 2017	Jun CAHN

PROCHLORPERAZINE MALEATE

TABLET;ORAL

COMPAZINE

+	@	GLAXOSMITHKLINE	EQ 5MG BASE	N010571	001		Mar CRLD
+	@		EQ 10MG BASE	N010571	002		Mar CRLD
+	@		EQ 25MG BASE	N010571	003		Mar CRLD

PROCHLORPERAZINE MALEATE

@	SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996	Mar DISC
@		EQ 10MG BASE	A040101	002	Jul 19, 1996	Mar DISC

PROCOMP

AB	!	JUBILANT CADISTA	EQ 10MG BASE	A040268	002	Feb 27, 1998	Mar CHRS
----	---	------------------	--------------	---------	-----	--------------	----------

PROGESTERONE

SYSTEM;VAGINAL

MILPROSA

+	!	FERRING PHARMS INC	1.78GM	N201110	001	Apr 29, 2020	Apr NEWA
---	---	--------------------	--------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION		PROMETHAZINE HYDROCHLORIDE					
AP	XGEN PHARMS	25MG/ML	A 040737	001	Apr 24, 2008	Feb	CAHN
AP		50MG/ML	A 040737	002	Apr 24, 2008	Feb	CAHN
SUPPOSITORY; RECTAL		PROMETHAZINE HYDROCHLORIDE					
	@ WATSON LABS INC	12.5MG	A 040479	001	Jun 24, 2003	Mar	DISC
	@	25MG	A 040479	002	Jun 24, 2003	Mar	DISC
SYRUP; ORAL		PROMETHAZINE HYDROCHLORIDE					
	@ PHARM ASSOC	6.25MG/5ML	A 040643	001	Apr 26, 2006	Jun	CAHN
	@ VINTAGE	6.25MG/5ML	A 040643	001	Apr 26, 2006	Jun	DISC

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		PROPAFENONE HYDROCHLORIDE					
AB	TWI PHARMS	225MG	A 212928	001	Jun 18, 2020	Jun	NEWA
AB		325MG	A 212928	002	Jun 18, 2020	Jun	NEWA
AB		425MG	A 212928	003	Jun 18, 2020	Jun	NEWA
AB	UPSHER SMITH LABS	225MG	A 212744	001	Jun 25, 2020	Jun	NEWA
AB		325MG	A 212744	002	Jun 25, 2020	Jun	NEWA
AB		425MG	A 212744	003	Jun 25, 2020	Jun	NEWA

PROPOFOL

INJECTABLE; INJECTION		PROPOFOL					
>D>	@ WEST-WARD PHARMS INT	10MG/ML	A 074848	001	Apr 19, 2005	Jul	CMFD
>A>	AB	10MG/ML	A 074848	001	Apr 19, 2005	Jul	CMFD

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL		PROPRANOLOL HYDROCHLORIDE						
>D>	AB	IMPAX LABS INC	10MG	A 071972	001	Apr 06, 1988	Jul	DISC
>A>		@	10MG	A 071972	001	Apr 06, 1988	Jul	DISC
>D>	AB		20MG	A 071972	002	Apr 06, 1988	Jul	DISC
>A>		@	20MG	A 071972	002	Apr 06, 1988	Jul	DISC
>D>	AB		40MG	A 071972	003	Apr 06, 1988	Jul	DISC
>A>		@	40MG	A 071972	003	Apr 06, 1988	Jul	DISC

PYRAZINAMIDE

TABLET; ORAL		PYRAZINAMIDE						
>D>	!	AKORN	500MG	A 081319	001	Jun 30, 1992	Jul	CTEC
>A>	AB	!	500MG	A 081319	001	Jun 30, 1992	Jul	CTEC
		!	500MG	A 081319	001	Jun 30, 1992	Feb	CHRS
			500MG	A 081319	001	Jun 30, 1992	Feb	CTEC
>D>		@ DAVA PHARMS INC	500MG	A 080157	001		Jul	CAHN
		@	500MG	A 080157	001		Feb	DISC
>A>	AB	MACLEODS PHARMS LTD	500MG	A 212541	001	Jul 27, 2020	Jul	NEWA
>A>		@ NOVITIUM PHARMA	500MG	A 080157	001		Jul	CAHN

PYRIMETHAMINE

TABLET; ORAL		DARAPRIM						
AB	+!	VYERA PHARMS LLC	25MG	N 008578	001		Feb	CFTG
TABLET; ORAL		PYRIMETHAMINE						
AB		CEROVENE INC	25MG	A 207127	001	Feb 28, 2020	Feb	NFTG

QUETIAPINE FUMARATE

TABLET; ORAL		QUETIAPINE FUMARATE						
AB		ZENNOVA	EQ 25MG BASE	A 090960	001	Mar 27, 2012	Feb	CAHN
AB			EQ 50MG BASE	A 090960	002	Mar 27, 2012	Feb	CAHN
AB			EQ 100MG BASE	A 090960	003	Mar 27, 2012	Feb	CAHN
AB			EQ 200MG BASE	A 090960	004	Mar 27, 2012	Feb	CAHN
AB			EQ 300MG BASE	A 090960	005	Mar 27, 2012	Feb	CAHN
AB			EQ 400MG BASE	A 090960	006	Mar 27, 2012	Feb	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@	MYLAN	EQ 5MG BASE	A076694	001	Dec 23, 2004	Mar	DISC
@		EQ 10MG BASE	A076694	002	Dec 23, 2004	Mar	DISC
@		EQ 20MG BASE	A076694	003	Dec 23, 2004	Mar	DISC
@		EQ 40MG BASE	A076694	004	Dec 23, 2004	Mar	DISC

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

!	SANDOZ	200MG	A088072	002		May	CHRS
		200MG	A088072	002		May	CTEC
!		300MG	A088072	001	Sep 26, 1983	Apr	CHRS
		300MG	A088072	001	Sep 26, 1983	Apr	CTEC
@	WATSON LABS	200MG	A083288	001		Apr	DISC
@		300MG	A085583	001		Apr	DISC

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar	NEWA
----	-----------	-----	---------	-----	--------------	-----	------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@	TEVA PHARMS	1.25MG	A077470	001	Jun 18, 2008	Mar	DISC
@		2.5MG	A077470	002	Jun 18, 2008	Mar	DISC
@		5MG	A077470	003	Jun 18, 2008	Mar	DISC
@		10MG	A077470	004	Jun 18, 2008	Mar	DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

@	AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018	Jun	DISC
@		EQ 300MG BASE	A209859	002	Sep 27, 2018	Jun	DISC
@	APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019	May	DISC
@		EQ 300MG BASE	A211893	002	Apr 05, 2019	May	DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AA	@ AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008	Apr	DISC
		BRECKENRIDGE	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Jul	CAHN
		@ HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	May	DISC
>A>	AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Jul	CAHN
		@ TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	ACIC PHARMS	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jul	CAHN
>D>	AB		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jul	CAHN
		@ AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan	DISC
		@	EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan	DISC
		@ HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Apr	DISC
		@	EQ 300MG BASE	A075165	002	Sep 30, 1998	Apr	DISC
>A>	AB	NOSTRUM LABS INC	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jul	CAHN
>A>	AB		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jul	CAHN
		@ STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Apr	DISC
		@	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan	DISC
		@	EQ 300MG BASE	A205512	002	Aug 22, 2016	Apr	DISC
AB	!		EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan	CHRS
		@	EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan	CAHN
AB			1GM	A210482	002	Oct 29, 2019	Jan	CAHN
>D>	AB	CIPLA	500MG	A211291	001	May 28, 2019	Jul	DISC
>A>		@	500MG	A211291	001	May 28, 2019	Jul	DISC
>D>	AB		1GM	A211291	002	May 28, 2019	Jul	DISC
>A>		@	1GM	A211291	002	May 28, 2019	Jul	DISC
AB		MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB		1GM	A212284	002	Feb 12, 2020	Jan	NEWA
AB	MICRO LABS	500MG	A211745	001	Feb 27, 2020	Feb	NEWA
AB		1GM	A211745	002	Feb 27, 2020	Feb	NEWA
AB	SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Mar	NEWA
AB		1GM	A212781	002	Mar 23, 2020	Mar	NEWA
AB	SUNSHINE LAKE	500MG	A211865	001	Mar 23, 2020	Mar	NEWA
AB		1GM	A211865	002	Mar 23, 2020	Mar	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@ WATSON LABS INC

EQ 0.5MG BASE

A201823 001 Jul 01, 2013 Mar DISC

@

EQ 1MG BASE

A201823 002 Jul 01, 2013 Mar DISC

REMIMAZOLAM BESYLATE

POWDER; INTRAVENOUS

BYFAVO

>A> +! ACACIA EQ 20MG BASE/VIAL

N212295 001 Jul 02, 2020 Jul CAHN

>A> +! COSMO EQ 20MG BASE/VIAL

N212295 001 Jul 02, 2020 Jul NEWA

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

@ ACTAVIS TOTOWA

0.5MG

A090008 001 Jan 22, 2014 Mar DISC

@

1MG

A090008 002 Jan 22, 2014 Mar DISC

@

2MG

A090008 003 Jan 22, 2014 Mar DISC

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

@ KADMON PHARMS LLC

200MG

A076203 001 Apr 06, 2004 Feb DISC

RIBAVIRIN

@ TEVA

200MG

A076277 001 Oct 04, 2004 Mar DISC

TABLET;ORAL

RIBAVIRIN

@ BEXIMCO PHARMS USA

200MG

A202546 001 Aug 12, 2014 Feb DISC

@

400MG

A202546 002 Aug 12, 2014 Feb DISC

@

500MG

A202546 003 Aug 12, 2014 Feb DISC

@

600MG

A202546 004 Aug 12, 2014 Feb DISC

@ KADMON PHARMS LLC

200MG

A077456 001 Dec 05, 2005 Feb DISC

@

400MG

A077456 002 Dec 05, 2005 Feb DISC

@

600MG

A077456 003 Dec 05, 2005 Feb DISC

@ ZYDUS PHARMS USA

400MG

A077094 002 Mar 16, 2007 Feb DISC

@

500MG

A077094 004 Apr 18, 2008 Feb DISC

@

600MG

A077094 003 Mar 16, 2007 Feb DISC

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

@ EMCURE PHARMS LTD

600MG/VIAL

A204101 001 Aug 18, 2014 May DISC

RILUZOLE

TABLET;ORAL

RILUZOLE

AB KENTON 50MG

A206045 001 Dec 09, 2019 Mar CAHN

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+! BIOHAVEN PHARM EQ 75MG BASE

N212728 001 Feb 27, 2020 Feb NEWA

RIPRETINIB

TABLET;ORAL

QINLOCK

+! DECIPHERA PHARMS 50MG

N213973 001 May 15, 2020 May NEWA

RISPERIDONE

TABLET; ORAL

RISPERIDONE

@ MYLAN	0.25MG	A076288	001	Sep 15, 2008	Jun	DISC
---------	--------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

@ ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011	Mar	DISC
@	1MG	A076996	002	Apr 19, 2011	Mar	DISC
@	2MG	A076996	003	Apr 19, 2011	Mar	DISC
@	3MG	A076996	004	Apr 19, 2011	Mar	DISC
@	4MG	A076996	005	Apr 19, 2011	Mar	DISC
@ HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	Apr	DISC
@	1MG	A076908	002	Mar 12, 2012	Apr	DISC
@	2MG	A076908	003	Mar 12, 2012	Apr	DISC

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

YUTOPAR

@ ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan	CMS1
---------------	---------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

@ APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	May	DISC
@	EQ 3MG BASE	A091072	002	May 16, 2013	May	DISC
@	EQ 4.5MG BASE	A091072	003	May 16, 2013	May	DISC
@	EQ 6MG BASE	A091072	004	May 16, 2013	May	DISC

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING; ORAL

RIZATRIPTAN BENZOATE

@ MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb	DISC
@	EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

@ TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008	Mar	DISC
@	100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008	Mar	DISC

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

@ MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Jun	DISC
AB @ STRIDES PHARMA	500MCG	A208247	001	Mar 30, 2020	Mar	NEWA

ROMIDEPSIN

SOLUTION; INTRAVENOUS

ROMIDEPSIN

+ TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574	001	Mar 13, 2020	Mar	NEWA
+!	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Mar	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

@ HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb	DISC
@	EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb	DISC
@	EQ 1MG BASE	A077852	003	May 05, 2008	Feb	DISC
@	EQ 2MG BASE	A077852	004	May 05, 2008	Feb	DISC
@	EQ 3MG BASE	A077852	005	May 05, 2008	Feb	DISC
@	EQ 4MG BASE	A077852	006	May 05, 2008	Feb	DISC
@	EQ 5MG BASE	A077852	007	May 19, 2008	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

+ @ GLAXOSMITHKLINE LLC	EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	DISC
-------------------------	-------------	---------	-----	--------------	-----	------

@ WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	Mar	DISC
@	EQ 4MG BASE	A200431	002	Jun 06, 2012	Mar	DISC
@	EQ 6MG BASE	A200431	003	Jun 06, 2012	Mar	DISC
@	EQ 8MG BASE	A200431	004	Jun 06, 2012	Mar	DISC
@	EQ 12MG BASE	A200431	005	Jun 06, 2012	Mar	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020	Mar	NEWA
AP		100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020	Mar	NEWA
AP		150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020	Mar	NEWA
AP		200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020	Mar	NEWA
>A>	HIKMA	40MG/20ML (2MG/ML)	A214074	001	Jul 20, 2020	Jul	NEWA
>A>	AP	150MG/30ML (5MG/ML)	A214074	002	Jul 20, 2020	Jul	NEWA
>A>	AP	150MG/20ML (7.5MG/ML)	A214074	003	Jul 20, 2020	Jul	NEWA
>A>	AP	200MG/20ML (10MG/ML)	A214074	004	Jul 20, 2020	Jul	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

	@ APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jun	DISC	
	@	10MG	A079145	002	Jul 19, 2016	Jun	DISC	
	@	20MG	A079145	003	Jul 19, 2016	Jun	DISC	
	@	40MG	A079145	004	Jul 19, 2016	Jun	DISC	
>D>	AB	JUBILANT GENERICS	5MG	A207062	001	Oct 31, 2016	Jul	CAHN
>D>	AB		10MG	A207062	002	Oct 31, 2016	Jul	CAHN
>D>	AB		20MG	A207062	003	Oct 31, 2016	Jul	CAHN
>D>	AB		40MG	A207062	004	Oct 31, 2016	Jul	CAHN
>A>	AB	RENATA	5MG	A207062	001	Oct 31, 2016	Jul	CAHN
>A>	AB		10MG	A207062	002	Oct 31, 2016	Jul	CAHN
>A>	AB		20MG	A207062	003	Oct 31, 2016	Jul	CAHN
>A>	AB		40MG	A207062	004	Oct 31, 2016	Jul	CAHN
	AB	SUNSHINE LAKE	5MG	A210667	001	Apr 01, 2020	Mar	NEWA
	AB		10MG	A210667	002	Apr 01, 2020	Mar	NEWA
	AB		20MG	A210667	003	Apr 01, 2020	Mar	NEWA
	AB		40MG	A210667	004	Apr 01, 2020	Mar	NEWA
	@ ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr	DISC	
	@	10MG	A212059	002	Nov 04, 2019	Apr	DISC	
	@	20MG	A212059	003	Nov 04, 2019	Apr	DISC	
	@	40MG	A212059	004	Nov 04, 2019	Apr	DISC	

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

>A>	+	MDD US	50MG	N207145	001	Mar 21, 2017	Jul	CAHN
>A>	+	!	100MG	N207145	002	Mar 21, 2017	Jul	CAHN
>D>	+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Jul	CAHN
>D>	+	!	100MG	N207145	002	Mar 21, 2017	Jul	CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

@ DAVA PHARMS INC 5MG

A075352 001 Nov 30, 1998 Feb DISC

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

>A>	@	I3 PHARMS	5MG	A074672	001	Apr 01, 1997	Jul	CAHN
>D>	@	MLV	5MG	A074672	001	Apr 01, 1997	Jul	CAHN
	@		5MG	A074672	001	Apr 01, 1997	Mar	CAHN

SELEXIPAG

TABLET; ORAL

UPTRAVI

+	!	ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan	CHRS
+			1.6MG	N207947	008	Dec 21, 2015	Jan	CHRS

SELPERCATINIB

CAPSULE; ORAL

RETEVMO

+		LOXO ONCOLOGY INC	40MG	N213246	001	May 08, 2020	May	NEWA
+	!		80MG	N213246	002	May 08, 2020	May	NEWA

SELUMETINIB SULFATECAPSULE;ORAL
KOSELUGO

+	ASTRAZENECA PHARMS	EQ 10MG BASE	N213756	001	Apr 10, 2020	Apr	NEWA
+	!	EQ 25MG BASE	N213756	002	Apr 10, 2020	Apr	NEWA

SEMAGLUTIDESOLUTION;SUBCUTANEOUS
OZEMPIC

+	NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan	NEWA
---	------	---------------------	---------	-----	--------------	-----	------

SERTRALINE HYDROCHLORIDECONCENTRATE;ORAL
ZOLOFT

AA	+	UPJOHN	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jun	CAHN
----	---	--------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Jul	DISC	
>A>		@	EQ 25MG BASE	A077977	001	Feb 06, 2007	Jul	DISC	
>D>	AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Jul	DISC	
>A>		@	EQ 50MG BASE	A077977	002	Feb 06, 2007	Jul	DISC	
>D>	AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Jul	DISC	
>A>		@	EQ 100MG BASE	A077977	003	Feb 06, 2007	Jul	DISC	
>D>			EQ 150MG BASE	A077977	004	Feb 06, 2007	Jul	DISC	
>A>		@	EQ 150MG BASE	A077977	004	Feb 06, 2007	Jul	DISC	
>D>			EQ 200MG BASE	A077977	005	Feb 06, 2007	Jul	DISC	
>A>		@	EQ 200MG BASE	A077977	005	Feb 06, 2007	Jul	DISC	
	AB	VIWIT PHARM	EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar	CAHN	
	AB		EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar	CAHN	
	AB		EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar	CAHN	
	AB		EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar	CAHN	
	AB		EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar	CAHN	
	AB		EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar	CAHN	
		ZOLOFT							
	AB	+	UPJOHN	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jun	CAHN
	AB	+		EQ 50MG BASE	N019839	001	Dec 30, 1991	Jun	CAHN
	AB	+	!	EQ 100MG BASE	N019839	002	Dec 30, 1991	Jun	CAHN
		+	@	EQ 150MG BASE	N019839	003	Dec 30, 1991	Jun	CAHN
		+	@	EQ 200MG BASE	N019839	004	Dec 30, 1991	Jun	CAHN

SEVELAMER CARBONATE

TABLET;ORAL

SEVELAMER CARBONATE

	AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar	NEWA
>D>	AB	IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017	Jul	DISC
>A>		@	800MG	A090975	001	Oct 23, 2017	Jul	DISC
>A>	AB	MYLAN	800MG	A201069	001	Aug 05, 2020	Jul	NEWA
>A>	AB	ZYDUS PHARMS	800MG	A207759	001	Aug 11, 2020	Jul	NEWA

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
REVATIO

	AB	+	UPJOHN	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Jun	CAHN
--	----	---	--------	-----------------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

>A>	AB	APTAPHARMA INC	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Jul	NEWA
	AB	TEVA PHARMS USA	EQ 10MG BASE/ML	A211534	001	May 29, 2020	May	NEWA

SOLUTION;INTRAVENOUS

REVATIO

	AP	+	UPJOHN	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Jun	CAHN
--	----	---	--------	--	---------	-----	--------------	-----	------

TABLET;ORAL

REVATIO

	AB	+	UPJOHN	EQ 20MG BASE	N021845	001	Jun 03, 2005	Jun	CAHN
--	----	---	--------	--------------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

	AB	APPCO	EQ 25MG BASE	A207178	001	Mar 02, 2020	Apr	CPOT
	AB		25MG	A207178	001	Mar 02, 2020	Feb	NEWA
	AB		EQ 50MG BASE	A207178	002	Mar 02, 2020	Apr	CPOT
	AB		50MG	A207178	002	Mar 02, 2020	Feb	NEWA
	AB		EQ 100MG BASE	A207178	003	Mar 02, 2020	Apr	CPOT
	AB		100MG	A207178	003	Mar 02, 2020	Feb	NEWA
>D>	AB	PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020	Jul	DISC

TABLET;ORAL

SILDENAFIL CITRATE

>A>	@	EQ 25MG BASE	A205791	001	Apr 23, 2020	Jul	DISC
AB		EQ 25MG BASE	A205791	001	Apr 23, 2020	Apr	NEWA
>D>	AB	EQ 50MG BASE	A205791	002	Apr 23, 2020	Jul	DISC
>A>	@	EQ 50MG BASE	A205791	002	Apr 23, 2020	Jul	DISC
AB		EQ 50MG BASE	A205791	002	Apr 23, 2020	Apr	NEWA
AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Jun	NEWA
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Jun	NEWA
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Jun	NEWA
AB	SUNSHINE LAKE	EQ 25MG BASE	A213032	001	Jun 11, 2020	Jun	NEWA
AB		EQ 50MG BASE	A213032	002	Jun 11, 2020	Jun	NEWA
AB		EQ 100MG BASE	A213032	003	Jun 11, 2020	Jun	NEWA
	VIAGRA						
AB	+ UPJOHN	EQ 25MG BASE	N020895	001	Mar 27, 1998	Jun	CAHN
AB	+	EQ 50MG BASE	N020895	002	Mar 27, 1998	Jun	CAHN
AB	+!	EQ 100MG BASE	N020895	003	Mar 27, 1998	Jun	CAHN

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB	HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020	Feb	NEWA
AB		8MG	A204793	002	Feb 14, 2020	Feb	NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

AMMONUL

AP	+! BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jun	CAHN
----	-----------	-----------------------------	---------	-----	--------------	-----	------

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

>D>	AP	EXELA PHARMA	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jul	CHRS
>A>	AP	!	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jul	CHRS
>D>	AP		0.9MEQ/ML	A211091	002	Jun 20, 2019	Jul	CHRS
>A>	AP	!	0.9MEQ/ML	A211091	002	Jun 20, 2019	Jul	CHRS
>D>	AP		1MEQ/ML	A211091	003	Jun 20, 2019	Jul	CHRS
>A>	AP	!	1MEQ/ML	A211091	003	Jun 20, 2019	Jul	CHRS
>D>	AP	! HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Jul	DISC
>A>		@	0.9MEQ/ML	A077394	001	Nov 09, 2005	Jul	DISC
>D>	AP	!	1MEQ/ML	A077394	002	Nov 09, 2005	Jul	DISC
>A>		@	1MEQ/ML	A077394	002	Nov 09, 2005	Jul	DISC
>D>		@ HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Jul	CMFD
>A>	AP		0.5MEQ/ML	A202679	001	Mar 07, 2017	Jul	CMFD

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	NEPHRON	9MG/ML	A211968	001	Apr 23, 2020	Apr	NEWA
	SODIUM CHLORIDE IN PLASTIC CONTAINER						
>D>	+ HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul	CDFR
	SOLUTION;INTRAVENOUS						
>A>	SODIUM CHLORIDE 14.6%						
>A>	+ HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul	CTNA
>A>	+ @	50MEQ/20ML (2.5MEQ/ML)	N018897	001	Jul 20, 1984	Jul	DISC
>A>	+	50MEQ/20ML (2.5MEQ/ML)	N018897	001	Jul 20, 1984	Jul	CPOT
>A>	+!	100MEQ/40ML (2.5MEQ/ML)	N018897	002	Jul 20, 1984	Jul	NEWA
	SODIUM CHLORIDE 23.4%						
>A>	+! HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Jul	NEWA
>A>	SODIUM CHLORIDE IN PLASTIC CONTAINER						
>A>	+ HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul	CDFR

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	CURIUM	100uCi	A071909	001	Feb 28, 1989	Feb	CAHN
AA		200uCi	A071910	001	Feb 28, 1989	Feb	CAHN

SODIUM IODIDE I-131SOLUTION;ORAL
HICON

AA	+	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011	Jan	CFTG
		SODIUM IODIDE I 131						
AA		INTL ISOTOPES	250-1000mCi	A209166	001	Feb 05, 2020	Jan	NFTG

SODIUM LACTATEINJECTABLE;INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER
+ @ HOSPIRA 5MEQ/ML

N018947 001 Sep 05, 1984 Jun DISC

SODIUM NITROPRUSSIDEINJECTABLE;INJECTION
SODIUM NITROPRUSSIDE

>D>	AP		AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017	Jul	DISC
>A>		@		25MG/ML	A209832	001	Dec 18, 2017	Jul	DISC

SODIUM OXYBATESOLUTION;ORAL
SODIUM OXYBATE

>D>	AA		HIKMA	500MG/ML	A202090	001	Jan 17, 2017	Jul	CPOT
>A>	AA			0.5GM/ML	A202090	001	Jan 17, 2017	Jul	CPOT
			XYREM						
>D>	AA	+	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jul	CPOT
>A>	AA	+		0.5GM/ML	N021196	001	Jul 17, 2002	Jul	CPOT

SODIUM PHENYLEBUTYRATETABLET;ORAL
SODIUM PHENYLEBUTYRATE
@ ALVOGEN 500MG

A090910 001 Nov 18, 2011 Jan DISC

SODIUM POLYSTYRENE SULFONATESUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
@ HIKMA 15GM/60ML

A089049 001 Nov 17, 1986 Feb DISC

SOFOSBUVIR; VELPATASVIRTABLET;ORAL
EPCLUSA
+ GILEAD SCIENCES INC 200MG;50MG

N208341 002 Mar 19, 2020 Mar NEWA

SOLIFENACIN SUCCINATESUSPENSION;ORAL
VESICARE LS
+! ASTELLAS 1MG/ML
TABLET;ORAL

N209529 001 May 26, 2020 May NEWA

AB			GRAVITI PHARMS	5MG	A211423	001	Dec 11, 2019	May	CAHN
AB				10MG	A211423	002	Dec 11, 2019	May	CAHN
AB			SUNSHINE LAKE	5MG	A213346	001	Apr 13, 2020	Mar	NEWA
AB				10MG	A213346	002	Apr 13, 2020	Mar	NEWA

SOLRIAMFETOL HYDROCHLORIDETABLET;ORAL
SUNOSI
+ JAZZ EQ 75MG BASE
+ 75MG
+! EQ 150MG BASE
+ EQ 150MG BASE
+ 150MG

N211230	001	Jun 17, 2019	Jan	CPOT
N211230	001	Jun 17, 2019	Jan	CAIN
N211230	002	Jun 17, 2019	Apr	CHRS
N211230	002	Jun 17, 2019	Jan	CPOT
N211230	002	Jun 17, 2019	Jan	CAIN

SPIRONOLACTONETABLET;ORAL
ALDACTONE

>D>	AB	+	GD SEARLE LLC	25MG	N012151	009	Dec 30, 1983	Jul	CAHN
>D>	AB	+		50MG	N012151	008	Dec 30, 1982	Jul	CAHN
>D>	AB	+		100MG	N012151	010	Dec 30, 1983	Jul	CAHN
>A>	AB	+	PFIZER	25MG	N012151	009	Dec 30, 1983	Jul	CAHN
>A>	AB	+		50MG	N012151	008	Dec 30, 1982	Jul	CAHN
>A>	AB	+		100MG	N012151	010	Dec 30, 1983	Jul	CAHN

STREPTOMYCIN SULFATEINJECTABLE; INJECTION
STREPTOMYCIN SULFATE

! XGEN PHARMS EQ 1GM BASE/VIAL A064210 001 Jun 30, 1998 Feb CAHN

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION
QUELICIN PRESERVATIVE FREE

+ @ HOSPIRA 50MG/ML N008845 002 Apr CRLD

+ @ 100MG/ML N008845 004 Apr CRLD

SUCCINYLCHOLINE CHLORIDE

AP ACCORD HLTHCARE 20MG/ML A213705 001 May 20, 2020 May NEWA

AP AMPHASTAR PHARMS INC 20MG/ML A213432 001 Jun 08, 2020 Jun NEWA

AP ASPIRO 20MG/ML A213810 001 May 04, 2020 Apr NEWA

AP GLAND PHARMA LTD 20MG/ML A214246 001 Jun 16, 2020 Jun NEWA

AP HIKMA 20MG/ML A213229 001 Jun 12, 2020 Jun NEWA

AP INDOCO 20MG/ML A214308 001 May 22, 2020 May NEWA

AP NIVAGEN PHARMS INC 20MG/ML A211625 001 May 19, 2020 May NEWA

SUCOSTRIN

+ @ APOTHECON 20MG/ML N008847 001 Apr CRLD

+ @ 100MG/ML N008847 003 Apr CRLD

SUCRALFATETABLET; ORAL
SUCRALFATE

AB NOSTRUM LABS INC 1GM A074415 001 Jun 08, 1998 May CMFD

SULFACETAMIDE SODIUMLOTION; TOPICAL
KLARON

AB +! BAUSCH 10% N019931 001 Dec 23, 1996 Mar CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP TEVA PHARMS USA 80MG/ML; 16MG/ML A073303 001 Oct 31, 1991 Mar CMFD

SUMATRIPTAN SUCCINATETABLET; ORAL
SUMATRIPTAN SUCCINATE

AB COREPHARMA EQ 25MG BASE A200263 001 Jun 19, 2012 Feb CAHN

AB EQ 50MG BASE A200263 002 Jun 19, 2012 Feb CAHN

AB EQ 100MG BASE A200263 003 Jun 19, 2012 Feb CAHN

TADALAFILTABLET; ORAL
TADALAFIL

>A> AB ACCORD HLTHCARE 10MG A209167 003 Oct 23, 2019 Jul NEWA

TAMSULOSIN HYDROCHLORIDECAPSULE; ORAL
TAMSULOSIN HYDROCHLORIDE

@ ANBISON LAB 0.4MG A211885 001 Oct 17, 2019 Apr DISC

TAPENTADOL HYDROCHLORIDESOLUTION; ORAL
NUCYNTA

+ @ COLLEGIUM PHARM INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 Feb CAHN

TABLET; ORAL
NUCYNTA

+ COLLEGIUM PHARM INC EQ 50MG BASE N022304 001 Nov 20, 2008 Feb CAHN

+ EQ 75MG BASE N022304 002 Nov 20, 2008 Feb CAHN

+! EQ 100MG BASE N022304 003 Nov 20, 2008 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

+ COLLEGIUM PHARM INC EQ 50MG BASE N200533 001 Aug 25, 2011 Feb CAHN

+ EQ 100MG BASE N200533 002 Aug 25, 2011 Feb CAHN

+ EQ 150MG BASE N200533 003 Aug 25, 2011 Feb CAHN

+ EQ 200MG BASE N200533 004 Aug 25, 2011 Feb CAHN

+! EQ 250MG BASE N200533 005 Aug 25, 2011 Feb CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET; ORAL

TAZVERIK

+! EPIZYME INC EQ 200MG BASE N211723 001 Jan 23, 2020 Jan NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

@ SUN PHARM INDS INC N/A N018467 001 Mar 16, 1982 Apr CAHN

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC-99M MEBROFENIN

AP SUN PHARM INDS INC N/A A078242 001 Jan 29, 2008 Apr CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP

SUN PHARM INDS INC N/A N018124 001 Apr CAHN

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

AP SOMMER PHARMS II LLC N/A A206489 001 Feb 06, 2020 Jan NEWA

AP SUN PHARM INDS INC N/A A208994 001 Jul 12, 2019 Apr CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO

AP SUN PHARM INDS INC N/A N019039 001 Jun 30, 1987 Apr CAHN

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M SESTAMIBI

AP CURIUM N/A A078098 001 Sep 22, 2008 Feb CAHN

AP SUN PHARM INDS INC 10-30mCi A079157 001 Jul 10, 2009 Apr CAHN

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+! SUN PHARM INDS INC N/A N017858 001 Apr CAHN

TELMISARTAN

TABLET; ORAL

TELMISARTAN

>A> @ CELLTRION 20MG A078710 001 Jan 08, 2014 Jul CAHN

>A> @ 40MG A078710 002 Jan 08, 2014 Jul CAHN

>A> @ 80MG A078710 003 Jan 08, 2014 Jul CAHN

>D> @ CIPLA 20MG A078710 001 Jan 08, 2014 Jul CAHN

>D> @ 40MG A078710 002 Jan 08, 2014 Jul CAHN

>D> @ 80MG A078710 003 Jan 08, 2014 Jul CAHN

@ JUBILANT GENERICS 20MG A204164 001 Aug 22, 2016 Jan DISC

@ 40MG A204164 002 Aug 22, 2016 Jan DISC

@ 80MG A204164 003 Aug 22, 2016 Jan DISC

AB MICRO LABS 20MG A207016 001 Oct 03, 2017 Apr CMFD

AB 40MG A207016 002 Oct 03, 2017 Apr CMFD

AB 80MG A207016 003 Oct 03, 2017 Apr CMFD

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB CHARTWELL 5MG A206413 001 Apr 12, 2016 Jun CAHN

AB 20MG A206413 002 Apr 12, 2016 Jun CAHN

AB 100MG A206413 003 Apr 12, 2016 Jun CAHN

AB 140MG A206413 004 Apr 12, 2016 Jun CAHN

AB 180MG A206413 005 Apr 12, 2016 Jun CAHN

AB 250MG A206413 006 Apr 12, 2016 Jun CAHN

TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

+ @ ARDELYX INC EQ 50MG BASE N211801 001 Sep 12, 2019 Mar DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

@ MYLAN 150MG A206569 001 Nov 27, 2018 Feb DISC

@ 200MG A206569 002 Nov 27, 2018 Feb DISC

@ 250MG A206569 003 Nov 27, 2018 Feb DISC

@ 300MG A206569 004 Nov 27, 2018 Feb DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ HERITAGE PHARMA EQ 1MG BASE A075614 002 Jan 30, 2001 Feb DISC

@ EQ 2MG BASE A075614 001 Jan 30, 2001 Feb DISC

@ EQ 5MG BASE A075614 003 Jan 30, 2001 Feb DISC

@ EQ 10MG BASE A075614 004 Jan 30, 2001 Feb DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB TWI PHARMS 2.5MG A211832 001 Jun 19, 2020 Jun NEWA

AB 5MG A211832 002 Jun 19, 2020 Jun NEWA

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB IMPAX 14MG A209677 001 Jun 17, 2020 Jun NEWA

@ MYLAN 7MG A209702 001 Feb 28, 2020 Mar DISC

AB 7MG A209702 001 Feb 28, 2020 Feb NEWA

@ 14MG A209702 002 Feb 28, 2020 Mar DISC

AB 14MG A209702 002 Feb 28, 2020 Feb NEWA

TERIPARATIDE

INJECTABLE; SUBCUTANEOUS

FORTEO

+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008 Jan CAIN

@ 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002 Jan CAIN

SOLUTION; SUBCUTANEOUS

BONSITY

ALVOGEN 0.62MG/2.48ML (0.25MG/ML) N211939 001 Oct 04, 2019 Jan CAIN

FORTEO

+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008 Jan CDFR

@ 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002 Jan CDFR

TESTOSTERONE

GEL, METERED; TRANSDERMAL

ANDROGEL

+ @ ABBVIE 12.5MG/1.25GM ACTUATION N021015 003 Sep 26, 2003 Mar DISC

TESTOSTERONE

BX ! ACTAVIS LABS UT INC 12.5MG/1.25GM ACTUATION A076737 003 Mar 09, 2015 Mar CHRS

BX 12.5MG/1.25GM ACTUATION A076737 003 Mar 09, 2015 Mar CTEC

AB XIROMED 1.62% (20.25MG/1.25GM ACTUATION) A210835 001 Apr 16, 2020 Apr NEWA

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB APOTEX 12.5MG A206093 001 Mar 17, 2020 Mar NEWA

AB 25MG A206093 002 Mar 17, 2020 Mar NEWA

AB PIRAMAL HLTHCARE UK 12.5MG A213316 001 Jan 22, 2020 Jan NEWA

AB 25MG A213316 002 Jan 22, 2020 Jan NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

>D> AB STRIDES PHARMA 250MG A212635 001 Mar 03, 2020 Jul DISC

>A> @ 250MG A212635 001 Mar 03, 2020 Jul DISC

AB 250MG A212635 001 Mar 03, 2020 Feb NEWA

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

>D>	AB		500MG	A212635	002	Mar 03, 2020	Jul	DISC
>A>		@	500MG	A212635	002	Mar 03, 2020	Jul	DISC
	AB		500MG	A212635	002	Mar 03, 2020	Feb	NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE;INTRAVENOUS

THALLOUS CHLORIDE TL 201

		@	CURIUM	2mCi/ML	A077698	001	Nov 09, 2006	Feb	CAHN
--	--	---	--------	---------	---------	-----	--------------	-----	------

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

			ALEMbic PHARMS LTD	300MG	A090430	001	Oct 27, 2010	Jun	CTEC
		@	HERITAGE PHARMA	300MG	A089763	001	Apr 30, 1990	Jun	DISC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

AB		MYLAN	10MG	A088004	002	Mar 15, 1983	Mar	CTEC
AB			25MG	A088004	003	Mar 15, 1983	Mar	CTEC
AB			50MG	A088004	004	Mar 15, 1983	Mar	CTEC
AB	!		100MG	A088004	001	Nov 18, 1983	Mar	CTEC
AB		SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Mar	CMFD
AB			25MG	A089953	003	Aug 01, 1986	Mar	CMFD
AB			50MG	A089953	002	Aug 01, 1986	Mar	CMFD
AB			100MG	A089953	001	Oct 07, 1988	Mar	CMFD

THIOTEPA

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

AP	+	!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	May	CPOT
AP	+	!		100MG/VIAL	N208264	002	Jan 26, 2017	May	CPOT

THIOTEPA

AP			MSN	15MG/VIAL	A213049	001	Mar 04, 2020	May	CPOT
AP				100MG/VIAL	A213049	002	Mar 04, 2020	May	CPOT

POWDER;INTRAVENOUS

TEPADINA

AP	+	!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Feb	CFTG
AP	+	!		100MG/VIAL	N208264	002	Jan 26, 2017	Feb	CFTG

THIOTEPA

AP			MSN	15MG/VIAL	A213049	001	Mar 04, 2020	Feb	NFTG
AP				100MG/VIAL	A213049	002	Mar 04, 2020	Feb	NFTG

TICAGRELOR

TABLET;ORAL

TICAGRELOR

AB			HEC PHARM CO LTD	90MG	A208508	001	Apr 06, 2020	Mar	NEWA
AB			SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Mar	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB			AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020	Mar	NEWA
AB				EQ 4MG BASE	A213544	002	Mar 24, 2020	Mar	NEWA
AB				EQ 6MG BASE	A213544	003	Mar 24, 2020	Mar	NEWA
AB		RUBICON		EQ 2MG BASE	A213798	001	May 27, 2020	May	NEWA
AB				EQ 4MG BASE	A213798	002	May 27, 2020	May	NEWA
AB				EQ 6MG BASE	A213798	003	May 27, 2020	May	NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

		@	MYLAN	300MG/5ML	A209554	001	Oct 13, 2017	Feb	DISC
--	--	---	-------	-----------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP	!		XGEN PHARMS	EQ 1.2GM BASE/VIAL	A065013	001	Aug 17, 2001	Feb	CAHN
----	---	--	-------------	--------------------	---------	-----	--------------	-----	------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@	MYLAN PHARMS INC	250MG	A 070259	001	Jan 02, 1986	Mar	DISC
@		500MG	A 070259	003	Mar 17, 1986	Mar	DISC

TOLCAPONE

TABLET; ORAL

TOLCAPONE

>A>	AB	ALVOGEN	100MG	A 207729	001	Jul 29, 2020	Jul	NEWA
-----	----	---------	-------	----------	-----	--------------	-----	------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LA

>D>	AB	+ PHARMACIA AND UPJOHN	2MG	N 021228	001	Dec 22, 2000	Jul	CAHN
>D>	AB	+!	4MG	N 021228	002	Dec 22, 2000	Jul	CAHN
>A>	AB	+ UPJOHN	2MG	N 021228	001	Dec 22, 2000	Jul	CAHN
>A>	AB	+!	4MG	N 021228	002	Dec 22, 2000	Jul	CAHN

TOLTERODINE TARTRATE

AB		AJANTA PHARMA LTD	2MG	A 213397	001	May 19, 2020	May	NEWA
AB			4MG	A 213397	002	May 19, 2020	May	NEWA

TABLET; ORAL

DETROL

AB	+	UPJOHN	1MG	N 020771	001	Mar 25, 1998	Jun	CAHN
AB		+!	2MG	N 020771	002	Mar 25, 1998	Jun	CAHN
		TOLTERODINE TARTRATE						
		@ MYLAN PHARMS INC	1MG	A 202641	001	Nov 27, 2012	Jan	DISC
		@	2MG	A 202641	002	Nov 27, 2012	Jan	DISC
>A>	AB	UNICHEM LABS LTD	1MG	A 205399	001	Aug 05, 2020	Jul	NEWA
>A>	AB		2MG	A 205399	002	Aug 05, 2020	Jul	NEWA
AB		UNIQUE PHARM LABS	1MG	A 204721	001	Jan 24, 2020	Jan	NEWA
AB			2MG	A 204721	002	Jan 24, 2020	Jan	NEWA

TOLVAPTAN

TABLET; ORAL

SAMSCA

AB	+	OTSUKA AMERICA PHARM	30MG	N 022275	002	May 19, 2009	May	CFTG
		TOLVAPTAN						
AB		ALKEM LABS LTD	30MG	A 211891	001	May 19, 2020	May	NEWA
AB			60MG	A 211891	002	May 19, 2020	May	NFTG
AB		APOTEX	30MG	A 207605	001	May 19, 2020	May	NFTG

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

>A>		@ CHARTWELL	25MG	A 078410	001	Sep 11, 2013	Jul	CAHN
>A>		@	50MG	A 078410	002	Sep 11, 2013	Jul	CAHN
>A>		@	100MG	A 078410	003	Sep 11, 2013	Jul	CAHN
>A>		@	200MG	A 078410	004	Sep 11, 2013	Jul	CAHN
>D>		@ LUPIN	25MG	A 078410	001	Sep 11, 2013	Jul	CAHN
>D>		@	50MG	A 078410	002	Sep 11, 2013	Jul	CAHN
>D>		@	100MG	A 078410	003	Sep 11, 2013	Jul	CAHN
>D>		@	200MG	A 078410	004	Sep 11, 2013	Jul	CAHN
AB		VIWIT PHARM	25MG	A 077733	001	Mar 27, 2009	Mar	CAHN
AB			25MG	A 077733	001	Mar 27, 2009	Mar	CAHN
AB			50MG	A 077733	002	Mar 27, 2009	Mar	CAHN
AB			50MG	A 077733	002	Mar 27, 2009	Mar	CAHN
AB			100MG	A 077733	003	Mar 27, 2009	Mar	CAHN
AB			100MG	A 077733	003	Mar 27, 2009	Mar	CAHN
AB			200MG	A 077733	004	Mar 27, 2009	Mar	CAHN
AB			200MG	A 077733	004	Mar 27, 2009	Mar	CAHN

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB		COREPHARMA	5MG	A 076894	001	May 31, 2005	Feb	CAHN
AB			10MG	A 076894	002	May 31, 2005	Feb	CAHN
AB			20MG	A 076894	003	May 31, 2005	Feb	CAHN
AB			100MG	A 076894	004	May 31, 2005	Feb	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

@ MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	May DISC
-----------------------	------	---------	-----	--------------	----------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan DISC
AP XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb CAHN

TABLET; ORAL

TRANEXAMIC ACID

@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan CAHN
------------------	-------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan NEWA
AB	100MG	A204852	002	Feb 05, 2020	Jan NEWA
AB	150MG	A204852	003	Feb 05, 2020	Jan NEWA
AB	300MG	A204852	004	Feb 05, 2020	Jan NEWA

TREPROSTINIL

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP DR REDDYS	1MG/ML	A210214	001	May 22, 2020	May NEWA
AP	2.5MG/ML	A210214	002	May 22, 2020	May NEWA
AP	5MG/ML	A210214	003	May 22, 2020	May NEWA
AP	10MG/ML	A210214	004	May 22, 2020	May NEWA

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT QUAGEN	0.025%	A213559	001	Jul 01, 2020	Jun NEWA
AT	0.1%	A213559	002	Jul 01, 2020	Jun NEWA
AT SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
AT	0.1%	A209828	002	Nov 23, 2018	Mar CTNA
AT	0.5%	A209828	003	Nov 23, 2018	Mar CTNA
AT STRIDES PHARMA	0.05%	A212356	001	Jun 01, 2020	May NEWA
>D> AT	0.1%	A211315	001	Mar 18, 2020	Jul DISC
>A> @	0.1%	A211315	001	Mar 18, 2020	Jul DISC
AT	0.1%	A211315	001	Mar 18, 2020	Mar NEWA
>D> AT	0.5%	A211315	002	Mar 18, 2020	Jul DISC
>A> @	0.5%	A211315	002	Mar 18, 2020	Jul DISC
AT	0.5%	A211315	002	Mar 18, 2020	Mar NEWA

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Jan DISC
@	0.25MG	A074031	002	Mar 25, 1994	Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB LUPIN LTD	250MG	A211637	001	May 21, 2020	May NEWA
AB RISING	250MG	A212238	001	Feb 20, 2020	Feb NEWA

TRIFAROTENE

CREAM; TOPICAL

AKLIEF

+! GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019	May CAHN
---------------------	--------	---------	-----	--------------	----------

>A>	<u>TRIEPTANOIN</u>								
>A>	LIQUID;ORAL								
>A>	DOJOLVI								
>A>	+!	ULTRAGENYX PHARM INC	100% w/w		N213687	001	Jun 30, 2020	Jul	NEWA
	<u>TRIPTORELIN PAMOATE</u>								
	INJECTABLE; INTRAMUSCULAR								
	TRELSTAR								
>D>	+!	ALLERGAN	EQ 3.75MG BASE/VIAL		N020715	001	Jun 15, 2000	Jul	CAHN
>D>	+!		EQ 11.25MG BASE/VIAL		N021288	001	Jun 29, 2001	Jul	CAHN
>D>	+!		EQ 22.5MG BASE/VIAL		N022437	001	Mar 10, 2010	Jul	CAHN
>A>	+!	VERITY	EQ 3.75MG BASE/VIAL		N020715	001	Jun 15, 2000	Jul	CAHN
>A>	+!		EQ 11.25MG BASE/VIAL		N021288	001	Jun 29, 2001	Jul	CAHN
>A>	+!		EQ 22.5MG BASE/VIAL		N022437	001	Mar 10, 2010	Jul	CAHN
	<u>TROMETHAMINE</u>								
	SOLUTION; INJECTION								
	THAM								
	+!	HOSPIRA	18GM/500ML (3.6GM/100ML)		N013025	002		Jun	CMFD
	<u>TROSPIMUM CHLORIDE</u>								
	CAPSULE, EXTENDED RELEASE; ORAL								
	TROSPIMUM CHLORIDE								
AB	GRANULES PHARMS		60MG		A213185	001	Apr 23, 2020	Apr	NEWA
	<u>TUCATINIB</u>								
	TABLET; ORAL								
	TUKYSA								
	+	SEATTLE GENETICS	50MG		N213411	001	Apr 17, 2020	Apr	NEWA
	+!		150MG		N213411	002	Apr 17, 2020	Apr	NEWA
	<u>URSODIOL</u>								
	CAPSULE; ORAL								
	URSODIOL								
AB	RISING		300MG		A213200	001	Feb 12, 2020	Jan	NEWA
	<u>VALACYCLOVIR HYDROCHLORIDE</u>								
	TABLET; ORAL								
	VALACYCLOVIR HYDROCHLORIDE								
	@	TEVA PHARMS	EQ 500MG BASE		A077655	001	May 24, 2010	Jan	DISC
	@		EQ 1GM BASE		A077655	002	May 24, 2010	Jan	DISC
AB	YILING PHARM LTD		EQ 500MG BASE		A209553	001	Mar 18, 2020	Mar	NEWA
AB			EQ 1GM BASE		A209553	002	Mar 18, 2020	Mar	NEWA
	<u>VALGANCICLOVIR HYDROCHLORIDE</u>								
	FOR SOLUTION; ORAL								
	VALGANCICLOVIR HYDROCHLORIDE								
AB	GRANULES PHARMS		50MG/ML		A213306	001	Jan 31, 2020	Jan	NEWA
	<u>VANCOMYCIN HYDROCHLORIDE</u>								
	FOR SOLUTION; ORAL								
	FIRVANQ KIT								
	+!	AZURITY	EQ 25MG BASE/ML		N208910	001	Jan 26, 2018	Jun	CAHN
	+!		EQ 50MG BASE/ML		N208910	002	Jan 26, 2018	Jun	CAHN
	VANCOCIN HYDROCHLORIDE								
>D>	ANI PHARMS INC		EQ 250MG BASE/5ML		A061667	002	Jul 13, 1983	Jul	CHRS
>A>	!		EQ 250MG BASE/5ML		A061667	002	Jul 13, 1983	Jul	CHRS
	INJECTABLE; INJECTION								
	VANCOMYCIN HYDROCHLORIDE								
AP	HAINAN POLY PHARM		EQ 500MG BASE/VIAL		A212332	001	Jun 12, 2019	Jun	CMFD
AP			EQ 1GM BASE/VIAL		A212332	002	Jun 12, 2019	Jun	CMFD
>A>	AP	HIKMA	EQ 500MG BASE/VIAL		A203300	001	Aug 11, 2020	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL		A203300	002	Aug 11, 2020	Jul	NEWA
>A>	!	HOSPIRA	EQ 1.5GM BASE/VIAL		A062912	003	Jul 10, 2020	Jul	NFTG
>D>	AP	MYLAN LABS LTD	EQ 10GM BASE/VIAL		A091554	001	Sep 19, 2011	Jul	CHRS
>A>	AP	!	EQ 10GM BASE/VIAL		A091554	001	Sep 19, 2011	Jul	CHRS
AP	PHARM ASSOC		EQ 500MG BASE/VIAL		A065401	001	Jun 30, 2008	Jan	CAHN
AP			EQ 1GM BASE/VIAL		A065401	002	Jun 30, 2008	Jan	CAHN

SOLUTION;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	May	CPOT
+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	May	NEWA
+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	May	CPOT
+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	May	NEWA
+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	May	CPOT
+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	May	NEWA
+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	May	CPOT

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

VARDENAFIL HYDROCHLORIDE

>A>	AB	ALEMBIC PHARMS LTD	2.5MG	A214031	001	Aug 04, 2020	Jul	NEWA
>A>	AB		5MG	A214031	002	Aug 04, 2020	Jul	NEWA
>A>	AB		10MG	A214031	003	Aug 04, 2020	Jul	NEWA
>A>	AB		20MG	A214031	004	Aug 04, 2020	Jul	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

+!	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Apr	NEWA
+!		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	+	UPJOHN	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jun	CAHN
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jun	CAHN
		@	EQ 100MG BASE	N020699	003	Oct 20, 1997	Jun	CAHN
AB	+!		EQ 150MG BASE	N020699	004	Oct 20, 1997	Jun	CAHN

VENLAFAXINE HYDROCHLORIDE

AB		INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Mar	NEWA
AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Mar	NEWA
AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

>A>		AUROBINDO PHARMA LTD	2.5MG/ML	A212965	001	Jul 06, 2020	Jul	NEWA
-----	--	----------------------	----------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AREVA PHARMS	10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Mar	NEWA
AP		CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020	Mar	NEWA
AP			10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020	Mar	NEWA

TABLET;ORAL

CALAN

>D>		@ GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988	Jul	CAHN
>D>	+	@	80MG	N018817	001	Sep 10, 1984	Jul	CAHN
>D>	+	@	120MG	N018817	002	Sep 10, 1984	Jul	CAHN
>D>		@	160MG	N018817	004	Feb 23, 1988	Jul	CAHN
>A>		@ PFIZER	40MG	N018817	003	Feb 23, 1988	Jul	CAHN
>A>	+	@	80MG	N018817	001	Sep 10, 1984	Jul	CAHN
>A>	+	@	120MG	N018817	002	Sep 10, 1984	Jul	CAHN
>A>		@	160MG	N018817	004	Feb 23, 1988	Jul	CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA		GRANULES PHARMS	500MG/PACKET	A213469	001	Apr 24, 2020	Apr	NEWA
----	--	-----------------	--------------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILAZODONE HYDROCHLORIDE

@	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Mar	DISC
@		20MG	A208212	002	Sep 30, 2019	Mar	DISC
@		40MG	A208212	003	Sep 30, 2019	Mar	DISC

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

AP	!	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Feb	CTEC
AP		TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Feb	CMFD

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

AP		GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020	Mar	NEWA
----	--	------------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

VORICONAZOLE

>D>	AB	APPCO	50MG	A206762	001	May 24, 2016	Jul	CAHN
>D>	AB		200MG	A206762	002	May 24, 2016	Jul	CAHN
>A>	AB	RISING	50MG	A206762	001	May 24, 2016	Jul	CAHN
>A>	AB		200MG	A206762	002	May 24, 2016	Jul	CAHN

ZALEPLON

CAPSULE; ORAL

ZALEPLON

@	TEVA PHARMS	5MG	A077239	001	Jun 06, 2008	Mar	DISC
@		10MG	A077239	002	Jun 06, 2008	Mar	DISC

ZIDOVUDINE

>A>		SOLUTION; ORAL						
>A>		RETROVIR						
>A>	AA	+! VIIV HLTHCARE	50MG/5ML	N019910	001	Sep 28, 1989	Jul	CDFR
>A>		ZIDOVUDINE						
>A>	AA	AUROBINDO	50MG/5ML	A077268	001	Sep 19, 2005	Jul	CDFR
>A>	AA	CIPLA LTD	50MG/5ML	A077981	001	Jun 26, 2008	Jul	CDFR
>D>		SYRUP; ORAL						
>D>		RETROVIR						
>D>	AA	+! VIIV HLTHCARE	50MG/5ML	N019910	001	Sep 28, 1989	Jul	CDFR
>D>		ZIDOVUDINE						
>D>	AA	AUROBINDO	50MG/5ML	A077268	001	Sep 19, 2005	Jul	CDFR
>D>	AA	CIPLA LTD	50MG/5ML	A077981	001	Jun 26, 2008	Jul	CDFR
		TABLET; ORAL						
		ZIDOVUDINE						
		@ MYLAN LABS LTD	100MG	N200732	001	Feb 23, 2011	Apr	CAHN

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AM	REAGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020	Apr	NEWA
----	---------	------------------------------------	---------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+!	UPJOHN	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jun	CAHN
AB	+		EQ 40MG BASE	N020825	002	Feb 05, 2001	Jun	CAHN
AB	+		EQ 60MG BASE	N020825	003	Feb 05, 2001	Jun	CAHN
AB	+		EQ 80MG BASE	N020825	004	Feb 05, 2001	Jun	CAHN

ZIPRASIDONE HYDROCHLORIDE

AB		CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Mar	CMFD
AB			EQ 40MG BASE	A208988	002	Aug 22, 2017	Mar	CMFD
AB			EQ 60MG BASE	A208988	003	Aug 22, 2017	Mar	CMFD
AB			EQ 80MG BASE	A208988	004	Aug 22, 2017	Mar	CMFD

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR
GEODON

AP	+!	UPJOHN	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jun CAHN
----	----	--------	-----------------	---------	-----	--------------	----------

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

	@	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Apr DISC
AP		INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb NEWA
AP		PUNISKA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN

ZOLMITRIPTANTABLET; ORAL
ZOLMITRIPTAN

AB		APPCO	2.5MG	A206973	001	Jun 30, 2017	Mar CAHN
AB			5MG	A206973	002	Jun 30, 2017	Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
ZOLMITRIPTAN

	@	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Feb DISC
	@		5MG	A202855	002	Sep 20, 2019	Feb DISC

ZOLPIDEM TARTRATETABLET; ORAL
ZOLPIDEM TARTRATE

	@	VINTAGE	5MG	A078616	001	Nov 21, 2008	Jun DISC
	@		10MG	A078616	002	Nov 21, 2008	Jun DISC
	@	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007	Apr DISC
	@		10MG	A077990	002	Apr 23, 2007	Apr DISC

TABLET, EXTENDED RELEASE; ORAL
ZOLPIDEM TARTRATE

AB		CENTAUR PHARMS PVT	6.25MG	A213592	001	Jun 04, 2020	Jun NEWA
AB			12.5MG	A213592	002	Jun 04, 2020	Jun NEWA

ZONISAMIDECAPSULE; ORAL
ZONISAMIDE

AB		AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Mar CMFD
AB			50MG	A077645	003	Sep 29, 2006	Mar CMFD
AB			100MG	A077645	001	Dec 22, 2005	Mar CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+!	GLAXOSMITHKLINE	250MG;125MG	N211733	001	Feb 28, 2020	Apr	CAHN
+!	PFIZER INC	250MG;125MG	N211733	001	Feb 28, 2020	Feb	NEWA

ADAPALENE

GEL; TOPICAL

ADAPALENE

	GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010	Mar	CMS1
	P AND L	0.1%	A090962	001	Jun 02, 2010	Apr	CMS1

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	Mar	CMFD
--	-----------------	-----------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	Apr	CMS1
--	------------------	----	---------	-----	--------------	-----	------

VOLTAREN ARTHRITIS PAIN

+!	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CTNA
+!		1%	N022122	001	Oct 17, 2007	Mar	CMS1

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

	HETERO LABS LTD III	EQ 20MG BASE	A208939	001	May 28, 2020	May	NEWA
		EQ 20MG BASE	A212507	001	Jun 02, 2020	May	NEWA
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020	Apr	NEWA

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

	DR REDDYS LABS LTD	EQ 20MG BASE	A211571	001	May 14, 2020	May	NEWA
	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020	Jun	NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan	CMS1
@	MYLAN	10MG	A075674	001	Dec 21, 2001	Jan	DISC
@	TEVA	10MG	A075312	001	May 31, 2001	Mar	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

>D>	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Jul	DISC
>A>	@	60MG	A212971	001	Feb 24, 2020	Jul	DISC
		60MG	A212971	001	Feb 24, 2020	Feb	NEWA
>D>		180MG	A212971	002	Feb 24, 2020	Jul	DISC
>A>	@	180MG	A212971	002	Feb 24, 2020	Jul	DISC
		180MG	A212971	002	Feb 24, 2020	Feb	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

@	GRANULES INDIA LTD	60MG	A211075	001	Oct 18, 2019	May	DISC
@		180MG	A211075	002	Oct 18, 2019	May	DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

	GRANULES INDIA LTD	600MG	A213420	001	May 08, 2020	Apr	NEWA
		1.2GM	A213420	002	May 08, 2020	Apr	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020	Mar	NEWA
		1.2GM;120MG	A213203	002	Mar 25, 2020	Mar	NEWA
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020	Apr	NEWA
		1.2GM;120MG	A212542	002	Apr 28, 2020	Apr	NEWA

IBUPROFEN

	TABLET;ORAL							
	IBUPROFEN							
	@ ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020	Jun	DISC	
>D>	VINTAGE PHARMS	200MG	A071639	001	Feb 02, 1988	Jul	DISC	
>A>	@	200MG	A071639	001	Feb 02, 1988	Jul	DISC	

KETOTIFEN FUMARATE

	SOLUTION/DROPS;OPHTHALMIC							
	KETOTIFEN FUMARATE							
	BAYSHORE PHARMS LLC	EQ 0.025% BASE	A204059	001	Jun 01, 2020	May	NEWA	

LEVOCETIRIZINE DIHYDROCHLORIDE

	TABLET;ORAL							
	LEVOCETIRIZINE DIHYDROCHLORIDE							
	HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020	Apr	NEWA	
	PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019	Feb	CMFD	

LEVONORGESTREL

	TABLET;ORAL							
	LEVONORGESTREL							
	APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan	CMFD	
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan	CAHN	
	@ NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Jun	CAHN	
	XIROMED	1.5MG	A205329	001	Sep 18, 2018	Feb	CAHN	

LORATADINE

	CAPSULE;ORAL							
	LORATADINE							
	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	May	CMFD	
>D>	STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020	Jul	DISC	
>A>	@	10MG	A211926	001	Jan 15, 2020	Jul	DISC	
	SYRUP;ORAL							
	LORATADINE							
	@ TEVA	1MG/ML	A075505	001	Nov 07, 2003	Apr	DISC	
	TABLET;ORAL							
	LORATADINE							
	@ MYLAN	10MG	A075790	001	Nov 07, 2008	Jan	DISC	
	@	10MG	A078447	001	Aug 12, 2011	Jan	DISC	
	TABLET, ORALLY DISINTEGRATING;ORAL							
	LORATADINE							
	@ ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003	Apr	DISC	

NAPROXEN SODIUM

	TABLET;ORAL							
	NAPROXEN SODIUM							
	@ YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019	Mar	DISC	

NICOTINE POLACRILEX

	TROCHE/LOZENGE;ORAL							
	NICOTINE POLACRILEX							
	DR REDDYS LABS SA	EQ 2MG BASE	A212983	001	Feb 21, 2020	Feb	NEWA	
>A>		EQ 2MG BASE	A213233	001	Aug 04, 2020	Jul	NEWA	
		EQ 4MG BASE	A212983	002	Feb 21, 2020	Feb	NEWA	
>A>		EQ 4MG BASE	A213233	002	Aug 04, 2020	Jul	NEWA	
	P AND L	EQ 2MG BASE	A212057	001	May 14, 2020	May	NEWA	
		EQ 4MG BASE	A212057	002	May 14, 2020	May	NEWA	

NONOXYNOL-9

	SPONGE;VAGINAL							
	TODAY							
	+ @ MAYER LABS INC	1GM	N018683	001	Apr 01, 1983	Mar	DISC	

OLOPATADINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC							
	OLOPATADINE HYDROCHLORIDE							
>A>	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul	CMS1	
		EQ 0.2% BASE	A209752	001	May 20, 2020	May	NFTG	
	MICRO LABS LTD INDIA	EQ 0.2% BASE	A204620	001	Jun 16, 2020	Jun	NEWA	

SOLUTION/DROPS;OPHTHALMIC

PATADAY ONCE DAILY RELIEF

	+!	NOVARTIS	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar	CTNA
	+!		EQ 0.2% BASE	N021545	001	Dec 22, 2004	Mar	CMS1
>A>	+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jul	CTNA
		PATADAY TWICE DAILY RELIEF						
	+!	NOVARTIS	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar	CTNA
	+!		EQ 0.1% BASE	N020688	001	Dec 18, 1996	Mar	CMS1
		PAZEO						
>A>	+!	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jul	CMS1

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

		HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020	Mar	NEWA
		P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020	May	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	@	ACTAVIS ELIZABETH	20MG;1.1GM	A204137	001	Jul 15, 2016	Mar	DISC
--	---	-------------------	------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

		LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jan	CMFD
			17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jan	CMFD

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@	APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000	May	DISC
	@		EQ 150MG BASE	A200172	001	May 31, 2012	Apr	DISC
	@	STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012	Apr	DISC
	@		EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr	DISC
	@		EQ 150MG BASE	A200536	001	Jun 28, 2011	Apr	DISC
	@		EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2020

NO JULY 2020 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	>A> 7803770	Apr 28, 2031	U-2009			
<u>ABAMETAPIR - XEGLYZE</u>						
N 206966 001	>A> 10292389	Dec 17, 2034	DP U-2863			
	>A> 7812163	Oct 28, 2026	DP U-2863			
	>A> 8212038	Jul 16, 2024	DP U-2863			
	>A> 9357783	Jul 16, 2024	DP			
	>A> 9839631	Jul 16, 2024	DS DP U-2863			
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115 001					CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001					NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10588895	Jul 07, 2020	U-2772		M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	>A> 10588895	Jul 07, 2020	U-2772			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	>A> RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	>A> RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	>A> RE43431	Jan 13, 2026	DS			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	10561808	Jan 01, 2032	DP			
	>A> 10695512	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10561808	Jan 01, 2032	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	10617695	Mar 19, 2027	DP U-1493			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	10350214	Apr 24, 2035	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	>A> 10646456	Jun 17, 2034	U-2808			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	>A> 10646456	Jun 17, 2034	U-2808			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001 >A>	10695329	Oct 16, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 002					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 003					M-257	Apr 10, 2023
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10624850	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001 >A>	10688091	Aug 17, 2035	DP			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001					NCE ODE-290	May 26, 2025 May 26, 2027
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10646512	Mar 25, 2032	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10583121	Jul 25, 2033	DP U-2763			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035	U-2844			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035	U-2844			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001					PC	Aug 29, 2020
<u>BACLOFEN - OZOBAX</u>						
N 208193 001	10610502	Aug 30, 2039	U-2779			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10633397	Apr 27, 2036	U-2816			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10633397	Apr 27, 2036	U-2816			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	10561808	Jan 01, 2032	DP			
	>A> 10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	10561808	Jan 01, 2032	DP			
	>A> 10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP			
	>A> 10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP			
	>A> 10695512	May 18, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002	7498343	Dec 01, 2026	DS DP U-1321			
	8546428	Mar 19, 2029	DS DP U-1321			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023	U-2747			
	9000041	Dec 23, 2023	U-2747			
	9624152	Dec 23, 2023	U-2748			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023	U-2746			
	9000041	Dec 23, 2023	U-2746			
	9624152	Dec 23, 2023	U-2749			
<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	10632197	Nov 15, 2037	DP U-2755			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10624918	Jun 03, 2029	U-916			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Jan 13, 2025	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP U-2627			
	>A> 10682364	Jun 10, 2031	DP			
	>A> 10688108	Jun 10, 2031	U-2627			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP U-2627			
	>A> 10682364	Jun 10, 2031	DP			
	>A> 10688108	Jun 10, 2031	U-2627			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024	U-2759		NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7033605	Oct 20, 2020	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025	U-2759			
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034	U-2759			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6579968	Jun 28, 2021	DS DP			
	6794489	Jun 28, 2021	DS DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	>A> 7888362	Apr 12, 2026	DS	Y		
	>A> RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	>A> 7888362	Apr 12, 2026	DS	Y		
	>A> RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	>A> 7888362	Apr 12, 2026	DS	Y		
	>A> RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	>A> 7888362	Apr 12, 2026	DS	Y		
	>A> RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	>A> 7888362	Apr 12, 2026	DS	Y		
	>A> RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	>A> 7888362	Apr 12, 2026	DS	Y		
	>A> RE48059	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569	001				NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866	001	>A> 10688094	Apr 30, 2032	U-2870		
		>A> 10688094	Apr 30, 2032	U-2871		
		>A> 10688094	Apr 30, 2032	U-2872		
		>A> 10688094	Apr 30, 2032	U-2873		
		>A> 10688094	Apr 30, 2032	U-2874		
		>A> 10688094	Apr 30, 2032	U-2875		
		>A> 10688094	Apr 30, 2032	U-2876		
		>A> 10688094	Apr 30, 2032	U-2877		
		>A> 10688094	Apr 30, 2032	U-2878		
		>A> 10688094	Apr 30, 2032	U-2879		
		>A> 10688094	Apr 30, 2032	U-2880		
		>A> 10688094	Apr 30, 2032	U-2881		
		>A> 10688094	Apr 30, 2032	U-2882		
		>A> 10688094	Apr 30, 2032	U-2883		
		>A> 10688094	Apr 30, 2032	U-2884		
		>A> 10688094	Apr 30, 2032	U-2885		
		>A> 10688094	Apr 30, 2032	U-2886		
		>A> 10688094	Apr 30, 2032	U-2887		
		>A> 10688094	Apr 30, 2032	U-2888		
<u>BUDESONIDE - UCERIS</u>						
N 203634	001	>A> 10660858	Sep 07, 2031	DP		
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586	002				CGT	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	001	10558394	Jun 25, 2031	DP		
		10592168	Jun 06, 2031	U-2489		
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819	002	>A> 10558394	Jun 25, 2031	DP		
		10592168	Jun 06, 2031	U-2489		
		>A> 10646484	Jun 22, 2038	U-2489		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001	10583110	Oct 27, 2030	U-2753		
		>A> 10716777	Oct 27, 2030	U-2856		
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001				NPP	Nov 05, 2022
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690	001				>A> NP	Jul 21, 2023
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001	10617668	May 11, 2031	DP U-2441		
		10617668	May 11, 2031	DP U-2632		
		10617668	May 11, 2031	DP U-2794		
		10617668	May 11, 2031	DP U-2795		
		10617668	May 11, 2031	DP U-2796		
		10617668	May 11, 2031	DP U-2797		
		10617668	May 11, 2031	DP U-2798		
		10617668	May 11, 2031	DP U-2799		
		10617668	May 11, 2031	DP U-493		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002	10617668	May 11, 2031	DP U-2441		
		10617668	May 11, 2031	DP U-2632		
		10617668	May 11, 2031	DP U-2794		
		10617668	May 11, 2031	DP U-2795		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	>A> 8680052	Mar 09, 2033	U-1715			
	>A> 8680052	Mar 09, 2033	U-2869			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	>A> 10709671	Jun 17, 2035	U-2862			
	>A> 10709673	Jun 17, 2035	DP			
	>A> 10709674	Jun 17, 2035	U-2780			
	>A> 10709674	Jun 17, 2035	U-2781			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001					>A> I-838	Jul 17, 2023
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	>A> 8268800	Aug 22, 2030	DS		>A> NCE	Jul 07, 2025
	>A> 8268800	Aug 22, 2030	DS	U-2865		
	>A> 8268800	Aug 22, 2030	DS	U-2866		
	>A> 8268800	Aug 22, 2030	DS	U-2867		
	>A> 8618075	Oct 16, 2028	U-2864			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	>A> 8618075	Oct 16, 2028	U-2867			
	>A> 9567363	Oct 16, 2028	DS			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	Sep 13, 2022
<u>CELECOXIB - ELYXYB</u>						
N 212157 001	10376527	May 27, 2036	DP U-2718		NP	May 05, 2023
	9572819	May 27, 2036	DP U-2718			
	9795620	May 27, 2036	DP U-2718			
	9949990	May 27, 2036	DP U-2718			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
	8487093	Nov 19, 2029	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001					NP	May 22, 2023
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	10624879	Jun 23, 2034	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
<u>CLONIDINE - CLONIDINE</u>						
N 022500 001	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLONIDINE - CLONIDINE</u>						
N 022500 002	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	>A> 10039718	Oct 06, 2032	DP			
<u>COBICISTAT; DARUNAVIR - PREZCOBIX</u>						
N 205395 001	>A> 10039718	Oct 06, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001 >A>	10039718	Oct 06, 2032	DP			
	6642245	Nov 04, 2020	U-2352			
	6642245	Nov 04, 2020	U-2765			
	7803788	Feb 02, 2022	U-2352			
	7803788	Feb 02, 2022	U-2765			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001 >A>	10039718	Oct 06, 2032	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001 >A>	10039718	Oct 06, 2032	DP			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10590102	Jun 30, 2036	DS DP U-1776			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10383820	Nov 22, 2036	DP U-2814			
	10383821	Nov 22, 2036	DP			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8039451*PED	Dec 11, 2026			NPP	Mar 23, 2023
	8168614	Jan 20, 2030	U-1932		PED	Jun 14, 2022
	8168614*PED	Jul 20, 2030			PED	Sep 23, 2023
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001					>A> NCE	Apr 30, 2024
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
	>A> 10653719	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001 >A>	10478453	Jan 15, 2039	DP U-2752			
	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
	>A> 10583155	Jan 15, 2039	DP U-2752			
	>A> 10653719	Jan 15, 2039	DP			
	>A> 10702490	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001					ODE-287	Aug 03, 2024
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					I-834	May 05, 2023
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					I-834	May 05, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	7049328	Jun 28, 2021	U-735			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001 >A>	10695398	Apr 27, 2032	U-1895			
	>A> 10729739	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002 >A>	10695398	Apr 27, 2032	U-1895			
	>A> 10729739	Feb 10, 2029	U-1978			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001 >A>	10702539	Jan 09, 2023	U-1597			
	>A> 10702539	Jan 09, 2023	U-2868			
	>A> 10702539	Jan 09, 2023	U-985			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DICYCLOMINE HYDROCHLORIDE - DICYCLOMINE HYDROCHLORIDE</u>						
A 212286 001					CGT	Nov 18, 2020
<u>DIHYDROERGOTAMINE MESYLATE - DIHYDROERGOTAMINE MESYLATE</u>						
A 212907 001					CGT	Nov 19, 2020
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001					M-260	Feb 05, 2023
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002					M-260	Feb 05, 2023
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001					I-827	Sep 19, 2022
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	10603282	Nov 29, 2036	DP			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10603281	Jun 08, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Apr 20, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Apr 20, 2023
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720		>A> NPP	Apr 27, 2023
	10478601	Apr 25, 2035	DP U-2721			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
	>A> 10682351	Sep 01, 2036	U-2850			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP		NP	May 29, 2023
	7179815	Mar 07, 2021	U-2842			
	7419983	Jul 06, 2024	DS DP			
	7462625	Jan 25, 2021	DS DP U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10646481	Aug 13, 2029	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Jun 24, 2026	DS DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Jun 24, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 7579449	Aug 01, 2028	DS		M-252	Mar 20, 2023
	8673927	May 04, 2027	U-1652	Y	M-258	Jul 03, 2022
	9173859	May 04, 2027	DP U-1772	Y		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 7579449	Aug 01, 2028	DS		M-252	Mar 20, 2023
	8673927	May 04, 2027	U-1652	Y	M-258	Jul 03, 2022
	9173859	May 04, 2027	DP U-1772	Y		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	>A> 7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
>A>	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
>A>	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
>A>	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10610489	Sep 30, 2030	DP			
>A>	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10610489	Sep 30, 2030	DP			
>A>	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10610489	Sep 30, 2030	DP			
>A>	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10610489	Sep 30, 2030	DP			
>A>	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	>A> 7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	>A> 7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	>A> 7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	>A> 7579449	Aug 01, 2028	DS			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP	Sep 25, 2020
					ODE-284	Sep 28, 2024
					ODE-285	Sep 28, 2024
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10610125	Jun 21, 2030	U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10610125	Jun 21, 2030	U-2087			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-826	Apr 08, 2023
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10258622	Nov 21, 2032	U-2802			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9474754	Aug 05, 2033	DP U-2802			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10561651	Feb 19, 2035	U-2745			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10561651	Feb 19, 2035	U-2745			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	>A> 10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	>A> 10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	>A> 10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	>A> 10702536	May 06, 2025	U-2501			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP	U-2751		
	9050348	Jul 10, 2028	DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10632066	Feb 01, 2039			U-2786	
	10632066	Feb 01, 2039			U-2787	
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP		U-2588	
	6515117	Oct 04, 2020	DS DP		U-2588	
	6872700	Jan 14, 2020			U-2588	
	6872700	Jan 14, 2020			U-2589	
	6872700	Jan 14, 2020			U-2590	
	6872700	Jan 14, 2020			U-2591	
	6936590	Oct 04, 2020			U-2588	
	7456254	Jun 30, 2025	DP		U-2588	
	7456254	Jun 30, 2025	DP		U-2589	
	7456254	Jun 30, 2025	DP		U-2590	
	7456254	Jun 30, 2025	DP		U-2592	
	7612176	Apr 13, 2025	DP		U-2588	
	7612176	Apr 13, 2025	DP		U-2589	
	7612176	Apr 13, 2025	DP		U-2590	
	7612176	Apr 13, 2025	DP		U-2592	
	8329648	Aug 18, 2026			U-2588	
	8329648	Aug 18, 2026			U-2589	
	8329648	Aug 18, 2026			U-2590	
	8329648	Aug 18, 2026			U-2593	
	8329648	Aug 18, 2026			U-2594	
	8329648	Aug 18, 2026			U-2595	
	8329648	Aug 18, 2026			U-2596	
	8361972	Mar 21, 2028			U-2588	
	8431685	Apr 13, 2025	DP		U-2588	
	8431685	Apr 13, 2025	DP		U-2589	
	8431685	Apr 13, 2025	DP		U-2590	
	8431685	Apr 13, 2025	DP		U-2598	
	8461105	Apr 13, 2025	DP		U-2588	
	8461105	Apr 13, 2025	DP		U-2589	
	8461105	Apr 13, 2025	DP		U-2590	
	8461105	Apr 13, 2025	DP		U-2598	
	8501698	Jun 20, 2027	DP		U-2588	
	8906851	Aug 18, 2026			U-2588	
	8906851	Aug 18, 2026			U-2589	
	8906851	Aug 18, 2026			U-2590	
	8906851	Aug 18, 2026			U-2593	
	9198925	Oct 04, 2020			U-2588	
	9238076	Apr 15, 2024	DP		U-2588	
	9238076	Apr 15, 2024	DP		U-2589	
	9238076	Apr 15, 2024	DP		U-2590	
	9238076	Apr 15, 2024	DP		U-2599	
	9884092	Aug 18, 2026			U-2588	
	9884092	Aug 18, 2026			U-2589	
	9884092	Aug 18, 2026			U-2590	
	9884092	Aug 18, 2026			U-2593	
	9884092	Aug 18, 2026			U-2594	
	9884092	Aug 18, 2026			U-2595	
	9884092	Aug 18, 2026			U-2596	
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP		U-2588	
	6515117	Oct 04, 2020	DS DP		U-2588	
	6872700	Jan 14, 2020			U-2588	
	6872700	Jan 14, 2020			U-2589	
	6872700	Jan 14, 2020			U-2590	
	6872700	Jan 14, 2020			U-2591	
	6936590	Oct 04, 2020			U-2588	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 10452815	Oct 22, 2039	U-2859		>A> NP	Jun 25, 2023
	>A> 10478441	May 03, 2033	U-2860			
	>A> 10478442	May 03, 2033	U-2860			
	>A> 10603290	Aug 02, 2037	U-2861			
	>A> 9549909	May 03, 2033	U-2858			
	>A> 9603814	May 03, 2033	U-2858			
	>A> 9603815	May 03, 2033	U-2858			
	>A> 9610260	May 03, 2033	U-2858			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10610523	Jan 25, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10610523	Jan 25, 2027	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS U-2709			
	10519252	Oct 20, 2023	DS U-2710			
	10519252	Oct 20, 2023	DS U-2711			
	10519252	Oct 20, 2023	DS U-2712			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021	DP U-1577			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719			
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 001	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123 002	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	>A> 10716868	Dec 30, 2035	U-2450			
<u>FLUOROESTRADIOL F-18 - CERIANNA</u>						
N 212155 001					NCE	May 20, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Sep 03, 2020	DP			
	>A> 8978647	Dec 06, 2030	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10624911	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	10208073	May 23, 2032	U-2301			
	10624911	Jun 02, 2037	DP			
	8426450	May 23, 2032	DS DP			
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			
	9403772	May 23, 2032	DS U-2301			
	9908907	May 23, 2032	DS DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	>A> 7745625	Nov 19, 2027	DS		>A> NCE	Jul 02, 2025
	>A> 8168615	Feb 25, 2025	DP			
	>A> 8461333	Feb 25, 2025	DS			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					M-259	Apr 10, 2023
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001 >A>	10668040	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001 >A>	10688518	Nov 12, 2036	DP			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
	>A> 10729720	Apr 21, 2035	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10653696	Jun 03, 2031	U-1456			
	>A> 10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10653696	Jun 03, 2031	U-1456			
	>A> 10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10653696	Jun 03, 2031	U-1456			
	>A> 10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10653696	Jun 03, 2031	U-1456			
	>A> 10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10653696	Jun 03, 2031	U-1456			
	>A> 10695350	Oct 24, 2034	U-2846			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10653696	Jun 03, 2031	U-1456			
	>A> 10695350	Oct 24, 2034	U-2846			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	8518929	Feb 09, 2030	U-1287			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	10631746	Aug 04, 2035	DP U-2815			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					>A> ODE-305 >A> GAIN	Mar 06, 2022 Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					>A> ODE-305 >A> GAIN	Mar 06, 2022 Mar 06, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10597384	Dec 04, 2028	DS DP U-2777			
	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778			
	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778			
	10646481	Aug 13, 2029	DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125	Jun 21, 2030	U-2784			
	10610125	Jun 21, 2030	U-2785			
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10532993	Jul 11, 2026	U-1524			
	>A> 10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Nov 10, 2030	DS DP U-1524			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LETERMOVIR - PREVMIS</u>						
N 209939 001	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVMIS</u>						
N 209939 002	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVMIS</u>						
N 209940 001	10603384	Feb 28, 2033	DP			
	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVMIS</u>						
N 209940 002	10603384	Feb 28, 2033	DP			
	RE46791	May 22, 2024	DS DP			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001					I-829	May 01, 2023
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	10603293	Jan 14, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10675325	Aug 11, 2031	DP			
	>A> 10702576	Aug 11, 2031	U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10555938	Mar 07, 2025	U-1316			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	10596107	Dec 23, 2036	DP U-2764			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10646437	May 03, 2033	DP			
	>A> 10688045	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	>A> 10695345	Aug 30, 2039	DP U-543			
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE39680	Jun 15, 2020	DS DP U-543			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	7763615	Dec 13, 2024	DS DP U-2836		>A> NCE	Jun 15, 2025
					>A> ODE-304	Jun 15, 2027
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP			
	10596278	Jul 25, 2038	DP			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 6667314*PED	Feb 06, 2022				
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7368460*PED	May 25, 2023				
	>A> 7576097	May 25, 2021	DS			
	>A> 7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 6667314*PED	Feb 06, 2022				
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7368460*PED	May 25, 2023				
	>A> 7576097	May 25, 2021	DS			
	>A> 7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 6667314*PED	Feb 06, 2022				
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7368460*PED	May 25, 2023				
	>A> 7576097	May 25, 2021	DS			
	>A> 7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 6667314*PED	Feb 06, 2022				
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7368460*PED	May 25, 2023				
	>A> 7576097	May 25, 2021	DS			
	>A> 7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 6667314*PED	Feb 06, 2022				
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7368460*PED	May 25, 2023				
	>A> 7576097	May 25, 2021	DS			
	>A> 7576097*PED	Nov 25, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
>A>	10709713	May 26, 2030	U-2750			
	8512727	Dec 25, 2022	DP U-2750			
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10561675	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003					M-244	Aug 12, 2022
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10610485	Jan 02, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
>A>	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
>A>	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
>A>	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
>A>	10722473	Nov 19, 2038	U-2357			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	>A> 10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	>A> 10722473	Nov 19, 2038	U-2357			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	6770262	Mar 29, 2021	U-2843			
	8334281	May 16, 2030	DP U-2843			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10596155	Jun 28, 2032	DP			
<u>METYSOSINE - METYSOSINE</u>						
A 213734 001					>A> CGT	Jan 20, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 001					>A> CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 002					>A> CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 003					>A> CGT	Jan 18, 2021
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 001					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 002					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10660904	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10517882	Oct 01, 2030	U-2647			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10213512	Oct 01, 2030	DP U-1631			
	10265404	Oct 01, 2030	DP			
	10322186	Oct 01, 2030	U-1631			
	8865139	Oct 01, 2030	DP U-1631			
	8945516	Oct 01, 2030	DP			
	8992896	Oct 01, 2030	DP U-1631			
	9675700	Oct 01, 2030	DP U-1631			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10098863	Feb 27, 2035	DP U-1384			
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP U-1384			
	10105337	Feb 27, 2035	DP			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035	U-1384			
	9511043	Feb 27, 2035	U-1384			
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035	U-1384			
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035	U-1384			
	9814692	Feb 27, 2035	U-1384			
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP U-1384			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001 >A>	10695303	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209 001					CGT	Sep 14, 2020
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001					I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Nov 10, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001 >A>	10676440	Sep 25, 2035	DS DP			
	6297375	Mar 17, 2023	DS			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
	>A> 7070581	Jun 23, 2023	DP			
	>A> 8517997	May 14, 2024	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001					I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002					I-825	Mar 09, 2023
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001					I-833 ODE-295	Apr 29, 2023 Apr 29, 2027
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10213572	Feb 12, 2036	DP			
	6758214	Feb 23, 2022	DP			
	7560076	Apr 21, 2027	DP			
	7618594	Oct 17, 2026	DP			
	9604028	Aug 13, 2029	U-2793			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	>A> 10238709	Feb 03, 2036	U-2857		>A> NP	Jun 26, 2023
	>A> 10695397	Feb 03, 2036	U-2857			
	>A> 8329198	Sep 17, 2029	DP			
	>A> 8535695	Sep 17, 2029	U-2857			
	>A> 9265812	Sep 17, 2029	DP			
	>A> 9566246	Sep 17, 2029	DP			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	10342850	May 15, 2038	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2480		I-831	May 08, 2023
	8071579	Aug 12, 2027	U-2819		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2820		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2821		>A> ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2480		I-831	May 08, 2023
	8071579	Aug 12, 2027	U-2819		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2820		ODE-283	Dec 27, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2821		>A> ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	>A> 10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	>A> 10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	>A> 10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10646485	Sep 02, 2036	DP U-1556			
	>A> 10668060	Dec 10, 2030	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	>A> 8357714	Aug 26, 2031	U-2849		>A> NP	Jul 08, 2023
	>A> 9867808	Aug 26, 2031	U-2849			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 001					M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 002					M-14	Oct 25, 2022
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	6936612	Jan 16, 2023	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
>A>	9604990	Oct 28, 2035	DS			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10646480	Aug 27, 2038	DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	8354430	Feb 06, 2026	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	8354430	Feb 06, 2026	U-1101			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	>A> 7041786	Jan 30, 2028	DS			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001	10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					>A> NCE	Jul 02, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	>A> 10703763	Feb 27, 2026	U-1708			
	>A> 10703763	Feb 27, 2026	U-2847			
	>A> 10703763	Feb 27, 2026	U-2848			
	>A> 10709694	Jul 24, 2029	U-2579			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	>A> 10703763	Feb 27, 2026	U-1708			
	>A> 10703763	Feb 27, 2026	U-2847			
	>A> 10703763	Feb 27, 2026	U-2848			
	>A> 10709694	Jul 24, 2029	U-2579			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9421195	Jul 24, 2029	U-1481			
<u>RILUZOLE - EXSERVAN</u>						
N 212640 001	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	8188113	Jul 27, 2030	DS DP		NCE	May 15, 2025
	8461179	Jun 07, 2032	DS DP		ODE-298	May 15, 2027
	8940756	Jun 07, 2032	U-2829			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					I-824	Oct 11, 2021
<u>RUCAPEPRIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2101			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10682338	Sep 04, 2035	U-2583			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	>A> 10519139	Aug 14, 2035	DS DP U-2584		>A> I-837	Jun 22, 2023
	>A> 10519139	Aug 14, 2035	DS DP U-2855			
	10544108	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-2855			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		>A> ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		>A> ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		>A> ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		>A> ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		>A> ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		>A> ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001					M-252	Jan 16, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003					M-252	Jan 16, 2023
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001					>A> ODE-231 >A> PED	Oct 26, 2025 Apr 26, 2026
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	>A> 10695365	Oct 22, 2033	DS		M-261	Apr 24, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	>A> 10695365	Oct 22, 2033	DS		M-261	Apr 24, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					NPP	Mar 19, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		NS	Mar 19, 2023
	7964580	Mar 26, 2029	DS DP U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9757406	Jan 30, 2034	DP			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001					NP PED	May 26, 2023 Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10512609	Sep 05, 2037	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10512609	Sep 05, 2037	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10682376	Nov 13, 2028	DP			
	10695367	Nov 13, 2028	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	>A> RE44733	Jan 27, 2026	DS DP U-1794		>A> M-262	Jun 09, 2023
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	>A> RE44733	Jan 27, 2026	DS DP U-1794		>A> M-262	Jun 09, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	10537554	Jan 29, 2036	U-72			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004					M-253	Jan 29, 2023
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 003					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050709 001					ODE-294	May 24, 2025
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	>A> 10548880	Aug 30, 2024	U-2677			
	>A> 10548880	Aug 30, 2024	U-2678			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	>A> 10548880	Aug 30, 2024	U-2677			
	>A> 10548880	Aug 30, 2024	U-2678			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	>A> 10548880	Aug 30, 2024	U-2677			
	>A> 10548880	Aug 30, 2024	U-2678			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610510	Jan 25, 2033	U-2805			
	10610511	Oct 10, 2034	U-2806			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
	>A> 10688071	Feb 24, 2030	DP U-2760			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Apr 13, 2032	U-2736		>A> I-835	Jun 18, 2023
	>A> 10245269	Apr 11, 2033	U-2737		>A> I-836	Jun 18, 2023
	>A> 10245269	Apr 11, 2033	U-2851		NCE	Jan 23, 2025
	>A> 10245269	Apr 11, 2033	U-2854		ODE-299	Jan 23, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	>A> 10369155	Oct 16, 2035	U-2736			
	>A> 10369155	Oct 16, 2035	U-2852			
	>A> 10369155	Oct 16, 2035	U-2853			
	>A> 10420775	Apr 13, 2032	U-2736			
	>A> 10420775	Apr 13, 2032	U-2852			
	>A> 10420775	Apr 13, 2032	U-2853			
	8410088	Apr 13, 2032	DS DP			
	>A> 8691507	Sep 12, 2031	U-2852			
	>A> 8765732	Apr 13, 2032	U-2852			
	>A> 8765732	Apr 13, 2032	U-2853			
	>A> 8895245	Sep 12, 2031	U-2852			
	9090562	Apr 13, 2032	DS DP			
	>A> 9175331	Sep 12, 2031	U-2852			
	>A> 9333217	Sep 12, 2031	U-2852			
	>A> 9334527	Sep 12, 2031	U-2852			
	>A> 9394283	Apr 11, 2033	DS DP U-2852			
	>A> 9394283	Apr 11, 2033	DS DP U-2853			
	9522152	Apr 13, 2032	U-2738			
	>A> 9549931	Apr 13, 2032	U-2736			
	>A> 9549931	Apr 13, 2032	U-2852			
	>A> 9549931	Apr 13, 2032	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	>A> 9889138	Oct 16, 2035	U-2736			
	>A> 9889138	Oct 16, 2035	U-2852			
	>A> 9889138	Oct 16, 2035	U-2853			
	>A> 9949999	Sep 12, 2031	U-2851			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2025	DS			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Apr 20, 2026	DS DP U-2507		>A> NPP	Jun 19, 2023
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Apr 20, 2026	DS DP U-2507		>A> NPP	Jun 19, 2023
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001					M-255	Feb 04, 2023
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	RE47526	Apr 09, 2024	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	7301023	Dec 08, 2020	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001 >A>	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002 >A>	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003 >A>	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004 >A>	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	10376525	May 14, 2027	U-1849			
	>A> 10716793	May 14, 2027	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001					>A> NCE	Jun 30, 2025
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-245	Jun 09, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
	10597400	Oct 17, 2036	U-2616			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001 >A>	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002 >A>	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm